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Abstract 
Background: The function of the gastrointestinal tract in monitoring and sealing the host 
interior from toxins, antigens and microbes, is termed the gut barrier. Disruptions in the gut 
barrier result in an increase in intestinal permeability (IP). Evidence suggests that the intestinal 
permeability barrier becomes compromised in acute pancreatitis (AP), chronic liver disease 
(CLD) and to a limited degree in chronic pancreatitis (CP). In acute pancreatitis, changes 
correlate with disease severity, multi-organ failure, mortality and outcome. Bacterial 
translocation and dysbiosis along with immunological responses have also been associated 
with changes in gut permeability. Confocal laser endomicroscopy (CLE) is a novel tool that 
has been used to investigate intestinal permeability in other gastrointestinal disease.   
Aims: To determine whether CLE can be used to assess intestinal permeability, bacterial 
translocation and endotoxaemia in patients with chronic pancreatitis, chronic liver disease and 
acute pancreatitis. To assess the responses of immunology and infection in patients with acute 
pancreatitis whilst also assessing changes related to increasing severity of disease in acute 
pancreatitis. 
 
Methods: 182 patients were recruited: 54 AP (Determinant Based Classification); 47 CP 
(surgically or conservatively managed); 33 CLD and 48 non-ulcer dyspepsia, rendering 13 
healthy controls. Blood was sampled and duodenal fluid aspirated for culture. CLE was 
performed in consenting patients and fluorescein leakage scored. Endotoxin antibodies, 
cytokine concentrations and lactulose mannitol ratios were measured; Diamine oxidase 
(DAO) concentrations were assayed in AP patients undergoing CLE. 
 
Results: Fluorescein leakage and lactulose mannitol ratios were significantly higher in 
patients with AP (p=0.0346 and p=0.046 respectively) and surgically managed CP (p=0.032, 
p=0.030) compared to healthy controls. Patients with AP more frequently showed positive 
duodenal bacterial cultures than controls (p=0.004); positive duodenal cultures were 
associated with fluorescein leakage (p=0.035). Plasma endotoxin antibody concentrations 
were decreased in AP compared to controls. Multiple cytokines showed significantly 
increased concentrations in severe AP. DAO concentrations were significantly increased in 
AP patients who showed fluorescein leakage at CLE (p=0.035). 
Conclusion: CLE identified increased IP in AP and surgically managed CP, associated with 
endotoxaemia, increased serum cytokines and DAO, with most marked changes in severe AP. 
The association of fluorescein leakage with duodenal bacterial proliferation in AP indicates 
major gut dysfunction that may account for bacterial translocation via epithelial gaps, 
contributing to AP severity. Endotoxaemia, positive duodenal bacterial cultures, and increased 
serum concentrations of several cytokines were associated with increasing severity of AP. The 
increase in positive duodenal bacterial cultures in patients who also demonstrated fluorescein 
leakage at CLE supports a hypothesis of bacterial translocation, suggesting that the 
gastrointestinal barrier is altered in AP. Evidence for increased IP was also observed in 
surgically managed CP patients, suggesting that the gut barrier may also be compromised in 
some CP patients.  
Competing Interests: None  
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1.1 Gastrointestinal Permeability 
The function of the gastrointestinal tract in monitoring and sealing the host interior 
from toxins, antigens and microbes, is termed the gut barrier. [1] Intestinal epithelial 
cells, the gut immune system, and immunologic responses serve as layers of defence. 
[2] The overall maintenance of gut barrier integrity is a dynamic process expending 
significant energy. The cellular processes generating energy and oxidation also 
enable the gut to perform this role. [5] Thus, nutritional deficiencies play a key role 
in the development of gut barrier dysfunction. [6] Disruptions in the gut barrier result 
in an increase in intestinal permeability. Various mechanisms of damage have been 
proposed which may lead to the translocation of endotoxin and enteric bacteria. [7] 
There is substantial evidence from both experimental acute pancreatitis in rodent 
models and clinical acute pancreatitis studied in different human populations, that 
the intestinal permeability barrier becomes compromised in this condition. This 
chapter reviews the literature related to intestinal permeability in acute pancreatitis, 
and the correlation between this and resultant bacterial and endotoxin translocation 
from the gut lumen into the circulation.  
Alterations in intestinal permeability (IP) have also been reported in chronic liver 
disease (CLD) and to a limited degree in chronic pancreatitis (CP). In acute 
pancreatitis, changes correlate with disease severity, multi-organ failure, mortality 
and outcome. [5] Increases in intestinal permeability also correlate with various 
disease severity markers including C-reactive protein concentration, serum cytokine 
concentrations, procalcitonin concentration. Apache II scoring, Atlanta criteria and 
the Determinant Based Classification allow classification of disease and grading of 
severity based on clinical parameters and also have been shown to correlate with 
changes in gastrointestinal permeability. Increased IP allows the passage of 
microbes, which are usually maintained within the gut lumen by physiological and 
homeostatic mechanisms, through the systemic circulation to extra-intestinal sterile 
sites, potentially exacerbating the severity of pancreatitis. [8] [9]  
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In patients with cystic fibrosis who have chronic pancreatitis, increased intestinal 
permeability has been reported compared with those without, and this is secondary 
to changes in villus and crypt tight junctions. [10] Cytokine balance has also been 
associated with increased pathogenic microbiota and gut permeability. [11]  
Bacterial translocation and endotoxaemia are also thought to exacerbate the severity 
of liver disease, leading to decompensation of cirrhosis, with spontaneous bacterial 
peritonitis, hepatic encephalopathy, hepatorenal syndrome and variceal bleeding. 
[12] [13] [14] Immunomodulatory, cellular and molecular events lead to changes in 
the expression of intestinal tight junction proteins, representing cellular mechanisms 
for intestinal barrier disruption and hyper-permeability. Patients with hepatic 
encephalopathy have been shown to have altered intestinal flora, increased serum 
endotoxin levels, and an increase in the serum concentrations of various cytokines 
(IL-6, Tumour Necrosis Factor-alpha (TNF)-α, IL-2, and IL-13). [15] Several tests 
can be used to examine intestinal barrier function. [5] [16] Transport of molecules 
across the intestinal epithelium takes place through two major routes, trans-cellular 
and paracellular. Transport of solutes across the transcellular route is carrier-
mediated and occurs with the help of transporters and channels whereas transport of 
molecules through the paracellular route across the intestinal epithelium occurs by 
the process of diffusion and it is not carrier-mediated. The intestinal epithelial barrier 
is key to this process. The disruption of this barrier system results in changes in 
intestinal permeability and the penetration of noxious substances. Assessment of 
intestinal permeability is done to assess the overall function of transport through the 
intestinal epithelial paracellular route. [17]  
There are series of aqueous pores along the crypt villous axis of the small intestine, 
with smaller pores at the villus tip and slightly larger ones at the crypts. Most of the 
probes used to measure intestinal permeability are water-soluble, which cannot 
penetrate the lipid cell membrane of enterocytes and thus use the paracellular route 
through the tight junctions. The smaller probes can easily pass through the small, 
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more numerous and more accessible tight junctions of the villous tips, whereas the 
larger probes have to make use of the larger, less accessible and less numerous pores 
at the crypt base.  
Intestinal permeability is measured with the help of a non-metabolizable probe 
molecules which pass across the mucosal barrier and are excreted in the urine after 
being absorbed into the systemic circulation. Quantitation of the probe in a timed 
urine or serum collection provides a measure of the fraction of ingested probe that 
has penetrated the mucosal barrier. Only a small proportion of this large probe 
should get through the intestinal mucosa, reach the circulation, get filtered by the 
kidney and get measured in the urine over a defined point of time. If there is an 
abnormality in the paracellular transport; the passage of the probe is enhanced and 
thus more is excreted in the urine which suggests abnormality in the intestinal 
permeability. Intestinal permeability can be assessed using a variety of marker 
probes such as lactulose, mannitol, rhamnose and cellobiose, polyethylene glycol 
(PEG) 400, PEG 1000, 51Cr-EDTA and 99mTc-DTPA. Multiple mucosal and non-
mucosal factors can affect the excretion of a single dose of a test probe and thus a 
dual sugar probe test is used for the assessment of intestinal permeability. This 
involves the simultaneous oral administration of a disaccharide and a 
monosaccharide and measurement of their excretion in urine over a defined period 
of time. Intestinal permeability is measured as the ratio of percentage of excretion 
of disaccharides/monosaccharides in the urine or serum. Expression of these 
excreted sugars as a ratio overcomes the individual variations of other factors. [18] 
The concentration of one or more sugar probe can be measured using enzyme assay, 
high performance liquid chromatography (HPLC), ion-exchange chromatography in 
combination with mass spectrometry and liquid chromatography with mass 
spectrometry. If the PEG has been used as a probe, then the concentration of the 
PEG can be assessed using capillary column gas chromatography. 
 
23 
 
Lactulose and mannitol ratio is the most commonly used test for assessment of 
intestinal permeability and the most reliable method of measurement of 
concentration of lactulose and mannitol is HPLC. HPLC is a chromatographic 
technique used to separate a mixture of compounds with the purpose of identifying, 
quantifying and purifying the individual components of the mixture. [17] 
High pressure liquid chromatography (HPLC) for the determination of lactulose and 
mannitol in serum, as opposed to urine, 90 minutes after ingestion of a sugar 
solution, is another reported method. [19] 
The small intestinal epithelium is in constant equilibrium with continuous villus cell 
shedding and crypt cell replacement. [20] [21] A gap may form from extruding cells; 
this is closed by neighbouring cells forming a tight junction beneath. Lack of closure 
leads to gaps in the villus architecture and these have been shown to increase in 
various gastrointestinal disorders including inflammatory bowel disease and 
gastrointestinal malignancies, due to the high turnover of shedding epithelial cells. 
[22] [23] [24] As detailed later, these gaps have been shown to correlate with loss of 
intestinal barrier function. [22, 25] Confocal laser endomicroscopy (CLE) is a novel 
diagnostic tool which allows the evaluation of in vivo mucosal histology and 
assessment of intestinal barrier function. This technique is discussed in more detail 
later in this introduction. 
 
1.2 The Gut Barrier and Intestinal Microbial Flora 
The intestinal epithelium is a critical component of the gut barrier and is composed 
of a single layer of intestinal epithelial cells (IECs) held together by tight junctions. 
[26] A single contiguous layer of epithelial cells provides a dynamic mechanical 
barrier between the host’s internal milieu and the external environment and this 
excludes potential pathogens. [27, 28] Rapid cell turnover and peristalsis clear 
adherent or entrapped microbes into the gut lumen. [29] However, multiple microbes 
are maintained within the gut lumen by physiological and homeostatic mechanisms. 
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DNA sequencing technology and computational biology advances have 
revolutionized the field of microbiomics. In healthy individuals, pro- and anti-
inflammatory signals are balanced such that commensal organisms are recognized 
and tolerated, while pathogens are prevented from penetrating the mucus layer and 
underlying epithelium. Examples include: E. coli, Enterobacter aerogenes, 
Enterococci, Pseudomonas aeruginosa, Proteus, Bacteroides, and Klebsiella. [9] A 
large-scale comparative analysis of 16S rDNA sequences has better characterised 
the adherent mucosal and faecal microbial communities. A total of 395 bacterial 
phylotypes were identified of which 244 were novel. Bacterial diversity within the 
human colon and faeces is significant and this study demonstrated a great degree of 
heterogeneity between individuals. [30] More recent reports discuss the diverse 
consortium of bacteria, fungi, protozoa, and viruses that inhabit the gut of all 
mammals. Studies in humans and other mammals implicate the microbiome in a 
range of physiologic processes vital to host health, making the gut microbiome an 
active participant in host physiology. States of dysbiosis are characterised by 
reduced diversity in the resident microbiota. [31] The fungal microbiome, the 
mycobiome, is beginning to gain recognition as a fundamental part of our 
microbiome. Compared to bacterial communities, the human gut mycobiome is low 
in diversity and dominated by yeast including Saccharomyces, Malassezia, and 
Candida. [32] Another recent review discusses recent advances in sequencing 
technologies and bioinformatics which have enabled new insights into the genomes 
of our microbial symbionts, their functional capacities, and the interactions between 
these microbes and their human host. Metabolic conversions of dietary components 
and pharmaceuticals that take place in the human distal gut, as well as their 
implications for human health are discussed. [33]  The human distal gut is home to 
a rich and dense microbial community with representatives of all three domains of 
life which are intricately connected with our physiology and health. The combined 
genomes of these microbes, collectively called the human microbiome, vastly 
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expand the metabolic capacities of our own genome, allowing us to break down and 
extract energy from dietary compounds that human enzymes cannot digest.  The 
main function of the mammalian gut microbiota is to assist with food digestion and 
energy extraction, by degrading dietary components such as fibre and cellulose that 
cannot be broken down and utilized by the host's functional capabilities alone. In 
addition, microbial colonization of the gut educates the host's immune system and 
helps to shape the correct development of anatomical structures in the intestinal tract. 
Our gut microbes are basically small biochemical factories, expanding our body's 
metabolic capacities many times.  
Microbiome composition not only varies between individuals but also over time. A 
person's individual gut microbiome composition appears to be relatively stable in 
the absence of disease and dietary or lifestyle changes but can quickly and 
dramatically respond to an altered diet, international travel, food poisoning, or 
antibiotic use. The fast response of the gut microbiome to such changes is thought 
to be the result of the rapid growth rate of many bacterial species and the regular 
large expulsion of gut contents. In addition to these rapid temporal responses, age 
has been shown to affect the composition of the gut microbiome as well, albeit at a 
much slower rate. While human enzymes in the small intestine break down most 
dietary ingredients such as proteins, starch and fatty acids into absorbable smaller 
molecules, such as amino acids, and monosaccharides, not all molecules present in 
the diet can be digested in this part of the gastrointestinal tract. The human genome 
does not encode for enzymes that break down complex proteins and complex 
carbohydrates, that is, fibres and other plant‐derived polysaccharides. These 
molecules will therefore reach the colon largely intact, where they can be digested 
by the gut microbiome. The most important function of the human microbiome in 
the distal gut is to extract energy from these otherwise indigestible dietary 
components.  
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The cytoskeleton, intercellular tight junctions and protein kinase C, provide a 
paracellular pathway between intestinal epithelial cells that permits the bidirectional 
passage of various substances and bacteria, and also plays a role in antigen sampling 
and presentation. [5] [34] (Figure 1) Bacteria can also penetrate intestinal epithelial 
cells by a mechanism similar to phagocytosis, the transcellular pathway. [6, 35] 
(Figure 1)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other features also limit the entry of noxious substances. For example, goblet cells 
secrete mucus and crypt cells secrete chloride-rich fluid, [36] which help prevent 
toxins from adhering to surface receptors, reducing transfer across the epithelial 
barrier and assisting toxin removal with gastrointestinal motility and chemotactic 
activity. [5] Gastric acid is bactericidal while pancreatic enzymes can damage 
Figure 1. 
Schematic diagram to demonstrate paracellular and transcellular absorption 
pathways across intestinal epithelial cells. 
EPITHELIAL CELL 
PARACELLULAR PATHWAY TRANSCELLULAR PATHWAY 
TIGHT JUNCTION 
PROTEINS 
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bacterial cell walls. [37] Immunoglobulin A (IgA) is also secreted into the gut and 
binds foreign antigens in the gut lumen, as well as those that have penetrated 
epithelial cell walls. The immunoglobulin-antigen complex is transported through 
the cell cytoplasm; it is then excreted into the gut lumen and eliminated. [5] 
Defensins, anti-microbial peptides produced by Paneth cells, are also directly toxic 
and cause disruption of bacterial cell membranes. Mediators such as nitric oxide 
have also been shown to regulate epithelial permeability. [38] M cells are specialised 
epithelial cells of the follicle-associated epithelium of the gastrointestinal tract. They 
have a high capacity for transcytosis of a wide range of microorganisms and 
macromolecules. They are believed to act as an antigen sampling system with rapid 
uptake and presentation of particular antigens and microorganisms to the immune 
cells of the lymphoid follicle leading to induction of an effective immune response. 
The resulting immune processes result in lymphocyte migration and allow for a line 
of defence against invading organisms that breach the epithelium. [5] [39] 
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Figure 2. Three axis aspects of intestinal microbiota composition. Adapted from Sekirov et al. [2] 
A: Composition of gut microbiota along the GI tract  
B: Surface layer variations of microbiome 
C: Temporal variations in microbial flora 
A 
29 
 
1.3 Altered Intestinal Permeability 
Proposed mechanisms of increased intestinal permeability include: mucosal 
ischaemia; ischaemia-reperfusion injury; impaired immune defences; and changes 
in the intestinal microbial population leading to bacterial overgrowth. Intracellular 
mechanisms including signal transduction; cellular signalling or adhesion molecule 
expression on endothelial and epithelial cells, may also be involved. [7]  
The most common and earliest organ to fail in severe acute pancreatitis is the lungs, 
but the exact pathophysiological mechanisms underlying the disease are still unclear. 
In experimental studies, interruption of mesenteric lymphatic flow has preventive 
qualities for acute lung injury in the setting of critical illness with various 
aetiologies. Experimentally, diversion of mesenteric lymph is able to prevent acute 
lung injury if done before its development, whereas a later intervention partially 
reduces the lung damage. Thus, experimental evidence implicates mesenteric lymph 
as a primary route for toxic factors to gain entry into the circulation. Interruption of 
this flow is able to prevent acute lung injury in critical illness. [40] Morphological 
changes have also been demonstrated to correlate with intestinal permeability 
alterations. [41] Processes that lead to oxidant stress cause damage to the epithelial 
cell cytoskeletons that regulate tight junctions. [5] Non-steroidal anti-inflammatory 
drugs and tacrolimus have been demonstrated to cause this form of damage. [42, 43] 
Cellular energy deprivation and related processes play a role in diseases associated 
with bowel injury or increased permeation. [5] The gut’s vulnerability to hypoxia is 
related to the villi’s microvascular network, which functions as a countercurrent 
exchanger between the arteriolar and venular endings, causing reduced oxygen 
tension at the villus tip. [6]  
Luminal material crosses the epithelial sheet via transcellular or paracellular 
pathways. Tight junctions between adjacent epithelial cells are the rate-limiting 
factor regulating paracellular permeability. [44] Disorganisation or damage to tight 
junctions results in disruption of the intestinal barrier and increased paracellular 
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permeability. [45] Relaxation of tight junctions by protein kinase C activation 
increases solute flow across the junctions and epithelium by decreasing resistance. 
[34] A very recent study of patients with acute pancreatitis who underwent duodenal 
biopsies to measure the expression of tight junction proteins (claudin-2 and claudin-
4) alongside lactulose-mannitol ratios, confirmed an increase in intestinal 
permeability in acute pancreatitis and demonstrated a reduction in claudin-4 
expression. [46]  
Infection with microbes results in upregulated expression of immunoregulatory 
genes in epithelial cells with increased production of pro-inflammatory cytokines or 
inadequate synthesis of anti-inflammatory cytokines. [5] [27] Intestinal epithelia 
bear functional receptors for a number of diverse cytokines including: IFN-γ, IL-2, 
IL-4, IL-10, IL-13, TNF-α, TGF-β, and hepatocyte growth factor. [47] TGF-β and 
IL-10 are thought to prevent or reverse impaired intestinal permeability. [27, 48] 
The cytokines cause changes in nitric oxide production, which results in relaxation 
of the cytoskeleton or oxidation / nitration of cytoskeletal proteins leading to 
increased antigen sampling. [49] [5] Nitric oxide may adversely contribute to 
cellular permeability in inflammatory conditions, by the formation of peroxynitrate, 
which causes DNA damage and activates poly ADP-ribose synthetase, which uses 
ATP. Both factors result in increased permeation. [50] Increased nitric oxide 
production in response to bacterial infection increases apoptosis. [28] A study 
involving rats challenged with lipopolysaccharide demonstrated that excessive 
production of nitric oxide contributed to increased gut mucosal permeability. [51] 
Cytokine-induced intestinal epithelial hyperpermeability is mediated by nitric oxide 
and interferon-, TNF- and IL-1 act synergistically to induce nitric oxide synthase 
expression. [52] IL-13 and IL-4 have also been shown to demonstrate an increase in 
paracellular permeability. [47] TNF-α lowers the transepithelial resistance between 
tight junctions leading to increased flow of solute between cells and across the 
epithelium. [34] The effects of TNF-α are enhanced by IFN-γ. [53] 
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  1.4 Epithelial Cell Shedding 
The small intestinal epithelium is in constant homeostasis with continuous villus cell 
shedding and crypt cell replacement. [20] [21] The equilibrium between the rate of 
apoptosis and shedding of epithelial cells at the villus tip, and the generation of new 
cells in the crypt, is key to maintaining tissue homeostasis. [26] Shedding of 
intestinal epithelial cells (IECs) from the epithelial monolayer with lack of closure 
may result in the formation of transient gaps or micro-erosions within the epithelial 
barrier and this may result in increased intestinal permeability. Interestingly, small 
intestinal epithelial cells are known to have the highest turnover of any fixed cell 
population in the human body, with complete renewal occurring every 2 to 6 days. 
[54] Cell division in the crypt results in a continuous supply of epithelial cells. These 
epithelial cells undergo apoptosis on reaching the villus tip, or extrusion zone, and 
are shed into the lumen. [55] Several mechanisms for this process have been 
proposed. Most involve complex alterations in tight junction proteins and 
cytoplasmic processes underneath the shedding cell. Studies examining these 
processes have used techniques such as electron microscopy and confocal 
microscopy. [56] [57]  
Creamer et al. confirmed the rapid turnover of intestinal epithelial cells in mice. [20] 
The mechanism of cell shedding remains controversial, though apoptosis has been 
suggested to occur. The life cycle of an intestinal epithelial cell is terminated by 
apoptosis and/or cell shedding. Apoptosis is initiated and cells finally lose anchorage 
and are shed into the lumen. They also lose their contact with the extracellular 
matrix. The mechanism of cell shedding is important as abundant cell shedding must 
be achieved without loss of intestinal barrier function. An impermeable substance 
has been found to plug the epithelial discontinuities that arise on the villus as a 
consequence of cell shedding, resulting in 3% of surface area having gaps near the 
villus tip. Gaps contain no cellular material, but are filled with a substance that 
maintains the epithelial barrier, despite discontinuities being present in the cellular 
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layer. The source and composition of this “plugging” substance is unknown, but it 
could be secreted by neighbouring epithelial cells, myofibroblasts, or the shed 
epithelial cells themselves. [58] Watson et al. emphasised that the intestinal barrier 
is sustained despite the high rate of cellular turnover in the epithelium. [21] Whilst 
investigating cell shedding and intestinal barrier function in mice, they demonstrated 
the presence of occasional gaps in the villus epithelium. Shed cells were largely 
intact, with limited evidence of caspase activity or apoptosis. [21] Cell shedding and 
gap formation were shown to increase in mice which had been injected 
intraperitoneally with TNF-α. The increased cell shedding following this treatment 
correlated with loss of integrity of gut barrier function. [22] Mice injected with 
lipopolysaccharide (LPS) also demonstrated epithelial cell shedding, endotoxaemia 
and subsequent intestinal leaks through gaps or paracellular spaces. Although 
systemic LPS administration significantly increased the leaks in gaps and 
paracellular spaces, it did not change the percentage of leaks in gaps and paracellular 
spaces compared with the control group. [59] [25]  
In both localised and systemic inflammation, homeostasis may be disturbed as a 
result of pathological IEC shedding. The increase in epithelial cell shedding and 
resultant epithelial gaps have been reported in some gastrointestinal disorders due to 
the high turnover of shedding epithelial cells. [22] In mice injected with TNF-α, 
increased cell shedding has been shown to correlate with loss of intestinal barrier 
function. [22, 25] Pathological epithelial cell shedding refers to the increased rate of 
villus epithelial cell apoptosis and extrusion that is observed in several disease states. 
[26]  
 
1.4.1 Diamine Oxidase  
Diamine oxidase (DAO), formerly called histaminase, is found in various tissues, 
but is especially active in the intestinal mucosa. Its function is the oxidative 
deamination of several polyamines, essential substances for cell proliferation, and it 
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is a regulating enzyme in rapidly proliferating tissues such as the intestinal mucosa. 
DAO is normally present in very small amounts in the circulation and its basal 
plasma levels are positively correlated with the maturity and integrity of the 
intestinal mucosa. [60] 
A study in China showed that a traditional drug, berberine, attenuated intestinal 
barrier function in an animal model of acute pancreatitis. Serum DAO activity and 
endotoxin levels were observed to be higher in the severe acute pancreatitis group 
than those in the Sham group and berberine pre-treatment was shown to significantly 
decrease serum DAO activity and endotoxin levels compared with levels in the 
severe acute pancreatitis group. Berberine treatment caused no significant effect on 
pancreatic histology, but ameliorated the intestinal mucosal barrier damage and 
membrane permeability that were associated with severe acute pancreatitis(SAP), as 
measured by serum DAO. This study showed that berberine may be associated with 
the inhibition of SAP-induced upregulation of myosin light chain measurements. 
The results from this study may lead to biased interpretation since pre-treatment in 
itself is likely to have resulted in amelioration of severity and resultant phemonena. 
A Chinese group studying the differences in the effect of enteral versus parenteral 
nutrition in severe acute pancreatitis also assessed gut barrier function by means of 
plasma DAO concentration, serum endotoxin, and urinary lactulose mannitol ratios. 
[61] Further clinical studies have also reported DAO as a serum marker for the same 
purpose. [62] [63] 
Thus, DAO is a well-recognised non-invasive biomarker of gut barrier dysfunction. 
It is easy to measure in serum and multiple reports of its use in this context have 
been noted in experimental models and human conditions. 
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1.5 Acute Pancreatitis  
The pancreas is a glandular organ which has both exocrine and endocrine functions, 
the latter within the pancreatic islets or islets of Langerhans and the former from 
acinar cells which form clusters, and are arranged in lobes separated by a thin fibrous 
barrier. The secretory cells of each acinus surround a small intercalated duct. 
Because of their secretory function, these cells contain many small granules of 
zymogens that are microscopically visible.  
Acute pancreatitis results from acute inflammation of the pancreas and is sometimes 
associated with a systemic inflammatory response that can impair the function of 
other organs or systems. There is a wide spectrum of disease from mild (80%), where 
patients recover within a few days, to severe (20%) in which patients often have 
prolonged hospital stays and need critical care support.  The diagnosis of severe 
acute pancreatitis depends on the presence of persistent organ failure (>48 hours) 
and the presence of local complications which usually become apparent later in the 
course of disease. [64] The two main classification systems used to stratify the 
severity of acute pancreatitis include the Atlanta Classification and the Determinant 
Based Classification. [65] [66] The latter enables classification into four categories: 
mild, moderate, severe and critical based on similar criteria to the Atlanta 
Classification with respect to the presence of transient or persistent organ failure and 
the presence of necrosis, sterile or infected. Opinions vary as to the efficacy of the 
two with comparison studies reporting  summaries that both perform equally. [67] 
[68] The aetiology of acute pancreatitis is varied. The commonest causes in Western 
society are gallstones (50%) and alcohol (25%). Rarer causes (<5% each) include 
drugs, endoscopic retrograde cholangiopancreatography (ERCP), 
hypertriglyceridaemia, hypercalcaemia, pancreas divisum, and some viral 
infections. About 10% of patients have idiopathic pancreatitis, where no cause is 
identified. The disease remains a clinical challenge due to limited understanding of 
its pathogenesis and multi-causality. It occurs in ~50/100,000 of the population, and 
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when it is severe (1 in 5 patients), it can result in local necrosis that contributes to 
multi-organ failure, and this is associated with mortality between 20-30%. [69]                   
Acute pancreatitis is diagnosed by the presence of two out of three of the following 
clinical criteria: a clinical history of abdominal pain in keeping with acute 
pancreatitis; increased serum amylase activity greater than three times the upper 
limit of normal; radiological changes in keeping with pancreatic inflammation. [66] 
The spectrum of disease extends from a mild oedematous-interstitial inflammation 
to severe necrotising acute pancreatitis with systemic complications developing in 
20-25% of affected individuals. [70] [71]  
Indeed, early stratification of disease severity improves clinical outcomes and 
significantly reduces the length of hospital stay. [72] Improvements in imaging, such 
as computerised tomographic (CT) scans, have not proven superior to clinical scoring 
systems in early prediction of acute pancreatitis severity. [73, 74] Patients who have 
local complications and organ failure have a high risk of mortality and should be 
managed in a specialist centre or a high dependency or intensive care setting. [65] 
Computed tomography should be performed 3-4 days after admission in patients 
with persistent systemic inflammatory response syndrome or organ failure to look 
for local complications.  
Markers of the systemic inflammatory response syndrome help to identify those 
patients who may develop persistent organ failure as per the determinant based 
classification. [75] [76] There are several different predictive scoring systems for 
disease severity based on physiological variables or single biochemical markers, but 
none has shown clear superiority. A recently published review reported a summary 
of the multiple acute pancreatitis scoring systems and the use of different imaging 
methods to predict disease severity: Ranson criteria, Glasgow criteria, Hong Kong 
Score, Acute Physiology and Chronic Health Evaluation II (APACHE II), computed 
tomography scoring systems, Bedside Index of Severity in Acute Pancreatitis 
(BISAP) score, Japanese Severity Score (JSS), Harmless Acute Pancreatitis Score 
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(HAPS), Pancreatitis Outcome Prediction (POP), Sequential Organ Failure 
Assessment (SOFA). CRP should also be included in this list of disease severity 
markers since it is actually the most effective, readily and easily available test which 
correlates well with disease severity. This article also described the Revised Atlanta 
Classification of acute pancreatitis (2012) and the correlation with computed 
tomography. [77] It is important to appreciate that these predictors of severity are 
based on clinical parameters, usually around the time of disease onset and do not 
allow us to assess prognosis. The assessment enables the appropriate triaging of 
patients and identification of those requiring higher level care. The Ranson Score is 
rarely utilised in the UK as the scoring includes the assessment of blood urea 
nitrogen which is a routine test in American practice, but not in British medicine. 
Glasgow criteria more favourable in the latter but again is an assessment formulated 
at the time of initial assessment. 
A large number of clinical biomarkers for acute pancreatitis severity have been 
investigated over the last two decades. These include routine biomarkers, (including 
creatinine and haematocrit) [78] [73, 78-81] pancreas-specific enzymes, (such as 
amylase, lipase, trypsinogen) [80-83], acute phase proteins such as C-reactive protein 
(CRP) and procalcitonin, [80, 81, 84], various cytokines (including IL-6; IL-8; IL-10; 
IL-12; IL-15, IL-17 and TNF-α) [80, 81] immunological components (such as 
phospholipase A and polymorphonuclear elastase), [81] transcriptomics, [85] 
proteomics, [86] and others (amyloid-A, carboxypeptidase B activating peptide and 
blood urea nitrogen). [81] A meta-analysis of 6 studies looked at the value of 
carboxypeptidase-B activation peptide (CAPAP) in predicting severity of acute 
pancreatitis on admission. Both serum and urinary CAPAP have the potential to act 
as a stratification marker on admission in predicting severity of acute pancreatitis. 
[83] However, none of these have yet been implemented in clinical practice due 
primarily to the cost implications involved.  
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Thus, the pathophysiology of pancreatitis incorporates both the localized destruction 
in the pancreas and the systemic inflammatory response that is postulated to be a 
result of premature activation of trypsinogen to trypsin within the acinar cell. 
Various causes for this have been proposed and in turn, it is suggested that further 
enzyme activation occurs, leading to localized tissue damage and release of Damage 
Associated Molecular Patterns (DAMPs). The release of DAMPs causes recruitment 
of neutrophils and initiation of the inflammatory cascade. This inflammatory 
cascade is what is thought to be responsible for the systemic manifestations of acute 
pancreatitis and can ultimately lead to increase capillary permeability and damage 
of endothelium with microvascular thrombosis that causes multiorgan dysfunction 
syndrome (MODS), the main cause of morbidity and mortality in acute pancreatitis. 
[87] 
Overall mortality rates in acute pancreatitis are cited to be between 2 and 6% in 
recent studies. [87, 88] Pancreatic necrosis leads to multiple organ dysfunction 
syndrome at a later stage in the disease process, [89] although this can also occur 
without the presence of pancreatic necrosis and often earlier. [90] A diagnosis of 
severe acute pancreatitis warrants admission to a critical care unit with careful 
supportive therapy, as treatment modalities remain limited. [69] Patients suffering 
from complications of infected pancreatic necrosis should be considered for early 
intervention. [70] Biomarkers are imprecise and despite multiple clinical trials over 
the last 40 years, there is no effective specific drug treatment for acute pancreatitis 
[91]. Microbial infection plays a key role in the pathogenesis, severity, outcome and 
prognosis of acute pancreatitis. Despite positive results with antibiotics in the past, 
recent trials have failed to confirm a role for antimicrobial prophylaxis, although 
antibiotic treatment using carbapenems or quinolones is still suggested by some 
clinicians for patients who have severe acute pancreatitis at admission. [92] Acute 
pancreatitis therefore remains a clinical challenge for surgeons, physicians and 
intensivists. Identification of severe disease is central to optimisation of treatment, 
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but remains a controversial clinical assessment. Clinical signs, biochemical markers, 
imaging methods and complex scoring systems are used in clinical practice to make 
the distinction between mild and severe acute pancreatitis. Many novel parameters 
have been investigated including interleukin-6 (IL-6) in early severity stratification 
and macrophage migration inhibitory factor as a marker of pancreatic necrosis. [69, 
71] With evidence of the effectiveness of IL-6 rising, its surrogate marker CRP 
inevitably acts as an excellent alternative that is cheap to perform and readily 
available. Specificity remains questionable, hence the lack of consensus regarding 
the most effective tool, and also there is a delay in the secondary rise in CRP after 
the initial IL-6 response. Necrotising pancreatitis is suspected when systemic 
inflammation persists for over a week after the onset of pancreatitis. Intervention is 
not recommended for at least 14 days after the onset of symptoms and patients 
should only be managed in specialist units by expert teams.  
More generally, the treatment of acute pancreatitis is limited to intravenous fluids 
and symptomatic management of pain and vomiting when the disease course is mild 
to moderate. In the more severe or critical courses, often there is a SIRS response 
with multi organ failure and intensive care support is warranted. Enteral nutrition by 
means of oral intake is recommended and encouraged as soon as it is feasible. [93] 
In cases of severe acute pancreatitis, where this is not an option, nasogastric feeding 
has been shown to be adequate, without the need for nasojejunal intubation. [94-96] 
The benefit of antibiotic therapy is questionable as previously discussed. [97] After 
resolution of severe acute pancreatitis, it is important to identify and treat the 
underlying cause of the episode and encouragement of alcohol cessation has been 
shown to be beneficial. [98] 
 
1.5.1 Gut barrier dysfunction and bacterial translocation in acute pancreatitis 
In severe acute pancreatitis, Gram-negative organisms infect pancreatic necrosis and 
intra-abdominal collections, and this results in a threefold increase in mortality. 
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Systemic Inflammatory Response Syndrome (SIRS) is commonly associated with 
morbidity, and mortality and results from a reaction to proteases, cytokines and other 
vasoactive mediators which are released at disease onset. [69, 70] SIRS must be 
differentiated from sepsis, since there is often no infective source and blood cultures 
are negative. The systemic reaction however involves a rise or fall in core 
temperature, tachycardia, tachypnoea and a rise in white cell count. A study of 
patients who had severe acute pancreatitis identified that an increase in intestinal 
permeability and higher endotoxaemia predicted poorer outcomes in patients who 
experienced complications. [99] Intestinal permeability, and serum concentrations 
of IL-6, TNF-α, and endotoxin were also reported to be significantly higher in 
patients with acute pancreatitis who had a high Balthazar CT severity index, 
indicating that these parameters are associated with severe acute pancreatitis and 
serious complications, and suggesting that they may potentially be reliable markers 
for predicting the prognosis of acute pancreatitis. [100]  
Potential mechanisms for the loss of intestinal barrier function that is observed in 
acute pancreatitis include reduced intestinal perfusion [101] and/or reperfusion 
injury following initial resuscitation, [102-105] increased intestinal epithelial 
apoptosis secondary to circulating cytokines [106] or loss of trophic luminal 
enzymes. [10] Furthermore, reduced intestinal motility can lead to alterations in 
intestinal microflora with overgrowth of Gram negative bacteria, [41] which further 
contributes to local inflammation and mucosal injury. [104, 107] A review of studies 
demonstrated that immunological, bacteriological and morphological components 
seem to interact and depend on each other, further highlighting the complexities of 
the mechanisms underlying loss of intestinal barrier function in acute pancreatitis. 
[108] Figure 3 demonstrates the multiple factors and time duration involved in the 
progression of acute pancreatitis. 
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Figure 3. A representation of progression of Acute Pancreatitis. 
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Table 1. Gut permeability in experimental acute pancreatitis 
Study   Model Species Therapeutic factors IP tested Findings 
Liu et al 
(1997) 
[109] 
Sodium taurocholate 
(3%, 1 ml/kg, i.d.) 
and trypsin (3000 
IU/kg, i.d.) 
Rats Human recombinant EGF 
(100 µg/kg, s.c.) 30 mins 
after operation twice daily 
for two days 
 
Bacterial Translocation 
• Minimised intestinal mucosa injury induced by AP 
• Reduced BT to blood, MLN, pancreas, spleen and liver 
Kouris et 
al (2001) 
[110] 
Sodium taurocholate 
(3%, 1 ml/kg, i.d.) 
and trypsin (3000 
IU/kg, i.d.) 
Rats GLP-2 analog ALX-0600 
(0.1 mg/kg, s.q.) 10 mins 
after operation twice daily 
for 3 days 
 
Transepithelial electrical 
resistance of the terminal ileum 
and BT 
• Reduced ileum transepithelial resistance 
• Reduced BT to MLN, pancreas and peritoneum 
• No significant effects on intestinal histopathology 
• No signiﬁcant effects on pancreatic histopathology 
Sun et al 
(2001) 
[111] 
Sodium taurocholate 
(5%, 1 ml/kg, i.d.) 
and trypsin (1.67 × 
105 U/kg, i.d.) 
Rats None  
Plasma D-lactate and endotoxin 
• Increased gut permeability 
Wang et 
al (2002) 
[112] 
Sodium taurocholate 
(5%, 1.5 ml/kg, i.d.) 
 
Rats 
Human recombinant GH 
(0.75 U/kg, s.c.) immediately 
after operation 
 
None 
• Down-regulated intestinal epithelial cell apoptosis 
Leveau et 
al (2005) 
[113] 
Sodium 
taurodeoxycholate 
(5%, 0.2 ml, i.d.) 
 
 
Rats 
PAF inhibitor lexipafant (5 
mg/kg, i.p.) 30 mins and 6 h 
after operation 
Bilateral measurement of 131I-
labeled human serum albumin 
from blood to intestinal lumen 
• Improvement in intestinal barrier dysfunction in AP 
• Reduction of intestinal IL-1 levels and local leukocyte recruitment 
Alhan et 
al (2006) 
[114] 
Caerulein (5 µg/kg/h 
for 6 h, i.v.), + 
Glycodeox. acid (10 
mM, 1.2 ml/kg, i.d.) 
 
 
Rats 
 
-3FA* (0.8 ml/kg/h, i.v.) 
and saline (5.2 ml/kg/h, i.v.) 
for 42 h 
 
24 h excretion of urine phenol 
sulfophthalein and BT 
• Reduced gut permeability 
• Reduced BT to pancreas, liver and spleen 
• Reduced pancreatic and lung inflammation 
• Reduced mortality 
Yasuda 
et al 
(2007) 
[115] 
Sodium 
deoxycholate (3%, 
0.1 ml, i.d.) 
 
 
 
Rats 
 
Caspase inhibitor Z-VAD-
fmk (500 µg/rat, i.p.) during 
induction of disease 
 
Leaked amount of FITC-
dextran outside of the intestinal 
pouch, endotoxin and BT 
• Locked intestinal mucosa caspase-3 activation 
• Reduced intestinal permeability and improved intestinal mucosa histopathology 
• No reduction in BT but reduced serum endotoxin levels 
• No significant effect on pancreatic histopathology 
Luan et 
al (2010) 
[116] 
Sodium taurocholate 
(5%, 1.5 ml/kg, i.d.) 
 
 
Rats 
EP (40 mg/kg, i.v.) 24 h after 
disease induction, every 6 h 
for 24 h 
 
Plasma DAO and endotoxin 
• Down-regulated intestinal mucosa HMGB1 
• Reduced plasma amylase, endotoxin, DAO and activity of intestinal mucosa MPO 
• Reduced plasma amylase and pancreatic histopathology 
Zhang et 
al (2010) 
[117] 
Sodium taurocholate 
(3.5%, 1 ml/kg, i.d.) 
 
Rats 
Danshen (10 ml, 15 g/rat, 
i.p.) 15 mins after disease 
induction, i.p. 
 
None 
• Reduced intestinal mucosa apoptosis and NF-kB activation in the treatment group 
Zou et al 
(2010) 
[118] 
Sodium taurocholate 
(5%, 1 ml/kg, i.d.) 
and trypsin (7500 
BAEF units/ml, i.d.) 
 
Pigs 
 
Enteral immunonutrition 24 h 
after disease induction* 
 
L/M, serum endotoxin and BT 
• Decreased gut permeability, serum endotoxin and BT 
• Improved intestinal mucosa histopathology 
• No significant effects on pancreatic histopathology 
Lu et al 
(2011) 
[119] 
  
Rats 
 
 
Evans blue assay for intestinal 
capillary leakage 
• Reduced intestinal capillary leakage was observed 
• Decreased elevated intestinal VASP and MMP-9 
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Zhongkai 
et al 
(2012) 
[120] 
Sodium taurocholate 
(2%, 1 ml/kg, i.d.) 
 
 
Rats 
 
 
VIP (5 nmol, i.p.) 5 mins 
after disease induction 
 
 
Serum endotoxin 
• Serum endotoxin levels decreased in the treatment group 
• Intestinal mucosa mRNA levels of TNF-α, IL-6 and IL-10, and TLR4 expression were 
reduced in the treatment group 
• Improved intestinal mucosa histopathology 
Chen et 
al (2012) 
[121] 
Sodium taurocholate 
(3%, 1 ml/kg, i.d.) 
 
 
Rats 
GLP-2 (0.1 mg/kg) 
immediately after operation 
twice a day for 3 days, i.p. 
 
 
Serum DAO activity 
• Serum DAO was decreased 
• Intestinal epithelial cell apoptosis was partly prevented 
• Reduced histopathological score of ileal mucosa 
Dang et 
al (2012) 
[122] 
Sodium taurocholate 
(5%, 1 ml/kg, i.d.) 
 
 
Rats 
TREM-1 inhibitor LP17 (1.0 
mg, i.v.), just before disease 
induction 
 
 
L/M 
• Reduced gut permeability 
• Reduced levels of serum DAO and D-lactose and BT 
• Reduced intestinal TREM-1, TNF-α, and IL-1β mRNA 
Lu et al 
(2013) 
[123] 
Sodium taurocholate 
(1 ml/kg, 5%) 
 
 
Rabbits 
Saizen (0.15 IU/kg, s.c.) 1 h 
after disease induction and 
24 h later after the first 
injection; Stilamin (3.5 
µg/kg/h, i.v.) 1 h after 
disease induction for 48 h 
 
 
Serum D-lactate 
• Serum D-lactate was significantly lower 
• Reduced intestinal mucosa epithelial cell apoptosis 
• Improved intestinal mucosa histopathology 
• Improved mortality 
Li et al 
(2013) 
[124] 
Sodium taurocholate 
(5%, 0.2 ml, i.d.) 
 
 
Rats 
Infliximab (8 mg/kg, i.v.); or 
infliximab (8 mg/kg) and 
octreotide (10 µg/kg, i.v.), at 
6 h after modelling 
 
 
Serum DAO and D-lactate 
• Significantly reduced serum amylase, DAO and D-lactate; 
• Improved intestinal motility and reduced intestinal injury 
• Combination of infliximab and octreotide had better effects than infliximab 
Tian et al 
(2013) 
[125] 
Caerulein (50 
µg/kg/h × 6, i.p.) 
followed by LPS (10 
mg/kg, i.p.) 
 
Mice 
 
None 
 
Serum DAO 
• Increased serum amylase, TNF-α and DAO 
• Increased oxidative stress markers in gut mucosa 
• Increased gut mucosa apoptosis 
Han et al 
(2013) 
[126] 
Sodium taurocholate 
(3.8%, 1 ml/kg, i.d. 
via pancreatic tail) 
 
Rats 
 
PN; EN; EN + Gln; PN + Gln 
 
None 
• Reduced severity of pancreatic histopathology 
• Reduced intestinal epithelial apoptosis 
Li et al 
(2013) 
[127] 
Sodium taurocholate 
(4.5%, 1 ml/kg, i.d.) 
 
Rats 
 
None 
 
None 
• IAP was 2-3 times higher than the control group 
• Amylase, TNF-α, creatinine, bilirubin, DAO and D-lactate gradually increased over time 
Sun et al 
(2013) 
[128] 
Sodium taurocholate 
(1 ml/kg, 4 %), i.d. 
 
 
Rats 
 
Melatonin (50 mg/kg, i.v.) 30 
mins before modelling 
 
BT (Bacterial DNA) 
• Serum and ileum DAO were significantly reduced 
• E. Coli DNA was lower in the treatment group 
• Mortality lower (21.43% vs 55.56%) 
Shen et 
al (2013) 
[129] 
  
Rats 
Continuous blood 
purification 
Intestinal occludin and ZO-1 
levels 
• Intestinal permeability was reduced 
• Intestinal proteins occludin and ZO-1 were decreased 
Tian et al 
(2013) 
[130] 
Caerulein (50 
µg/kg/h × 6, i.p.) 
followed by LPS (10 
mg/kg, i.p.) 
 
 
Mice 
 
 
None 
 
Serum DAO, ZO-1, E-cadherin 
• Increased serum amylase, TNF-α and DAO; 
• Over-expressed miR-155 
• Under-expressed proteins of RhoA, ZO-1 and E-cadherin 
Liang et 
al (2014) 
[131] 
Sodium taurocholate 
(1 ml/kg, 2.5 or 
5%), i.d. 
 
Rats 
 
None 
Serum endotoxin, DAO, D-
lactate and BT 
• Gut permeability increased over time and it was correlated with taurocholate dose 
• Intestinal mucosal injury correlated taurocholate dose 
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Tu et al 
(2014) 
[132] 
Sodium taurocholate 
(1 ml/kg) 
 
Rats 
 
MSCs were injected via the 
dorsal penile vein 1 h later 
 
Serum DAO 
• Reduced gut permeability 
• Decreased intestinal mucosa histopathology score 
• Reduced systemic inflammation 
Tang et 
al (2014) 
[133] 
Sodium taurocholate 
(1 ml/kg, 3%) 
Rats Berberine 50mg/kg in 1ml 
N/Saline / 200g body weight 
i.g. od for 5 days 
Serum DAO, ET, ZO-1, 
occludin mRNA, Bacterial 
culture of MLNs 
• No significant changes to histology 
• Decrease in serum DAO and ET 
• Decrease in bacterial translocation 
• No influence on ZO-1 and occludin mRNA expression in SAP 
Deitch et 
al (2014) 
[134] 
Sodium taurocholate 
(5%, 1 ml/kg, i.d.) 
with simultaneous 
intraperitoneal 
deposition of 
Caerulein. 
Rats and 
Mice 
None Plasma FD-4 (fluorinated 
Dextran) further to intraluminal 
ileal injection, Villi injury and 
mucus coverage, mucus protein 
carbonyl and nitrated tyrosine 
residues 
• The intestinal mucus layer is lost after AP 
• Loss of unstirred mucus layer is associated with: 
o gut barrier failure; 
o with ROS- and RNI- mediated structural changes to the mucus layer 
o occurring before microscopic morphological evidence of damage to the underlying mucosa 
 
Ling et al 
(2014) 
[135] 
Sodium taurocholate 
(0.5% for mild AP; 
3.8% for severe AP) 
Rats None Cultured epithelial cells were 
infected with αSNAP shRNA 
Cell apoptosis by flow 
cytometry- Occludin 
• In SAP, Intestinal villi showed oedema, atrophy, necrosis and shedding of IEC 
• IP in rats with AP increased significantly 
• Increased TNF-α and endotoxin in SAP 
• Down-regulated expression of αSNAP and IEC occluding in SAP 
Machado 
et al 
(2016) 
[136] 
Sodium taurocholate 
into biliopancreatic 
duct 
Rats None COX-2 and TJ protein and gene 
expression 
 
• Significantly higher number of bacterial colonies in pancreas of elderly  
• Intestinal damage in AP is exacerbated by aging 
• Increase in bacterial colonies was associated with a more severe intestinal inflammatory 
response, associated increase in expression of COX-2 and decrease in TJ proteins 
• COX-2 inhibition could potentially be a therapeutic target in the elderly 
Feng et 
al (2018) 
Caerulein (50 
µg/kg/h × 4, i.p.) 
followed by LPS 
(7.5 mg/kg x 2, i.p.) 
Rats Dachengqi Decoction 
(DCQD) 
Serum amylase, TNF-α, IL-1β, 
IL-2, and IL-6 by ELISA 
Intestinal tissue by histology 
Capillary permeability by 
Evans blue extravasation assay 
AQP-1, MMP9, and JAM-C  
• DCQD can reduce capillary endothelial damage in acute pancreatitis-associated intestinal 
injury and the mechanism may be associated with the regulation of endothelial barrier 
function-associated proteins AQP-1, MMP9, and JAM-C 
• DCQD attenuated SAP intestinal injury and lowered the levels of serum amylase, TNF-α, 
IL-1β, IL-2, and IL-6 effectively[137] 
Bai et al 
(2017) 
[138] 
5% sodium 
taurocholate 
injection (1ml/kg 
body mass) i.d. 
Rats Dai-Huang-Fu-Zi-Tang 
(DHFZT)  
 • DHFZT inhibited the openness of the mitochondrial permeability transition pore (MPTP)  
• It reduced the contents of serum D-lactic acid and activity of diamine oxidase activity 
• It relieved histopathological manifestations and epithelial cells injury of intestine  
Cao et al 
(2018) 
[139] 
Sodium taurocholate 
(350 mg/kg, 3.5 %), 
i.d 
Rats Free total rhubarb 
anthraquinones (FTRAs) (36 
/ 72 mg/kg) 12 hours later 
ET, IL-1β, TNF-α, and NO in 
the blood and TNF-α, IL-1β in 
the intestinal tissues  
 
• Decreased levels of ET, IL-1β, TNF-α, and NO in the blood and TNF-α, IL-1β, and protein 
extravasation in the intestinal tissues in SAP rats 
• FTRAs could protect intestinal injury and improve intestinal mucosal barrier function 
through regulating immune function of SAP rats 
• FTRAs may have the potential to be developed as the novel agent for the treatment of SAP 
clinically 
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Table 2. Summary of clinical studies evaluating intestinal permeability in severe acute pancreatitis 
Authors Year Patient 
Cohort 
Classification 
Tool  
Key Methods Key Results Further Conclusions 
Ammori et 
al [140]  
1999 • 85 AP 
• 56 MAP 
• 29 SAP 
• 25 Controls 
Atlanta 
Criteria 
• Urinary excretion 
of PEG-3350:PEG-
400 
• Increased IP and endotoxaemia as 
AP severity increased and relative to 
controls 
• IP highest in SAP with MOF or death 
• Gut barrier dysfunction plays a role 
in sepsis development, MOF and 
resultant mortality 
Juvonen et 
al [141] 
2000 • 23 AP 
• 15 MAP 
• 8 SAP 
• 20 Controls 
Atlanta 
Criteria 
• Lactulose / 
Rhamnose test on 
day 2 and on 
recovery 
 
• Increased IP and decreased 
absorption capacity in AP 
• Findings exacerbated in SAP 
• All indices normalised during 
recovery 
• Gut permeability increased in AP, 
and increased further in SAP 
McNaught 
et al [142] 
2002 • 59 AP 
• 24 SAP 
• 35 MAP 
Modified 
Glasgow 
Criteria 
• Lactulose / 
Rhamnose test 
• Culture of 
nasogastric aspirate 
• Colonisation with enteric bacteria in 
SAP 
• Differences in IP were not seen 
• AP is associated with BT and gut 
origin sepsis 
Rahman et 
al [101] 
2003 • 61 AP 
• 19 SAP 
• 42 MAP 
• 12 Controls 
Atlanta 
Criteria 
 
• Urinary excretion 
of PEG-3350 and 
PEG-400 
• A strong correlation between IFABP 
levels and gut macromolecular 
permeability 
• IgM anti-endotoxin antibodies 
decreased as IFABP levels increased 
• IFABP is a marker of intestinal 
ischaemia 
• Loss of intestinal mucosal integrity 
is related to SAP 
Ammori et 
al [143] 
2003 • 60 AP 
• 48 MAP 
• 12 SAP 
Atlanta 
Criteria 
• PEG-3350 • Correlative increase in IP, 
endotoxaemia and calcitonin 
precursor (CTpr) levels as AP 
severity increased 
• Weak positive correlation between 
CTpr and CRP levels 
• In AP, CTpr levels were reflective 
of IP 
Rahman et 
al [7] 
2003 • 65 AP 
• 20 SAP 
• 45 MAP 
• 20 Controls 
Atlanta 
Criteria 
• Urinary PEG 
3350/4000 ratio 
• Urinary nitrite excretion correlated 
with increasing IP in AP, and with 
endotoxaemia 
• Endotoxaemia is central to the 
mechanism of septic complications 
in SAP 
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Penalva et 
al [144] 
2004 • 68AP 
• 51MAP 
• 17 SAP 
• 13 Controls 
Atlanta 
Criteria 
 
• Lactulose: 
Mannitol ratio on 
admission and day 
15 
• Increase in IP as severity of AP 
increased 
• Increase in endotoxaemia as severity 
and course increased 
• No significant correlation with 
cytokines 
• IP and inflammatory response may 
be independent of each other 
Nagpal et al 
[145] 
2006 • 52 AP 
• 16 SAP 
• 30 MAP 
• 46 Controls 
Atlanta 
Criteria 
• Lactulose: 
Mannitol urinary 
ratio on days 1, 4 
and 7 
• Increased IP in AP patients compared 
with controls 
• IP increased as AP severity increased 
 
• IP also increases with the time 
course of disease 
Liu et al 
[104] 
2008 • 68 AP 
• 18 SAP 
• 26 MAP 
• 20 Controls 
Atlanta 
Criteria 
• Urinary lactulose: 
• Mannitol ratio 
• Increase in IP early in AP and in 
correlation with severity and MOF 
• Increase in IP correlated with 
increase in endotoxaemia and TNF- 
• Patients with severe mucosal 
dysfunction had a higher rate of 
septic complications 
Pan et al 
[146] 
2010 • 32 AP 
• 25 SAP 
• 7MAP 
Atlanta Criteria 
 
• Urinary Lactulose: 
Mannitol ratio 
• Increase in IP, CRP, IFABP as 
severity of AP increased 
• IFABP indicates gut dysfunction 
and predicts prognosis and clinical 
AP course 
Amicucci et 
al [147] 
2016 • 63 AP 
• 21 SAP 
• 42 MAP 
Atlanta Criteria 
 
• Lactulose: 
Mannitol ratio on 
days 0, 1, 3, 7, 9, 
and 11 
• Increase in intestinal barrier 
dysfunction and endotoxaemia in 
SAP compared with MAP 
• Severe AP can lead to systemic 
endotoxaemia contributing to SIRS 
and MOF 
Du et al 
[148] 
2017 • AP 
• Controls 
Continued 
Blood 
Purification  
• DAO, ET, Rho-
kinase, Protein F-
actin and Claudin 
1, TNFα 
• Increased levels of serum DAO, 
endotoxin and intestinal epithelial 
monolayer permeability when compared 
with normal controls 
• ROCK mRNA expression and serum 
TNF-α level were increased 
• After CBP treatment, levels of serum 
DAO, endotoxin and intestinal epithelial 
monolayer permeability decreased 
• CBP can effectively improve intestinal 
mucosal barrier dysfunction 
• The beneficial effect is associated with 
the improvement of cytoskeleton and 
tight junction proteins  
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One of the most serious consequences of gut barrier dysfunction is bacterial 
translocation, or passage of viable indigenous bacteria from the mucosal surface to 
extraintestinal sterile sites. Changes in intestinal flora, relative mucosal ischaemia 
and impaired immune surveillance are all thought to contribute to this phenomenon. 
[149] Most bacteria associated with pancreatic and peri-pancreatic infections are 
indigenous enteric species, implicating the gut as their origin. [8, 41, 107, 150] 
Indeed as early as 1976, a study by Holden et al. reported that the enteric organisms 
E. coli and Klebsiella spp. were responsible for infections during acute pancreatitis. 
[151] Suggested routes of spread include direct transmural migration to the 
peritoneal cavity or retroperitoneum and pancreas; lymphatic spread; 
haematogenous spread and transmission via contaminated bile. Indeed, recent 
experimental reports have reported inactivation of antimicrobial agents by bile, 
leading to colonisation of the biliary tree with enteric organisms, excretion in bile 
and re-infection of the host via the entero-hepatic circulation. As well as contributing 
significantly to morbidity and mortality in human disease, bacterial infection of 
pancreatic and extra-pancreatic sites has been shown to increase disease severity, 
morbidity and mortality in experimental models of acute pancreatitis. [152] 
Experimental models and controlled clinical studies of acute pancreatitis also 
provide ample evidence for an association between intestinal barrier dysfunction and 
acute pancreatitis. Acute pancreatitis has been shown to lead to increased mucosal 
permeability to macromolecules. [7, 153] Experimental acute pancreatitis in rodents 
(rats and mice), induced by intraperitoneal caerulein or ductal infusion of 
taurocholate is associated with increased ileal villus cell shedding, raised serum 
endotoxin levels as well as E. coli DNA in postcaval blood.[127, 128, 130-132] (See 
table 1) Apoptosis of gut epithelial cells has also been observed to increase during 
experimental acute pancreatitis, thus contributing to increased mucosal permeability 
to endotoxin and viable bacteria. [45, 106, 112, 154] Pancreatitis-associated ascitic 
fluid has also been found to contain factors which accelerate the apoptosis of 
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intestinal epithelial cells in culture, [45] a phenomenon mediated through caspase 
activation. [115] Bacterial translocation itself has been reported in a number of 
studies, [41, 155] and indeed it has been found to be increased following laparotomy 
in humans, proposing a possible mechanism for the high mortality observed in 
patients who undergo surgery for acute pancreatitis. [41, 156] Traditionally, open 
necrosectomy was the only tool available for surgical treatment of pancreatic 
necrosis. This was found to be associated with high mortality rates up to 40%. A 
more recent study of a step-up approach in treatment and minimally invasive 
necrosectomy, showed an overall mortality of 10.38%. [157] In a study of patients 
undergoing open necrosectomy, more than a quarter were found to develop early 
infection of pancreatic necrosis within the first week of illness. [158, 159] In an 
analysis of long-term outcomes of trial participants, the step-up approach for 
necrotizing pancreatitis was found to be superior to open necrosectomy, without 
increased risk of reinterventions. [160] A published review of local practice 
examined the outcomes from minimal access retroperitoneal pancreatic 
necrosectomy and open pancreatic necrosectomy for severe necrotizing pancreatitis 
in a single centre. Intensive care admission was required less frequently in the former 
cohort and the mortality rate was reported as 15.3% compared with 23.3% in the 
open necrosectomy group. Mortality and complication rates improved with time and 
experience. [161] 
A study detailed in Table 2, supported the theory of bacterial translocation and gut 
origin of sepsis, but not that these factors resulted from intestinal barrier dysfunction. 
[142] Reports of microcirculatory changes in the pancreas, colon, liver and lungs, at 
different stages during severe acute pancreatitis also suggest that these contribute to 
the multiple organ dysfunction syndrome in acute pancreatitis. [162] Fluid depletion 
contributes to relative intestinal ischaemia and alters the pancreatic microcirculation, 
increasing pancreatic ischaemia and exacerbating the systemic inflammatory 
response syndrome (SIRS) leading to multisystem organ failure. [103] Ammori et 
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al. conducted a clinical study involving examination of the terminal ileum of three 
patients with severe acute necrotising pancreatitis who underwent pancreatic 
debridement and ileocolic resection, and seven control patients. They demonstrated 
significant atrophy of mucosal villi with reduction in mast cell numbers in patients 
who had severe necrotising pancreatitis compared with controls, and this correlated 
with an increase in intestinal permeability and bacterial translocation. [163]  
There are, therefore, several experimental and clinical studies that have 
demonstrated a clear association between the severity of acute pancreatitis and gut 
barrier dysfunction (tables 1 and 2), together with a plausible biological mechanism 
(bacterial translocation) that may lead to an exacerbation of the disease.  
 
1.5.2 Effect of nutrition on gut barrier function in acute pancreatitis 
Studies demonstrating a benefit of correcting gut barrier dysfunction mainly relate 
to the use of enteral nutrition. The historical management of severe acute pancreatitis 
involved allowing the pancreas and gut to rest as enteral nutrition (EN) was thought 
to stimulate the production and release of pancreatic enzymes and further aggravate 
retroperitoneal inflammation. [69] Extensive research has however recently shown 
that enteral feeding is safe, [164] [165] [166] and even beneficial as it protects 
against intestinal mucosal atrophy and bacterial translocation. [118] Prevention of 
gastrointestinal dysfunction is based on the recovery and maintenance of mucosal 
integrity, which requires adequate provision of oxygen and nutrients. [6] A 
systematic review of eight trials reported that in patients with acute pancreatitis, 
enteral nutrition significantly reduced mortality, multiple organ failure, systemic 
infections, and the need for operative interventions compared to patients who 
received total parenteral nutrition (TPN). [167] Kotani et al. similarly reported 
significantly less bacterial translocation and a lower blood endotoxin concentration 
in rodents treated with enteral nutrition rather than TPN. A difference in survival 
was however not seen. [168] A randomised prospective trial of patients with severe 
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acute pancreatitis who were treated with enteral nutrition demonstrated a reduction 
in septic complications. [165] Windsor et al. reported a reduction in septic 
complications, APACHE-II scores and CRP levels when patients were treated with 
enteral nutrition as opposed to TPN. An increase in serum IgM anti-endotoxin 
concentrations was found in the parenterally fed patients, but remained unchanged 
in those who had been fed enterally. [166] Early enteral feeding through the 
nasogastric route was found not to be inferior to the nasojejunal route in patients 
with severe acute pancreatitis. [169] One study of patients with severe acute 
pancreatitis who were treated with either enteral or parenteral nutrition, reached a 
contradictory conclusion when no significant differences were found between the 
two groups with respect to intestinal permeability, endotoxin levels or cytokine 
responses. A greater number of overall complications with enteral nutrition was 
however reported in this study. [170] A very recent published guideline for 
intensivists looked at various uses of enteral nutrition in critically unwell patients 
and concluded that they suggest using EN in patients with severe acute pancreatitis. 
[171] 
Combined nutritional therapy, consisting of enteral and parenteral nutrition, was 
found not to reduce intestinal permeability, infection rates or mortality. 
Hyperglycaemia and deranged liver enzymes also occurred more frequently. [172] 
A recent published review reports that the goal of nutritional support in acute 
pancreatitis is to reduce inflammation, prevent nutritional depletion, correct a 
negative nitrogen balance, and improve outcomes.  Nutrition maintains the integrity 
of the gut barrier, decreases intestinal permeability, downregulates the systemic 
inflammatory response, maintains intestinal microbiota equilibrium, and reduces the 
complications of the early phase of SAP, improving morbidity and possibly 
improving mortality. [173] 
A study of 70 patients with severe acute pancreatitis randomly divided subjects into 
two groups including a group of patients having parenteral nutrition and a group that 
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had enteral nutrition. Changes in IP were subsequently assessed. Interestingly, 
before the intervention, both groups had similar levels of serum endotoxin and 
lactulose/mannitol ratios. One and two weeks after the intervention, the serum 
endotoxin level and the lactulose/mannitol excretion rate of urine of the group with 
PN were significantly higher than the group EN. [174] 
 
1.5.3 Effect of fluid resuscitation on gut barrier function in acute pancreatitis  
Fluid replacement is crucial in severe acute pancreatitis, as patients may develop a 
vascular leak syndrome which results in hypovolaemia and hypotension that can in 
turn lead to renal complications. Early fluid resuscitation is associated with a 
reduced incidence of SIRS and organ failure at 72 hours. [103] A study comparing 
the effects of different resuscitation fluids demonstrated that a combination of 
normal saline, hydroxyethyl starch and glutamine was more efficient in resuscitating 
patients with severe acute pancreatitis (SAP) (by relieving inflammation and 
sustaining the intestinal barrier) than normal saline alone. [175] However, in a 
separate study looking at the effect of glutamine on gut permeability, no significant 
effect was identified with respect to inflammation, endotoxemia or infectious 
complications in severe acute pancreatitis. [176] A recent review of AP substantiates 
that the foundation of management remains early aggressive fluid resuscitation. 
Lactated Ringer's solution is the recommended fluid. The fluid resuscitation is 
monitored with a combination of blood urea nitrogen, haematocrit, and urine output, 
monitoring every 4 to 6 hours in first 24 hours of resuscitation to adjust the fluid 
rate. Continued non-response indicates a high likelihood of ensuing multi-organ 
failure and is grounds for upgrading the level of care. [87] 
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1.5.4 Effect of antibiotic therapy on gut barrier function in acute pancreatitis 
Many clinicians have advocated the use of prophylactic antibiotic therapy in patients 
with acute pancreatitis in whom there is necrosis or proven infection. [69] The 
choice of antibiotic seems most frequently to be imipenem or a quinolone, due to 
good pancreatic tissue penetration and a broad spectrum of activity against enteric 
organisms. [177] In one study of patients who had severe acute pancreatitis, subjects 
randomly received either standard therapy or selective decontamination with oral 
amphotericin or norfloxacin. Pancreatic infection with necrosis and mortality were 
significantly decreased in the treated group. [178] 
Significant controversy remains with regards to antibiotic use however, and a 
number of large multi-centre randomised, controlled trials have found no evidence 
to support their use. The use of ciprofloxacin and metronidazole in patients with 
pancreatic necrosis resulted in no differences in the rates of infected or systemic 
complications, or mortality, in patients who received antibiotic prophylaxis 
compared to those who did not. [179] A recent review confirmed no clinical benefit 
or reduction in morbidity or mortality from administering prophylactic antibiotics to 
patients who had severe acute pancreatitis. The use of antibiotics was however 
recommended in patients who had severe acute pancreatitis and multi-organ failure 
at admission; in patients with shock; for patients who developed acute respiratory 
distress syndrome, pancreatic necrosis or clinical signs of sepsis during the course 
of their disease; and for patients with positive cultures from any source. [92] False 
negative blood cultures in septic patients make the latter more difficult. [180]  
Early evidence from animal studies and a small placebo-controlled trial suggested 
that probiotic prophylaxis stabilised intestinal barrier dysfunction, minimised 
bacterial translocation and reduced infectious complications. [181] [182] A major 
randomised placebo-controlled trial of probiotic prophylaxis in severe acute 
pancreatitis however contradicted these findings and demonstrated a significant 
increase in mortality associated with probiotic administration (due to small bowel 
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ischaemia and jejunal necrosis), and showed no reduction in infection rates. [35] The 
role of probiotics was also in the process of being evaluated in a smaller scale study, 
but this trial was terminated prematurely due to the findings of the prior probiotic 
trial. However, from the 50 patients who were included prior to termination, no 
significant benefit of probiotics was seen on gut permeability or endotoxaemia in 
acute pancreatitis. [183] Several recent reports have shown that probiotics can 
reverse the leaky gut by enhancing the production of tight junction proteins; 
however, additional and longer-term studies are still required. Conversely, 
pathogenic bacteria that can facilitate a leaky gut and induce autoimmune symptoms 
can be ameliorated with the use of antibiotic treatment. Therefore, it is hypothesized 
that modulating the gut microbiota can serve as a potential method for regulating 
intestinal permeability and may help to alter the course of autoimmune diseases in 
susceptible individuals. [184] 
Selective bacterial decontamination of the gut and early enteral feeding have 
therefore failed to make a significant impact on the clinical course of severe acute 
pancreatitis and do not appear to prevent bacterial translocation. [185] 
Thus, on review of the evidence and with particular focus on the PROPATRIA trial, 
probiotics are not recommended for use in patients with acute pancreatitis, though it 
is arguable that an alteration of the gut bacterial load with ‘healthy bacteria’ should 
enhance. The outcomes of the studies have to be considered carefully as the patients 
affected are likely to have been acutely unwell individuals with multiple factors 
contributing to morbidity and mortality and an element of chance may be 
contributory to the reported outcomes. 
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1.5.5 Effect of immunonutrition on gut barrier function in acute pancreatitis  
Enterocytes are major consumers of glutamine as an energy source and the 
exogenous administration of this amino acid is associated with increased villus 
height and DNA content, improved intestinal perfusion and decreased bacterial 
translocation. [6] [186] Arginine is an antecedent of nitric oxide and targets intestinal 
blood vessels improving gut ischaemic conditions, restoring intestinal mucosal 
integrity and also promoting immune function. [118] Zou et al. therefore 
investigated the use of enteral immunonutrition (EIN) in experimental pancreatitis 
in pigs, by adding glutamine and arginine to the conventional enteral feeding 
regimen along with probiotics. [118] Pigs with severe acute pancreatitis which were 
treated with TPN demonstrated clear changes in villus architecture and disruption of 
the gut barrier. The villi of pigs which were treated with EN or EIN however showed 
normal architecture. EIN was seen to improve villus height and mucosal thickness, 
suggesting that it can prevent mucosal atrophy, extend absorptive capacity and 
maintain villus integrity. [118] Those pigs which were treated with EN and EIN 
showed a decrease in intestinal permeability after a plateau phase. This was 
particularly enhanced in the EIN group. [118] A prospective, randomised clinical 
trial has also demonstrated favourable responses following the administration of 
EIN. The diet in this study included arginine, omega-3 fatty acid, and an RNA-
enriched enteral diet. [187] Qin et al. also reported positive outcomes related to gut 
permeability and reduced septic complications with EIN. Their adjunctive treatment 
was Lactobacillus plantarum, a bacterial species which has been documented to 
have strong anti-inflammatory and immunomodulatory effects. [188] 
EN therefore enhances intestinal perfusion, preserves mucosal mass and intestinal 
microbial ecology, and has been shown to reduce septic morbidity in high-risk 
patients. [189] Addition of immunonutritional factors seems to add significant 
benefit. Its administration in patients with severe acute pancreatitis is safe and 
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feasible, and has been shown to significantly reduce systemic inflammation and 
septic complications. [107] 
 
1.5.6 Potential therapeutic targets of gut barrier function in acute pancreatitis 
Preservation or restoration of gut barrier function may have a beneficial effect on 
sepsis related morbidity in acute pancreatitis and may reduce mortality. [107] 
Several factors which are thought to maintain or reverse integrity of the gut barrier 
have therefore been investigated for their therapeutic potential in experimental 
models. These are summarised in table 2. Few human studies have however been 
carried out to date. A randomised double blind, placebo-controlled study in 1995, 
assessed the effects of Lexipafant, a platelet activating factor (PAF) inhibitor and 
demonstrated a reduction in the incidence of organ failure and in serum IL-8 and IL-
6 concentrations. [190] These findings were replicated in Scotland in a similar study 
that was undertaken in eleven hospitals. [191] A subsequent larger randomised, 
double blind, placebo controlled, multicentre trial investigated this same mediator, 
but no effect on organ failure or mortality was demonstrated. More rapid decreases 
in serum IL-8 and E-selectin levels were seen, but no differences in absolute levels 
were observed. [192] Continuous blood purification (CBP) has been shown to 
improve gut barrier dysfunction through improvement of cytoskeletal instability and 
by downregulating inducible nitric oxide synthase, through the removal of excess 
pro-inflammatory factors. [62] A prospective study of 40 patients with sustained 
severe acute pancreatitis who were given traditional Chinese medicine (Dachengqi 
decoction) has also been reported. The Chinese herbal medicine was given to half of 
the cohort and, when compared to controls, treated patients showed a significant 
improvement in intestinal permeability and a significantly lower incidence of 
multiple organ dysfunction syndrome and pancreatic infection. [193]  
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1.5.7 Interventional Treatments in acute pancreatitis 
Local complications of pancreatitis include early peripancreatic fluid collection and 
pancreatitic /peripancreatic necrosis (less than 4 weeks), and late pancreatic 
pseudocyst and walled-off necrosis (more than 4 weeks). Acute peripancreatic fluid 
collection resolves spontaneously in most cases, and less than 10% result in 
pancreatic pseudocysts. Most of these pseudocysts resolve with observation alone 
with periodic radiological follow-up. Drainage is only recommended in 
symptomatic, infected or rapidly enlarging pseudocysts. The drainage modalities 
include endoscopic or open, the endoscopic approach being the preferred modality. 
[87] 
The management of necrotic collections remains challenging. If sterile, intervention 
becomes necessitated if it causes symptoms such as persistent abdominal pain, 
nausea, vomiting, gastric outlet obstruction, bowel obstruction or disrupted 
pancreatic duct. A third of this necrosis become infected. Infection results in clinical 
deterioration, lengthens the recovery and is associated with high mortality. 
Antibiotics are required when infected necrosis develops. Diagnosis of infected 
necrosis is established in the presence of gas bubbles within on imaging and CT-
guided percutaneous aspiration culture. Surgical necrosectomy is needed if patients 
continue to deteriorate clinically despite antibiotics. In stable patients, antibiotics are 
continued for 4 to 6 weeks and necrosectomy performed after the wall matures. The 
initial approach includes less invasive modalities which include endoscopic and 
percutaneous drainage and surgical debridement is reserved for unsuccessful cases. 
Further management depends upon the aetiology of pancreatitis. In 
gallstone pancreatitis, early cholecystectomy is strongly recommended. Early ERCP 
(within 24 hours of presentation) is of benefit in cases of concurrent cholangitis and 
obvious biliary obstruction. 
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1.5.8 Intestinal permeability and severity of acute pancreatitis 
Detection of an increase in endotoxaemia has been documented in patients with 
severe pancreatitis. Serum tumour necrosis factor concentrations are also correlated 
with disease severity and endotoxaemia and this cytokine has been proposed as a 
potential prognostic marker. [194] [140] Ammori et al. demonstrated that plasma 
levels of calcitonin precursors on the day of admission may predict disease severity 
more accurately than the APACHE II scoring system. [195] Cytokines, endotoxin, 
mast cells and mediators such as platelet-activating factor, oxygen free radicals, 
adhesion molecules and polymorphonuclear enzymes are all produced and liberated 
from pancreatic tissue in response to acinar cell necrosis. They contribute to early 
pancreatitis-induced systemic epithelial barrier dysfunction. [104] [196] Endotoxin 
also penetrates the epithelial mucosa when intestinal permeability increases. In 
response to reports of the correlation between endotoxin and the development of 
multi-organ failure, Windsor reported a series of 33 patients and showed that the 
initial trend in Acute Physiology Score and the concentration of endogenous IgG 
antiendotoxin core antibody, though not direct endotoxin, provided a means of 
identifying patients who had acute severe pancreatitis and were at high risk of 
developing multi-organ failure. [197] A similar study demonstrated that the presence 
of endotoxaemia accompanied by a fall in antiendotoxin antibody titres predicted 
poor outcome in patients with acute pancreatitis. [198] Gianotti postulated that once 
enteric bacteria reach pancreatic tissue, they can trigger an infection that can worsen 
the course of the disease. The worsening of pancreatitis might promote further 
passage of bacteria and endotoxin from the gut lumen and promote a self-
perpetuating septic state. [199] Acute pancreatitis also resulted in increased 
intestinal permeation and the magnitude of this permeation correlated with disease 
severity in an experimental animal model. [200] Another similar study involving 
experimental pancreatitis reported increases in intestinal permeability which 
correlated with increases in plasma endotoxin concentrations and bacterial 
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translocation. Electron microscopy of ileal mucosa showed shortened microvilli and 
discontinuous tight junctions when compared to the normal villus cells of control 
rats. [201] Luan et al. demonstrated a significant increase in intestinal tissue high-
mobility group box 1 (HMGB1) concentrations in rats which had severe acute 
pancreatitis. [116] Hotz et al. demonstrated that impairment of colonic capillary 
blood flow correlated with increased intestinal permeability, occurred early in acute 
pancreatitis and correlated with disease severity.  
A number of clinical studies have also demonstrated a relationship between 
increased intestinal permeability and the severity of acute pancreatitis. Some of these 
studies have also identified potential markers that correlate with the severity of 
disease. To date none of these have been brought into routine clinical practice. These 
studies have been summarised in Table 2.
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1.5.9 Cytokines in Acute Pancreatitis 
Inflammatory cytokines are thought to play a major role in the pathogenesis of 
pancreatitis and the inflammatory response. A number of studies have therefore 
investigated the roles of individual cytokines as potential biomarkers in acute 
pancreatitis, but there are fewer reports in which more global changes in cytokine 
expression in acute pancreatitis have been assessed. The measurement of cytokine 
concentrations appears to provide a more accurate and objective method for the 
assessment of the severity of acute pancreatitis. In cases of acute pancreatitis with 
limited extent of injury, spontaneous resolution of the inflammation occurs. When 
inflammation persists, mediators are released into the circulation leading to the 
malfunction of various organs and a systemic inflammatory response. 
After the initial acinar cell injury, local and systemic inflammatory responses are 
triggered. Inflammatory cells migrate into the interstitium by adhering to the 
endothelium and escaping from the microcirculation. The mechanisms by which 
inflammatory cells adhere to endothelial cells are determined by a variety of 
mediators or cytokines which are released at sites of tissue damage. Cytokines hold 
the key to both the local and the systemic inflammatory responses in acute 
pancreatitis. The inflammatory process results in excessive leukocyte activation and 
increased migration of neutrophils to the inflamed area, with a consequent release 
of pro-inflammatory mediators including interleukins (IL-1b, IL-6, IL-8, IL-10, IL-
18) and TNF-α. (Figure 4) These mediators have been shown to influence the 
progression of a pancreatic infection to necrosis and consequently to SIRS and 
multi-organ failure. [202] Monocytes produce interleukin (IL)-6, a pro-
inflammatory cytokine which is known to be involved in the pathogenesis of acute 
pancreatitis. Through the subsequent release of CRP, it is one of the most useful 
parameters for predicting the severity of an episode of acute pancreatitis. 
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Figure 4. Schematic diagram to summarise the involvement of various cytokines in acute pancreatitis.  
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Interleukin-12 is also produced by monocytes and is a well-known inducer of the T-
helper (Th) 1 cell immune response whereby T cells are induced to secrete interferon 
(IFN)-γ, IL-2 and TNF-α. The T lymphocytes secrete immunomodulatory cytokines 
that regulate the development and effector functions of their subset Th1 and Th2 
cells. One study of immunological parameters in acute pancreatitis showed that the 
T-cell population is affected in pancreatitis and that CD4+ and CD8+ T-cell numbers 
are significantly reduced. The percentage of IL-6-producing monocytes was 
significantly higher in patients with acute pancreatitis. [203] Interleukin 6 is the 
principal mediator of the acute phase protein response and may be a natural host 
defence mechanism. It is an excellent marker of the severity of acute pancreatitis 
with peak concentrations (three to six times baseline) occurring at 48 hours and 
preceding rises in serum concentrations of the acute phase protein C-reactive 
protein. Values correlate with disease severity and predict outcome. [204] [205] A 
further study also showed that IL-6 had the highest significance as a predictor of 
acute pancreatitis severity. [206]  
A study investigating serum TNF-α concentrations in acute pancreatitis did not find 
a significant increase between patients who had acute pancreatitis and controls, but 
did report increased expression of this cytokine when compared with patients with 
CP. Elsewhere it has been reported that tumour necrosis factor-alpha is detectable in 
the serum of 10-40% of acute pancreatitis patients and it is an appropriate target for 
anti-cytokine therapy in acute pancreatitis. TNF-α is a pleiotropic predominantly 
macrophage-derived cytokine that is thought to be involved in pathophysiological 
responses in cases of severe injury or sepsis, providing an autocrine and paracrine 
signal. [194]   
TNF- α is among one of the inflammatory cytokines that is produced once necrosis 
develops. Nuclear factor –кB (NF-кB), a transcription factor associated with early 
gene activation, plays a critical role in the development of necrosis and, TNF-α is a 
cytokine primarily derived from macrophages which plays a major role in formation 
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of many pathophysiological responses of the organism to injury or disease. Systemic 
symptoms in septic shock, which is associated with increased TNF-α level, shows a 
close resemblance in patients with severe acute pancreatitis. [207]All of this kind of 
complications may be due to cellular response such as excessive neutrophil 
activation, increased capillary permeability and direct cellular toxicity. Current 
research is working towards TNF as a potential target for therapy in AP since 
blocking the production and the effects of this cytokines is a strategy that makes 
sense in its treatment. A recent case report however reports a case of AP induced by 
the very agent to be considered in its treatment, infliximab, a monoclonal anti-TNF-
α antibody. [208] 
It is considered that TNF-α increases the vascular permeability by a direct effect on 
vascular endothelium and also by indirect mechanisms involving leukocytes. In this 
way it increases the collection and activation of leukocytes in inﬂammation area. It 
is known that activated leukocytes secrete various mediators under the effect of 
TNF-α which is known to increase the vascular permeability. [209] 
Innate immune cells and mediators are intrinsically linked to the pathogenesis of AP. 
Cathelicidins are innate immunity-derived antimicrobial peptides that exert 
immunomodulatory effects on various host cells. How cathelicidins are involved and 
modulate the severity and inflammatory responses of AP remains unclear, but a 
recent study in experimental acute pancreatitis using CRAMP gene-deficient 
cnlp-/- mice and their wild-type C57BL/6J littermates demonstrated that 
cnlp-/- mice exhibited a more severe phenotype and inflammatory response 
following AP induction compared with the wild-type mice, as evidenced by 
increased serum amylase levels, pancreatic myeloperoxidase release, and early 
inflammatory mediator TNF-α production. Histological examination confirmed that 
CRAMP deficiency worsened the pancreatic inflammatory condition. These results 
indicate that CRAMP may be considered a novel modulatory mediator in mouse 
experimental AP. [210] 
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Platelet activating factor (PAF) is a potent biological mediator that exerts its effects 
in a variety of cells and tissues. PAF primes polymorphonuclear (PMN) white cells 
and acts as a mediator for the interaction between PMN cells and endothelial cells, 
facilitating the migration of activated white cells into tissue spaces. [204] As 
described above, a platelet activating factor (PAF) inhibitor, Lexipafant, 
demonstrated a reduction in the incidence of organ failure in patients with severe 
acute pancreatitis. Seven of 12 patients with severe acute pancreatitis who received 
Lexipafant recovered from organ failure compared with only two of 11 patients with 
severe acute pancreatitis who had placebo. The study suggested a rationale for 
further clinical trials with the potent PAF antagonist Lexipafant in human acute 
pancreatitis. [190] Interleukin 1 is regarded as an early inducer of many of the 
systemic and acute phase responses to injury. It is difficult to measure in serum and 
its natural antagonist, interleukin 1 receptor antagonist may more accurately reflect 
the degree to which IL-1 stimulation has occurred.  IL-1 and TNF-α are thought to 
induce the release of IL-6 and IL-8. [211] 
IL-8 has been reported to show increased expression in the early phase of acute 
pancreatitis. It is released by many cell lines in the presence of activated neutrophils 
and is considered to be one of the main secondary mediators of TNF-α induced 
neutrophil activation. It is a polymorphonuclear cell activating peptide and seems to 
be the earliest cytokine to appear in the serum of patients with acute pancreatitis and 
is reported to correlate with severity of disease. [212] 
Interleukin-10 is a naturally occurring anti-cytokine that inhibits several functions 
of macrophages including tumour necrosis factor and IL-1 production and the 
release of oxygen free radicals. Like IL-1ra, it is a naturally occurring inhibitor. In 
experimental acute pancreatitis in mice, recombinant IL-10 reduced acinar cell 
necrosis and tumour necrosis factor mRNA expression. [204] It has an anti-
inflammatory role inhibiting the synthesis and release of other pro-inflammatory 
cytokines and free oxygen radicals from macrophages and T-helper lymphocytes. 
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On the other hand, it shows a positive effect on the proliferation and differentiation 
of B lymphocytes and promotes the production of immunoglobulins. [206] 
IL-1 and IL-6 are thought to induce the synthesis of C-Reactive Protein (CRP) by 
hepatocytes in acute pancreatitis. CRP is currently the most clinically used non-
specific inflammatory marker in acute pancreatitis patients, but a delay is often seen 
in its increase, and this can be explained by this secondary release. [202] TNF-α, IL-
1b and IL-8 can stimulate the release of MMP-9, which damages basement 
membranes and alters intestinal permeability. [211] Other mechanisms for the 
alteration in epithelial permeability have also been investigated and proposed. One 
such study has reported that IFN-γ acts synergistically with IL-1b and TNF-α to 
induce the functional expression of NO synthase and therein provide a mechanism 
to induce intestinal epithelial hyperpermeability. [52] A more recent study reports a 
T-helper 1 profile that was associated with severe AP and a T-helper 2 profile with 
mild or moderately severe AP. The same authors also report an IL13/IFNγ ratio of 
potential value to predict the prognosis in AP. [213] 
Our own research group undertook a meta-analysis on the value of 
carboxypeptidase-B activation peptide in predicting severity of acute pancreatitis on 
admission. We concluded that both serum and urinary CAPAP have the potential to 
act as a stratification marker on admission in predicting severity of acute 
pancreatitis. [83] 
This brief overview of cytokines expressed in acute pancreatitis demonstrates that 
both pro-inflammatory and anti-inflammatory cytokines are released during the 
disease process. Pro-inflammatory mediators in acute pancreatitis include TNF-α, 
IL-1, IL-2, IL-6, and IL-18, and IL-8, platelet-activating factor, and reactive-oxygen 
and reactive-nitrogen species. With the release of these pro-inflammatory mediators, 
anti-inflammatory cytokines are concomitantly produced, leading to a compensatory 
response syndrome. High circulating concentrations of the anti-inflammatory 
mediators such as TNF-α receptors, IL-10, and IL-1ra have also been documented 
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in acute pancreatitis. [214] Thus, a number of inflammatory mediators have been 
shown to be involved in the development of acute pancreatitis. The pathways of 
damage are similar, whatever the aetiology of pancreatitis, with three phases of 
progression: local acinar injury, systemic response, and generalised sepsis. The pro-
inflammatory response is countered by an anti-inflammatory response, and an 
imbalance between these two systems leads to localised tissue destruction and 
distant organ damage. [215] Cytokines are involved in all aspects of the cascade 
leading to systemic inflammatory response syndrome and multiple organ 
dysfunction syndrome and indeed also in the release of mediators that are likely to 
exacerbate alterations in intestinal permeability. 
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1.6 Chronic Pancreatitis 
To support a study looking at acutely unwell patients, we were required to establish 
protocols in more stable patients with reported changes in intestinal barrier function. 
We thus undertook a pilot study looking at patients with CP and CLD, both with 
literature reporting alterations in gut permeability.  
Chronic pancreatitis is a disease with an incompletely understood pathogenesis that 
features progressive inflammatory change in the pancreas, resulting in progressive, 
permanent structural damage. Chronic pancreatitis should be in the differential 
diagnosis of a patient with typical features of epigastric pain with radiation to the 
back, steatorrhea, weight loss, or recurrent acute pancreatitis. It is characterized by 
atrophy and fibrosis of the exocrine tissue with or without chronic inflammation. 
[216]  
As expressed in the guidelines and in a recent retrospective study, there needs to be 
more stringent application of the systems used for diagnosing chronic pancreatitis 
with revision of the current terminology 'indeterminate', 'suggestive', 'possible', and 
'early' chronic pancreatitis. A number of patients with chronic abdominal pain 
syndrome find themselves with a label of chronic pancreatitis despite minimal 
changes on EUS. [216] 
Intestinal permeability changes have been reported, though limited, and will be 
described in the following section. The disease is associated with increasing 
exocrine insufficiency (steatorrhoea) and often later endocrine dysfunction 
(diabetes), with progressive fibrosis and atrophy. [217] Prevalence has been reported 
to be approximately 30 per 100,000 and is higher in populations which have a high 
alcohol intake. The incidence varies from 5-11 per 100,000 in men to 2-3 per 
100,000 in women. [218-221] As a result of increased alcohol consumption, the 
disease has an increasing incidence. The commonest cause is long-standing 
excessive ethanol consumption, [222] [223] followed by hypertriglyceridemia, 
autoimmune pancreatitis, and disease caused by genetic abnormalities (e.g. 
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hereditary pancreatitis caused by mutations of the cationic trypsinogen gene, 
PRSS1) or in association with genetic abnormalities (e.g. mutations of the cystic 
fibrosis transmembrane conductance regulator, CFTR, or serine protease inhibitor 
Kazal type 1, SPINK-1). [224] About 10% of cases are idiopathic. [219] 
Morphologically, chronic pancreatitis is characterised by loss of tissue parenchyma, 
especially acinar cells, an inflammatory infiltrate and varying amounts of fibrosis 
that hardens and distorts the gland and its surroundings. [91] Pancreatic stellate cells 
are the mediators of fibrosis in the pancreas, and lead to the formation of 
extracellular matrix in interstitial spaces. [225] This process leads to progressive loss 
of the lobular morphology and structure of the pancreas, deforming the large ducts 
and leading to changes in the islets. This pancreatic fibrosis is initiated by injury to 
the pancreas, the mechanism of which depends on the underlying disease aetiology. 
The exact pathogenesis of chronic pancreatitis is unknown, but several hypotheses 
have emerged as to its mechanism, reflecting the different processes that may apply 
due to the variety of different aetiological factors implicated in the disease. [226] 
The diagnosis of chronic pancreatitis is often difficult because symptoms are 
frequently non-specific, there is no reliable means to identify early disease and more 
advanced disease can often only be confirmed by complex imaging. Due to the deep-
seated retroperitoneal nature of the organ, histological diagnosis is awkward and 
requires specialist input. [91] Diagnostic imaging studies include endoscopic 
ultrasound (EUS), more recently with endoscopic ultrasound elastography with or 
without contrast, endoscopic retrograde cholangiopancreatography (ERCP), 
computerised tomography (CT) and magnetic resonance imaging (MRI) with MR 
cholangiopancreatography (MRCP). [227] [228] Ultrasound and CT are best for the 
late findings of chronic pancreatitis but are limited in the diagnosis of early or mild 
pancreatitis. Intraductal pancreatic calcifications are the most specific and reliable 
sonographic and CT signs of chronic pancreatitis. [229] CT is helpful for the 
diagnosis of complications of chronic pancreatitis and for other conditions that can 
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mimic chronic pancreatitis. [216] Compared to US and CT, MRI is a more sensitive 
imaging tool for the diagnosis of chronic pancreatitis. Ductal abnormalities are very 
specific and reliable MRI signs of chronic pancreatitis. Signal intensity changes in 
the pancreas, seen on MRI, may precede ductal abnormalities and suggest early 
chronic pancreatitis. Stimulation of the pancreas using IV secretin may improve the 
diagnostic accuracy in the detection of ductal and parenchymal abnormalities seen 
in chronic pancreatitis. [216] MRCP is increasingly being used, as it is a safe, non-
invasive modality, does not involve radiation, and does not cause acute pancreatitis. 
[230] After secretin injection, duodenal fluid volume can be calculated and used as 
a marker of secretory function. Endoscopic Ultrasound (EUS) has an increasing role 
in the diagnosis and management of chronic pancreatitis. EUS in some studies has 
been shown to be as effective as ERCP in diagnosing CP. [231] EUS can also 
demonstrate abnormalities in many individuals without definite ERCP features. 
[232] It allows high resolution imaging of both the parenchyma and pancreatic ducts. 
Experienced clinicians can detect early stage CP with good inter-observer agreement 
(92%). [232] Recent guidance has been given in the diagnosis of CP using EUS; this 
is referred to as the Rosemont classification.[233] The gold standard for diagnosis 
of chronic pancreatitis is histopathology, but this is rarely available unless surgery 
has been undertaken. [234] The diagnosis of advanced CP may be more 
straightforward if there are calcifications within the gland. These may be picked up 
with a plain abdominal X-ray, although calcifications are not completely exclusive 
to CP. [235, 236] Calcifications typically develop years after the onset of symptoms 
in alcoholics (median 8.7 years) and even longer in early onset idiopathic 
pancreatitis (24.9 years). [237] The main diagnostic challenge is detecting early 
stage disease.  
Indirect pancreatic function tests generally are sensitive for steatorrhea, and useful 
in quantifying the degree of exocrine insufficiency. They are moderately sensitive 
and specific for diagnosing advanced chronic pancreatitis, but are less so for 
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diagnosing early chronic pancreatitis. The faecal elastase assay, can be limited in 
specificity. Faecal chymotrypsin may be useful in detecting compliance with 
exogenous pancreatic enzyme supplementation. Faecal fat assays are sensitive for 
steatorrhea but are of limited utility due to the cumbersome nature of patient 
collection and lab handling of samples. In addition, strict adherence to dietary 
recommendations for several days is required. Direct pancreatic function tests have 
high sensitivity for detecting late chronic pancreatitis, but lower sensitivity for early 
chronic pancreatitis. The traditional secretin and CCK tests performed with the oro-
duodenal tube pancreas fluid collection are highly accurate, but require fluoroscopy 
for confirmation of tube placement and are not widely utilized. An endoscopic 
pancreatic function test can also be considered. As structural severity worsens in CP, 
exocrine function declines and pancreatic function tests correlate accordingly as do 
EUS findings. [216] 
Direct pancreatic exocrine function tests have been acknowledged as reliable 
confirmatory methods to diagnose or exclude chronic pancreatitis. Tube-based 
versions of these tests measure the organ’s secretory capacity (enzymes and/or 
bicarbonate) in response to hormonal stimulants (cholecystokinin [CCK] and/or 
secretin). Measurement of the concentrations of cytokines and other pro-
inflammatory molecules in pancreatic secretions has also been proposed, but has not 
yet been substantiated.  The sensitivities of pancreatic function tests depending on 
duodenal intubation to sample pancreatic juice range from 72-94%, with specificity 
of 80-90% when compared with histology. Unfortunately, due to the prolonged 
duodenal intubation times required and technical demands of tube-based pancreatic 
function testing, this approach has fallen out of favour and is no longer available in 
the UK. [227] Elsewhere, notably in the USA, endoscopic sampling of duodenal 
juice collected after pancreatic stimulation has been developed and is now available 
in several centres, but this approach samples for shorter periods than the original 
tube-based tests (15 min compared to over two hours), is labour intensive and more 
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invasive, and has yet to be adopted in the UK. In the UK and elsewhere, tubeless 
pancreatic function tests are used such as faecal elastase activity and the 
Pancreolauryl test. However, these have lower sensitivities and specificities, and 
although they are more widely used, are less reliable. Thus a gold standard 
alternative test to those currently available would be an invaluable addition to the 
diagnostic algorithm for patients with suspected chronic pancreatitis. Endocrine 
testing does not feature as part of the diagnostic pathway in Chronic Pancreatitis. 
However diabetes is a well-recognised late feature of the disease. Little is known 
about pancreatic endocrine function before the development of DM in CP. A study 
of patients CP patients had higher fasting and random glucose levels, without a 
compensatory increase in insulin secretion suggesting subtle early islet dysfunction. 
Better understanding of the progression from endocrine dysfunction to diabetes 
mellitus is critical to develop screening tools for early detection and intervention. 
[216] 
Autoimmune pancreatitis accounts for about 5% of all pancreatitis, and it is 
associated with an increase in serum immunoglobulin G4 which is a diagnostic 
criterion. Interestingly, the gastric Helicobacter pylori infection has been shown to 
be associated with AIP. This bacterium is known to trigger immune responses 
against host tissues via several molecular mimicry pathways.  Other suggestions link 
bacterial infections with the development of AIP. In a mouse model, Escherichia 
coli induces a severe pancreatic inflammation and fibrosis similar to the human AIP. 
Numerous studies have reported that specific microbial antigens may trigger the 
development of AIP activating immune responses. [238]  
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1.6.1 Gut barrier dysfunction and bacterial translocation in chronic pancreatitis 
Reports of alterations in intestinal permeability, bacterial translocation and 
endotoxaemia in chronic pancreatitis are limited. In CP, increased IP has been 
reported in cystic fibrosis patients who have pancreatic insufficiency compared to 
those without, secondary to changes in intestinal epithelial tight junctions. [10] The 
concentrations of circulating cytokines have been associated with increased 
concentrations of pathogenic microbiota in the gut, and gut permeability. [11]  
Alterations of gut microbiota have been reported in pancreatic diseases.  In 
particular, the gut microbiota may be affected by malnutrition or impaired exocrine 
pancreas function that is associated with pancreatic diseases. [239] One recent study 
conducted a comprehensive analysis of gut microbiota in patients with type 1 
autoimmune pancreatitis, a pancreatic manifestation of the systemic IgG4-related 
disease, and chronic pancreatitis to enable a comparison between altered immune 
reactions in autoimmune pancreatitis and/ or long-standing malnutrition in CP and 
to assess the influence on gut microbiota.  Gut microbiota profiles were different 
between patients with AIP and those with CP; namely, the proportions of 
Bacteroides, Streptococcus and Clostridium species were higher in patients with CP, 
for reasons yet unknown.  Pancreatic diseases such as pancreatic cancer, chronic 
pancreatitis and autoimmune pancreatitis are often accompanied by pancreatic 
exocrine insufficiency which could affect the gut microenvironment and microbiota.  
It is reasonable to assume that altered immune reactions in AIP and long-standing 
malnutrition in CP modify the dysbiosis. [240]  
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1.7 Chronic Liver Disease 
Intestinal permeability changes in CLD have been reported and will be discussed in 
the forthcoming section. Cirrhosis is a consequence of chronic liver disease and is 
characterised by replacement of liver tissue by fibrosis, scar tissue and regenerative 
nodules leading to loss of hepatic function. Uncorrected long-term, this is likely to 
lead to portal hypertension and death from liver failure, variceal haemorrhage or 
malignant transformation (hepatoma / hepatocellular carcinoma). Cirrhosis is most 
commonly caused by excess alcohol consumption, hepatitis B or C infection, and 
non-alcoholic fatty liver disease (NAFLD), but also has many other autoimmune and 
metabolic causes. Some cases are idiopathic. It is difficult to estimate the exact 
prevalence of cirrhosis as there is often undiagnosed disease and previously 
undiagnosed cirrhosis is often found at post mortem examinations. The incidence of 
cirrhosis is estimated at approximately 7000 per year in the UK. An analysis 
published in the Lancet showed that between 1960 and 2002, total recorded alcohol 
consumption in Britain doubled. [241] Mortality in women from cirrhosis has also 
increased significantly.  
Patients with cirrhosis of the liver may present in a variety of ways and with various 
clinical findings. The history and physical examination can provide clues as to the 
presence of cirrhosis and suggest its aetiology. Routine laboratory tests are generally 
not diagnostic, but can suggest the presence of liver disease by means of an elevated 
prothrombin time and total bilirubin, and reduced platelet count and serum albumin 
with abnormalities in serum aminotransferase levels. Radiographic findings can also 
suggest the presence of cirrhosis by detecting the presence of complications such as 
ascites, hepatocellular carcinoma and hepatic or portal vein thrombosis, but are not 
adequately sensitive or specific to use as a primary diagnostic modality. A review of 
the treatment of liver disease and cirrhosis is outside the remit of this chapter. 
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   1.7.1 Gut barrier dysfunction and bacterial translocation in chronic liver disease 
Gut barrier dysfunction, endotoxaemia and bacterial translocation also compound 
liver disease severity, and lead to decompensation of cirrhosis as a result of 
spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome 
and variceal bleeding. [12] [13] [14] Immunomodulatory, cellular and molecular 
events lead to changes in intestinal tight junction proteins, cellular mechanisms 
which may lead to intestinal barrier disruption and hyper-permeability. Patients with 
hepatic encephalopathy show an altered intestinal microbiome, increased serum 
endotoxin levels, and increases in serum cytokine concentrations (particularly IL-6, 
TNF-α, IL-2, and IL-13). [15] There is considerable evidence to demonstrate that 
intestinal permeability increases in patients with liver cirrhosis, and that the 
impairment in intestinal barrier function may contribute to severe septic 
complications in these patients. Gut-derived complications in liver cirrhosis and 
altered intestinal permeability result in bacterial or endotoxin translocation-related 
systemic disorders such as spontaneous bacterial peritonitis, hyperdynamic state, 
portal hypertension, hepatorenal syndrome, hepatic encephalopathy, and multiple 
organ failure. [242] [243] This is further supported by studies which have shown 
significantly increased intestinal permeability in patients with ascites compared to 
healthy controls, as opposed to patients without ascites when compared with healthy 
controls. [244]  
Increased intestinal permeability is also thought to be a major risk factor for the 
development of acute on chronic liver failure and has been linked to disease 
progression and to infectious complications. However, it has not yet been 
systematically evaluated in this cohort of patients. A recent study evaluating urinary 
lactulose:mannitol ratios in such patients showed significantly higher intestinal 
permeability in patients with acute on chronic liver failure when compared to normal 
controls. This difference normalised post treatment, suggesting that gut permeability 
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improved in patients with chronic liver failure once the acute illness had resolved. 
[245]  
Different aetiologies of liver cirrhosis, including alcohol and obesity, are associated 
with different gut microbiota profiles and differing mechanisms of developing liver 
fibrosis. [246] [247] Alcohol abuse impairs the function of the intestinal barrier, 
which might enhance the translocation of bacterial toxins, thereby contributing to 
inflammatory processes in alcoholic liver disease. [248] Chronic endotoxin 
exposure, suggesting intestinal permeability alterations, has also been identified in 
patients with non-alcoholic steatohepatitis. [249] Cirrhosis per se has been shown to 
be associated with increased intestinal permeability as assessed by 
lactulose:mannitol ratios. [250] [251]  
Dysfunction of the intestinal epithelial barrier may therefore enhance the risk of 
translocation of bacteria and bacterial products into the systemic circulation, and 
thereby contribute to the pathogenesis of chronic liver diseases and the development 
of complications. [244] 
 
1.8 Gut barrier dysfunction and bacterial translocation in patients with a 
history of gastrointestinal surgery  
A few reports of gut barrier dysfunction post-surgery have been published, though 
those studies that have been reported tend to be limited to a period soon after an 
operation rather than after much time has elapsed. One such study investigated 63 
patients undergoing elective abdominal surgery and assessed bacterial culture, 
microbial DNA, plasma D-lactate and plasma endotoxin up to 2 days post-surgery. 
All patients were observed for a subsequent period of 30 days for infectious 
complications. The investigators concluded that increased intestinal permeability 
was closely related with bacterial translocation and that the latter occurred most 
commonly early after surgery. It was also postulated that postoperative SIRS and 
infection might bear a close relationship with bacterial translocation. [252] Increases 
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in intestinal permeability and endotoxaemia have also been reported during open 
cholecystectomy and in the peri-operative period. This study was also limited to 48 
hours post-surgery. [253] An operation directly involving the stomach and 
gastrointestinal tract, the Roux-en-Y gastric bypass has also been found to cause 
increased intestinal permeability in 16 morbidly obese patients at varying times, but 
this study also, demonstrated similar findings after 6 months. [254]  
Interestingly, cardiac surgery also appears to cause an increase in intestinal 
permeability and endotoxaemia. Findings were more pronounced in patients who 
became unwell and developed multiple organ dysfunction and, once again, long term 
follow up data were not reported. [255] [256] In the case of cardiac surgery, a further 
study did postulate a hypothesis for the observed alterations in gut permeability. 
Mean arterial pressure is reduced during hypothermic cardiopulmonary bypass, 
whilst maintaining generally acceptable levels of haemodynamic performance. This 
intestinal hypoperfusion may be responsible for the altered intestinal permeability 
that was observed. [257] Similarly, a significant increase in intestinal permeability 
has been reported in patients after elective and emergency major vascular surgery. 
It has been suggested that this was due to reperfusion injury rather than the ischaemic 
period of the intestine itself. [258] Again, lactulose:mannitol ratios were assessed up 
to 48 hours after the operation. 
It would be interesting to understand the mechanisms involved in altered intestinal 
permeability in patients who have undergone surgery of the gastrointestinal tract as 
well as the indirect effects from other forms of surgery. At present, the long-term 
effects of surgery on gut barrier function remain largely unknown and it would be 
useful to test whether the documented short-term alterations persist, increase or 
return to normal.  
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1.9 Techniques used to measure intestinal permeability 
Several tests have been developed to examine intestinal barrier function and these 
are summarised in Table 3. These tests take into account the epithelial barrier and 
intestinal permeability. [5] Other factors that need to be accounted for include: the 
concentration gradient; epithelial surface area; permeation time and the barrier’s 
permeability properties. [16] Most of the tests are non-invasive and involve 
measurements of changes in absorption and subsequent urinary excretion of specific 
non-metabolised compounds which have different sizes and routes of absorption. A 
small and water-soluble test substance is used as a probe and is administered orally. 
This substance must be quantitatively cleared by the kidney and excreted in the urine 
and a breach in the mucosal barrier causes an increase in uptake of the substance in 
the bowel and a subsequent increase in urinary excretion. [16] Due to pre and post 
mucosal influences on probes, a single test substance has been deemed an inaccurate 
indicator of permeability. The ratio of two substances with varying molecular 
weights is therefore now used instead. [18] Four major classes of probes are used: 
ethylene glycol polymers (PEG-400), oligosaccharides (lactulose), monosaccharides 
(mannitol), and radiolabelled chelates (Cr-EDTA). The probes cross the epithelial 
barrier by means of paracellular, transcellular aqueous, and transcellular lipid routes. 
The excretion ratio is expressed as a function of the two probes used. The smaller 
sugar is absorbed via the transcellular route, by active transport or simple diffusion, 
whereas the larger sugar diffuses passively via the paracellular route. Quantitation 
of the probe in a timed urine or serum collection provides a measure of the fraction 
of ingested probe that has penetrated the mucosal barrier. Only a small proportion 
of this large probe should get through the intestinal mucosa, reach the circulation, 
get filtered by the kidney and get measured in the urine over a defined point of time. 
If there is an abnormality in the paracellular transport; the passage of the probe is 
enhanced and thus more is excreted in the urine which suggests abnormality in the 
intestinal permeability. Intestinal permeability can be assessed using a variety of 
F 
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marker probes such as lactulose, mannitol, rhamnose and cellobiose, polyethylene 
glycol (PEG) 400, PEG 1000, 51Cr-EDTA and 99mTc-DTPA. Multiple mucosal 
and non-mucosal factors can affect the excretion of a single dose of a test probe and 
thus a dual sugar probe test is used for the assessment of intestinal permeability. This 
involves the simultaneous oral administration of a disaccharide and a 
monosaccharide and measurement of their excretion in urine over a defined period 
of time. Intestinal permeability is measured as the ratio of percentage of excretion 
of disaccharides/monosaccharides in the urine or serum. Expression of these 
excreted sugars as a ratio overcomes the individual variations of other factors. [18] 
The concentration of one or more sugar probe can be measured using enzyme assay, 
high performance liquid chromatography (HPLC), ion-exchange chromatography in 
combination with mass spectrometry and liquid chromatography with mass 
spectrometry. If the PEG has been used as a probe, then the concentration of the 
PEG can be assessed using capillary column gas chromatography. 
Lactulose and mannitol ratio is the most commonly used test for assessment of 
intestinal permeability and the most reliable method of measurement of 
concentration of lactulose and mannitol is HPLC. HPLC is a chromatographic 
technique used to separate a mixture of compounds with the purpose of identifying, 
quantifying and purifying the individual components of the mixture. [17] 
High pressure liquid chromatography (HPLC) for the determination of lactulose and 
mannitol in serum, as opposed to urine, 90 minutes after ingestion of a sugar 
solution, is another reported method. [19] 
In rodent models, intestinal permeability can also be measured by assessing the in 
vivo leakage of radio-labelled albumin or by the in vitro passage of smaller 
molecular markers using Ussing chambers. [259]  
More recently, the assessment of cell shedding from the epithelium of the villus tip 
has been proposed as a marker of intestinal permeability. Small intestinal epithelial 
gaps have also been identified in humans by means of confocal endomicroscopy. [4] 
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[26] An increase in the number and density of gaps has been demonstrated in patients 
with certain gastrointestinal conditions, as detailed below. The confocal 
endomicroscopy features associated with increased intestinal permeability can be 
rapidly identified with high inter- and intra-observer agreement. [260] 
 
1.10 Confocal Laser Endomicroscopy 
Confocal microscopy is a method used to obtain cross sectional images at a chosen 
microscopic level – a ‘slice’ – that is too small to be seen with the naked eye and 
shows the features of individual cells. The method uses chemicals that are loaded 
into cells and when these are excited with light of certain wavelengths, they emit 
light of different wavelengths, a phenomenon termed fluorescence. This fluorescent 
light is then used to generate an image which provides information about the nature 
of cells and their specific states, for example whether they are undergoing apoptosis 
or necrosis. The technique has been used for many years in laboratories around the 
world, and recently has begun to be used directly in patients for the diagnosis and 
treatment of disease.  
Confocal probes have now been put into endoscopes (confocal endomicroscopy) so 
that microscopic examination of the intestinal mucosa can be made. Work conducted 
using the technique of confocal endomicroscopy has identified epithelial gaps in the 
intestinal mucosa of mice and humans and their number increases dramatically in 
various inflammatory disease states. (Figure 5) [21] Administration of TNF- 
greatly increases the appearance of epithelial gaps, most likely through the induction 
of epithelial apoptosis. This process is reversed by the administration of anti-TNF-
α antibody, which prevents bacterial translocation in cirrhosis. [261] Trophic factors 
also reduce this process. [110, 154, 262, 263] Intestinal epithelial apoptosis has been 
demonstrated to be markedly increased in conditions associated with elevated 
cytokine levels, and this leads to increased intestinal permeability and barrier 
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dysfunction. [45, 106, 115, 264] Bacterial overgrowth [265] and loss of tight 
junctions [45] have been ruled out as explanations for this process.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Confocal imaging of intact 
small intestine and effect of TNF-α seen 
with acriflavine stain: (A) Human ileal 
villi showing epithelial gaps; (B) Villi at 
higher power; (C) Villi at deeper tissue 
plane. Figure courtesy of Keisslich et al. 
[4] 
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Table 3. Gut permeability tests 
Gut epithelial barrier integrity Mechanisms Specificity Notes 
I-FABP 
I-FABP is a small cytosolic protein (14-15 kDa) exclusively expressed on the tops of villi in 
mature enterocytes and is rapidly released into circulation upon enterocyte damage 
Enterocyte necrosis 
Non-invasive (blood/urine); Gut 
specific 
Serum DAO 
DAO is an enzyme that catalyses the oxidation of diamines, in human and rodents, DAO 
specifically located at mature villous cells in intestinal mucosa 
Integrity and 
maturity of small 
intestine mucosa 
Non-invasive (blood); Gut 
specific 
αGST 
αGST is predominately expressed in liver, kidney and intestine. It belongs to GSTs families 
which conjugate a range of toxic and foreign compounds within the cell to glutathione 
executing cell protection, antioxidation and detoxification activities 
Intestinal epithelial 
cell damage 
Non-invasive (blood); Not gut 
specific 
Tight junction proteins (ZO proteins, 
claudin proteins and F-actin) 
Tight junction proteins are components that form paracellular intestinal barrier 
Paracellular 
intestinal barrier 
damage 
Non-invasive (blood); Despite 
predominately gut origin but 
may involve other sources 
Functional assessment  
L/M ratio; PEGs; D-Xylase; L/R 
ratio; Multisugar probes; 51Cr-EDTA 
Large size molecules would traverse the epithelium by paracellular pathways via tight 
junction if it is impaired 
Paracellular 
intestinal barrier 
damage 
Non-invasive (urine); Consider 
pre-/post-mucosal, mucosal 
conditions for test used 
L-citrulline 
L-citrulline is a nonprotein amino acid almost entirely generated by enterocyte in small 
intestine from glutamine 
Enterocyte mass 
loss or dysfunction 
Non-invasive (blood); Gut 
specific; Circulating levels 
confounded by renal function 
Gastric mucosal PiCO2 
Increase in gastric CO2 production is associated with anaerobic metabolism in the regional 
splanchnic perfusion 
Gut mucosal 
perfusion 
Reflecting regional splanchnic 
perfusion status; Invasive; Not 
organ specific 
Intestinal epithelial cell shedding 
Intestinal epithelial cells are constantly shed leaving gaps in the epithelial monolayer. In 
inflamed mucosa, the sealing mechanism fails with loss of barrier function 
CLE: fluorescein 
leakage by CLE 
Invasive procedure requiring 
trained endoscopist 
Bacterial translocation (BT)  
Endotoxins 
Bacterial components such as lipopolysaccharides are increased when commensal bacteria 
translocate into circulation 
Direct evidence of 
BT 
Non-invasive (blood); Relative 
low sensitivity 
DNA/RNA Bacterial breakdown products 
Direct evidence of 
BT 
Non-invasive (blood); Technique 
demanding 
EndoCAb Antibodies to endotoxins are consumed and reflect circulation endotoxin levels 
Indirect evidence of 
BT 
Non-invasive (blood); Technique 
demanding 
D-lactate Bacterial fermenting product 
Indirect evidence of 
BT 
Non-invasive (blood); Not organ 
specific 
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Confocal laser endomicroscopy (CLE) is a novel diagnostic tool which enables 
assessment of in vivo mucosal histology, and assessment of intestinal barrier 
function, during endoscopy. It allows for the performance of real time histology 
during endoscopy by observation of the mucosal layer of the gastrointestinal tract at 
the cellular level. CLE uses a fibre-optic cable to convey blue laser light to a 
miniaturised confocal microscope integrated into the 12-mm-diameter tip of an 
endoscope. [266] The laser light is focused on an area of interest and back-scattered 
light is then refocused onto the detection system by the lens. The back-scattered light 
passes through a pinhole aperture which increases the resolution of the image. Laser 
light collected from the tissue in focus by the confocal microscope is transferred to 
the photodetector. The intensity of the photo signal is measured to create a two-
dimensional image. The image depth can be adjusted by moving the microscope 
optics. CLE provides subcellular resolution with 1000-fold magnification. (Figure 
6) Multiple images at varying depths can be taken at the same point of mucosa. 
(Figure 7) 
Patient preparation for confocal endomicroscopy is the same as the preparation for 
conventional endoscopy. The procedure is performed under conscious sedation or 
general anaesthesia depending on the clinical indications. The endoscope is fragile 
due to the multiple components within it and, in particular, the laser element must 
be handled with care. Two screens are required to ensure simultaneous visualisation 
of the mucosa macroscopically and the fluorescence. (Figure 8) 
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Normal Endoscopy  
•  ~30X 
•  No microscopic 
 details 
Zoom Endoscopy  
• ~100X 
•  Crypts visible 
CLE 
•  ~1000X 
• Cellular resolution  
       of crypts 
• In vivo histology 
Figure 6.  Demonstration of level of magnification with normal endoscopy to zoom endoscopy 
compared with confocal laser endomicroscopy (CLE) - Images adapted with courtesy from Pentax – 
Best of 2nd International Endomicroscopy Meeting 
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Figure 7. The scope tip is held in a stable position with contact with the mucosa. Images are taken to a set depth as per 
the above magnification producing a z-stack of images of increasing depth. 
Images adapted with courtesy from Pentax – Best of 2nd International Endomicroscopy Meeting 
 
83 
 
                                                                                             
 
 
 
 
 
 
 
 
 
 
Acriflavine hydrochloride, cresyl violet and fluorescein sodium are the fluorescent 
dyes that can be used during CLE. Fluorescein is FDA (Food and Drug 
Administration authority) - approved for diagnostic angiography of the retina and a 
further study has looked specifically at its safety during CLE. [267] Of 2272 
procedures undertaken in which 2.5-5ml of 10% sodium fluorescein was injected 
intravenously in each subject, mild reactions were noted in only 1.4% of individuals, 
including nausea/vomiting, transient hypotension without shock, injection site 
erythema, diffuse rash and mild epigastric pain. Thus, fluorescein use was reported 
to be safe for use for gastrointestinal CLE with few acute complications. Intravenous 
fluorescein has very rapid distribution in the vasculature, and can be visualised by 
confocal imaging within seconds of administration. Acriflavine however is not FDA 
approved as it is potentially mutagenic due to binding to nucleic acids. It also has 
limited penetration and gives uneven staining. Cresyl violet has limitations due to 
Figure 8. Confocal laser endomicroscopy system with 2 screens and image 
analyser. Images adapted with courtesy from Pentax – Best of 2nd 
International Endomicroscopy Meeting 
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the fact that it does not demonstrate the vascular structure of the tissue being studied 
well. Hence, fluorescein is the most widely used dye in CLE. Once the fluorescein 
dye has been absorbed by the vasculature, it is taken up by the intervillous capillaries 
resulting in a horizontal cross section on the endomicroscopy screen, comparable to 
H & E staining on conventional histology, as demonstrated in figure 9. These images 
can be taken and stored on the hard drive provided with the CLE system. 
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Figure 9. A demonstration of in vivo histology as per confocal laser endomicroscopy compared to conventional histology – 
horizontal cross-section. Images adapted with courtesy from Pentax – Best of 2nd International Endoscopy Meeting.  
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The technique of confocal endomicroscopy has been used to evaluate various upper 
gastrointestinal disorders such as Barrett’s oesophagus, gastric carcinoma and 
coeliac disease. It also has applications in the lower gastrointestinal and biliary tracts 
and can assist in the diagnosis of conditions such as colonic polyps, ulcerative colitis 
and pancreaticobiliary strictures. The use of CLE in IBD, polyps and Barrett’s 
oesophagus is extensive and the technique is now used for clinical evaluation and 
therapy. [268] A very recent report of the use of CLE for the evaluation of 
pancreaticobiliary strictures and pancreatic cystic lesions showed that CLE has the 
ability to determine the malignant potential of such lesions that are so difficult to 
characterise. The technique therefore also has the potential to increase the diagnostic 
yield of endoscopic retrograde cholangiopancreatography and endoscopic 
ultrasound. [269, 270] 
CLE has also been used for the assessment of small intestinal epithelial gaps, but no 
single approach for their assessment and interpretation has yet been validated. [271]  
Various methods of interpretation of gut barrier function by CLE have been reported. 
[271] Features suggestive of increased IP can be determined with high inter-/intra-
observer agreement from confocal endomicroscopy images and without previous 
pathology training. [272] One study which reported mucosal barrier defects in 
gastric intestinal metaplasia demonstrated an impaired paracellular barrier and 
confirmed the findings using electron microscopy. [273] CLE has previously 
identified epithelial gaps in the ileal and duodenal mucosa of patients who had 
inflammatory bowel disease (IBD) and this correlated with increased IP and clinical 
relapse. [274] [275] [1] [4] The findings in the duodenum, an area usually unaffected 
in IBD, suggest that increased cell shedding and barrier loss may be underlying 
pathogenic mechanisms. [23] CLE has also demonstrated the presence of 
intramucosal bacteria in vivo in patients with IBD, [276] and increases in epithelial 
gaps and IP in patients with irritable bowel syndrome. [277] Increased gaps have 
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also been demonstrated by CLE in indomethacin-induced enteropathy. [277] [278] 
[279] It is therefore reasonable to hypothesise that cell shedding is increased in 
inflammatory diseases where there is evidence of involvement of the intestine 
directly or indirectly. On the basis that epithelial cells destined for extrusion from 
the intestinal surface should stain positive for activated caspase-1 or -3 on mucosal 
biopsy samples, investigators compared stained terminal ileum biopsy samples with 
CLE images from the same site in patients with IBD, IBS and healthy controls. 
Intestinal epithelial gap density via CLE correlated strongly with quantitative 
analysis of immune-histochemical staining of mucosal biopsy samples. [280] 
Studies reporting intestinal permeability changes as evidenced by CLE, have each 
used the standard principle of fluorescein leakage into the extravascular space, but 
have had subtle differences in terms of specific methodology. One such study which 
analysed mucosal healing in patients with ulcerative colitis for example used 10 CLE 
images obtained from each colon for analysis. To examine intestinal permeability, 
they measured fluorescence signal intensity (FSI) inside the vessel and outside the 
vessel lamina propria in six standardised ﬁelds per image, and then mean values 
were calculated for each patient. The FSI gradient between vessels and lamina 
propria was calculated. Figure 10 shows a representational image od a duodenal 
villus as seen by CLE and by conventional histology. 
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A lower FSI gradient indicated increased ﬂuorescein leakage into the extra vascular 
space and reﬂected increased vascular permeability. [281] In a second study, again 
looking at patients with ulcerative colitis, segmental optical (by CLE) and tissue 
biopsies were taken. In order to avoid motion artefacts and acquire better orientation 
of the imaged area, an image reconstruction algorithm using a video mosaicing 
technique was employed. This group measured fluorescence intensity, related to the 
Figure 10. Comparison of confocal images with conventional histological 
images of duodenal villi. A: Confocal image delineating the fine slender 
finger-like projections of the duodenal villi; B: Histological image of 
duodenum. [3]  
 
B 
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fluorescein leakage in a region of interest, by using special dedicated software. [282] 
In a further study of inflammatory bowel disease, images stacks (Z-stacks) at a given 
area were collected from the surface of the epithelium down to the lamina propria 
(optical biopsy). The endomicroscopic images of the terminal ileum were analysed 
for the presence of gaps, micro-erosions and ﬂuorescein leakage. The overall 
perimeter of the villi in each image was measured using Image J and the proportion 
of affected cells per perimeter was calculated (in percentage per optical analysis, 
which represented a z-stack of images in a given mucosal area). This detailed 
analysis was entitled the Watson grading system. Grading was based on the amount 
of cell shedding and the intensity of the luminal ﬂuorescein signal on single good 
quality images from four separate ﬁelds of view within the terminal ileum. [1] 
(Figure 11) A similar concept was employed by another group in patients who had 
irritable bowel syndrome. The primary outcome was the density of epithelial gaps 
(gaps/cells counted) in adequately imaged villi using CLE. Images were reviewed 
by two independent blinded reviewers. [277] 
 
     
 
     
 
 
 
            
 
B 
Figure 11. Confocal 
imaging of small intestine 
with intravenous 
fluorescein:  
(A) ‘Plume’ of fluorescein 
entering intestinal lumen 
through epithelial gap. (B) 
Demonstration of bacteria 
within a villus using 
fluorescein stain. Arrows 
represent intensely 
fluorescent shedding cells 
seen en face. Images 
courtesy of Watson et al. [1] 
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Confocal Laser Endomicroscopy is therefore proving to be a rapidly advancing field 
of research. In the study described in this thesis, CLE was used to assess epithelial 
barrier integrity and intestinal permeability in patients with chronic liver disease, 
chronic pancreatitis and acute pancreatitis. It is the first such study to examine such 
parameters using this modality. Detailed methods and results will follow in the 
forthcoming chapters.  
 
1.11 Summary 
Alterations in intestinal permeability, bacterial translocation and endotoxaemia have 
been reported in acute pancreatitis and chronic liver disease, and to a limited degree 
in chronic pancreatitis. In acute pancreatitis, changes have been shown to correlate 
with disease severity, multi-organ failure, mortality and outcome.  
Several tests can be used to examine intestinal barrier function and most commonly 
the ratio of two substances is used. D-amine oxidase is another test that can be used 
and there are multiple reports of its use in experimental models of acute pancreatitis 
and a few in human subjects.  
Novel methods to investigate intestinal permeability have been more recently 
reported. CLE is one such diagnostic tool. It enables in vivo mucosal histology and 
the assessment of intestinal barrier function, during endoscopy. We have therefore 
investigated whether CLE can be used to assess intestinal permeability in patients 
with acute and chronic pancreatitis and have compared the results with those 
obtained from non-invasive measurements of intestinal permeability in the same 
subjects. 
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CHAPTER 2 
HYPOTHESES, AIMS AND OBJECTIVES 
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2.1 Hypotheses 
At the start of this thesis, I set out to conduct an investigation into intestinal permeability, 
bacterial translocation and gut barrier dysfunction in patients with acute pancreatitis. To 
facilitate this, a decision was made to investigate patients with stable chronic disease in the 
first instance. The following hypotheses were proposed to be tested: 
1. Intestinal permeability alterations can be seen in patients with chronic pancreatitis, 
chronic liver disease and acute pancreatitis. 
2. Confocal laser endomicroscopy can be used as a tool to assess alterations in intestinal 
permeability in pancreatic disease and in chronic liver disease. 
3. Pro-inflammatory cytokines are involved in the loss of barrier function in acute and 
chronic disease, and correlate with severity of disease in acute pancreatitis.  
4. Alterations in gastrointestinal permeability are associated with gut barrier dysfunction 
and alterations in the gut microbiome. 
 
 
2.2 Aims 
To determine whether CLE can be used to assess intestinal permeability, bacterial 
translocation and endotoxaemia in patients with chronic pancreatitis, chronic liver disease and 
acute pancreatitis. 
To assess the responses of immunology and infection in patients with acute pancreatitis whilst 
also assessing changes related to increasing severity of disease in acute pancreatitis. 
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2.3 Objectives 
In order to test the identified hypotheses and aims, we designed a study to be able to examine 
each of the required parameters. We set out to test the hypothesis that intestinal permeability 
alters in patients with chronic pancreatitis, chronic liver disease and acute pancreatitis and 
investigated whether these changes are associated with systemic endotoxin concentrations and 
bacterial translocation.  
A measure of intestinal permeability was investigated with the novel tool, CLE, alongside the 
gold standard lactulose:mannitol test, whilst endotoxaemia was also measured. Further 
analyses to enable the differentiation of severity of acute pancreatitis in relation to systemic 
cytokine responses whilst also examining duodenal microbial growth in an attempt to assess 
bacterial translocation and the gut microbiome were carried out.  
In summary, we aimed to determine whether in vivo CLE has a clinical role for assessing the 
integrity of the intestinal permeability barrier in inflammatory pancreatic and liver disorders, 
whilst assessing immunological and infection responses also. 
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CHAPTER 3 
METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
3.1 Study population 
We conducted a two tier study, initially investigating patients with CP and CLD then patients 
with AP.  
CP patients were recruited from outpatient clinics and had a diagnosis based on clinical and 
imaging diagnostic criteria. They were subcategorised into surgically managed CP and 
conservatively managed CP. Aetiology was variable. CLD patients, classified with cirrhosis 
according to the Child’s Pugh Score, were approached following referral to the endoscopy 
service for variceal screening or from the wards. [283] Aetiology was again variable. Control 
subjects were referred for endoscopy to investigate dyspepsia, but did not have alarm features 
or pre-existing comorbidities. Subsequent selection was based on these subjects having a 
normal gastroscopy and negative Helicobacter pylori (H. pylori) tests, rendering a likely 
diagnosis of non-ulcer (functional) dyspepsia. 
Patients with a diagnosis of AP with serum amylase activity >450 U/l and consistent 
symptoms, fulfilling Revised Atlanta Classification diagnostic criteria, were recruited 24-48 
hours after admission at the Royal Liverpool University Hospital. [66] Subsequent 
classification was as mild, moderate, severe or critical AP using the determinant based 
classification (DBC) system. [65]  
 
3.2 Study Design 
A proof of principle study was initially undertaken in which we investigated stable patients 
who had chronic disease: CP and CLD. Once experimental protocols had been established, a 
study of patients with acute illness (AP), was subsequently carried out. A further study of 
patients with severe acute pancreatitis admitted to ITU was proposed, but an application / 
amendment for ethical approval to acquire assent from next of kin was unsuccessful. 
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3.3 Ethics  
This study was granted approval by the North West Research Ethics Committee under two 
study codes: 11/H1005/6 and 12/NW/0420. An amendment to the study 12/NW/0420 was 
proposed to enable recruitment of ITU patients unable to consent through the process of assent 
by next of kin, but this was declined by the regional ethics committee due to the invasive 
nature of the primary procedure. Identified patients were invited to participate in the study and 
informed consent was obtained. 
 
3.4 Documentation 
Patient information leaflets, consent forms and case record forms (CRFs) were designed and 
prepared for recruitment and for recording all data collected during the study (see 
Appendices). All documents were scrutinised and approved by the local ethics committee, 
prior to ethical approval being granted. CRFs were completed in a clear, legible manner by 
investigating team members during the course of the study. Records identifying the subject 
were kept confidential. All participants were allocated a study ID number at the time of 
recruitment with a prefix – CEM.  
 
3.5 Safety Considerations 
The study was conducted with close attention to patient safety. Consenting patients who were 
recruited underwent upper gastrointestinal tract endoscopy at the Endoscopy Unit in the 
Department of Gastroenterology at the Royal Liverpool and Broadgreen University Hospitals 
NHS Trust. British Society of Gastroenterology guidelines for safety and sedation in 
endoscopy were adhered to as is routine practice in this unit. All procedures were carried out 
by trained, competent endoscopists.  
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3.6 Assessment of Intestinal Permeability 
3.6.1 Confocal laser endomicroscopy 
CLE was performed under conscious sedation with midazolam and pethidine by one of two 
fully trained endoscopists (SB and JG) using endoscope EC-3870CILK (Pentax, Tokyo, 
Japan.) After completion of the macroscopic examination, 5ml 10% fluorescein was 
administered intravenously and serial confocal images were acquired from the second part of 
the duodenum. The duodenal wall was then flushed with 10mls sterile water and duodenal 
fluid was aspirated for microbiology (see below). Two gastric antral mucosal biopsies were 
taken and a rapid urease test conducted to assess for the presence of H. pylori. All recorded 
images were re-evaluated by two co-authors (SB and JA) and selected for analysis based on 
defined inclusion and exclusion criteria. (Table 4) Selected images were analysed and scored 
by two independent, blinded collaborators/authors (CD and DL) for the presence or absence 
of fluorescein, the white element of each image, outside of the villous capillary network. 
Images were scored as 1 - ‘positive for leakage’ or 0 - ‘negative for leakage’. (Figure 12) An 
average score based on the total score over the total number of images was calculated and the 
information populated onto a scoring sheet as seen in figure 13.   
Table 4. Image Selection Criteria 
Inclusion Criteria Exclusion Criteria 
 
• Still image / absence of movement 
artefact 
• Image in focus 
• Uniform / near uniform perfusion 
• Full contact across whole or 
majority of image 
• Balanced exposure (brightness and 
contrast) 
 
• Movement artefact within image 
• Out of focus image 
• Areas of image under or over-
perfused 
• Image too bright 
• Image too dark despite 
manipulation  
• Repeated image 
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A     
 B 
 
 
 
Figure 12. Fluorescein leakage or ‘score 1’ positive image 
demonstrated in B and a negative or ‘score 0’ image as per A. 
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Figure 13. Scoring Sheet 
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3.6.2 Sugar absorption tests 
A dual sugar absorption test was used to assess IP. A solution of 5g lactulose and 2g mannitol, 
dissolved in 100ml of water, was prepared by the clinical trials pharmacy department, and this 
was further diluted to a 300ml solution at the time of administration, following a 6 hour fast. 
The solution was administered orally or via a nasogastric tube, immediately after collection 
of a 3.5ml blood sample for serum (Gold BD Vacutainer® SST™) to determine baseline 
levels. After a further 90-minute fasting period, a further 2ml serum sample was taken. 
Samples were centrifuged at 1500g/min for 10 minutes (Heraeus Megafuge 16R) and serum 
was aspirated, aliquoted and stored at -80°C. Batches were later analysed using HPLC (Dionex 
DX-500 BiolC HPLC system, California) as described by Fleming et al. [19] The ratio of the 
serum concentrations of lactulose and mannitol was recorded as the index marker for IP.  
 
3.7 Venous Blood Sampling 
A total of 20ml of blood was taken from each patient under aseptic conditions: 2ml whole 
blood in a lavender BD Vacutainer® K2 EDTA Tube; 4.5 ml blood in a blue BD Vacutainer® 
K2 Na Citrate Tube; 3.5 ml serum in a gold BD Vacutainer® SST™ Tube and 5ml blood in a 
blue culture bottle and 5ml in a purple blood culture bottle.  Each tube was inverted ten times 
and transported to the PBRU laboratory as soon as possible. Sample processing and storage is 
detailed below. 
 
3.7.1 Blood Cultures 
Blood cultures were loaded onto a BacT/ALERT® 3D automated microbial detection system 
(bioMerieux, Marcy l’Etoile, France) and incubated for an extended period of ten days. 
Positive blood cultures were to be cultured onto Columbia blood agar, MacConkey agar, 
fastidious anaerobic agar and fastidious anaerobic agar with neomycin (Oxoid, Basingstoke, 
UK) and incubated for 48 hours. Blood cultures remaining negative for the ten-day incubation 
period were subcultured onto the above media and plates were incubated for five further days. 
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3.7.2 Measurement of diamine oxidase 
A 3.5ml blood sample was taken from each subject (Gold BD Vacutainer® SST™), 
centrifuged at 1500g/min for 10 minutes at 20°C (Heraeus Megafuge 16R) and serum was 
carefully aspirated, aliquoted and stored at -80°C. Diamine oxidase (DAO) levels were 
measured in the serum of all patients with AP and controls who underwent CLE and whose 
images were subsequently included in the study for analysis and scoring. Identified serum 
samples were assayed using an ELISA kit with an antibody specific to DAO (USCN Life 
Science Inc.) according to the manufacturer’s instructions. The concentration of DAO was 
determined by comparison to a standard curve. 
 
3.7.3 Measurement of Endotoxin 
3.7.3.1 Measurement of anti-endotoxin antibodies 
A 4.5 ml peripheral venous blood sample was taken from each subject for plasma sampling 
(Blue BD Vacutainer® K2 Na Citrate Tube) and this was centrifuged at 1600rcf for 15 minutes 
at 20°C. The plasma supernatant was carefully extracted, aliquoted and stored at -80°C. 
Plasma samples were later used for the measurement of antibody to endotoxin core (EndoCAb; 
Hycult Biotechnology, Netherlands) by measurement of levels of endogenous IgG and IgM 
EndoCAb by a direct ELISA. The test was conducted as per the manufacturer’s instructions, 
and a drop in antibody levels was reported directly proportional to the severity of 
endotoxaemia.  
 
3.7.3.2 Measurement of direct endotoxin 
Limulus amoebocyte lysate assay was measured in the serum of selected patients, by Charles 
Rivers Laboratories, according to the manufacturer’s instructions. 
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3.7.4 Measurement of cytokines 
The collection and preparation of serum has been described above. Bio Rad Bio-Plex Human 
Cytokine, Chemokine and Growth Factor Multiplex Assay 27 Plex Panel Kits (Bio-Rad 
Laboratories Inc.) were used to measure the concentrations of multiple cytokines. Data were 
read on the Bio Rad Bio-Plex 200 instrument and associated Bio-Plex Manager Software 
version 5.0. Concentrations of cytokines were calculated using standard curves. 
 
3.7.5 Helicobacter pylori testing by serology 
In the pilot study, H. pylori testing by rapid urease testing was not routinely performed unless 
clinically indicated, and so all patients recruited had retrospective testing of serum IgG using 
stored serum samples. Frozen serum samples were removed from the freezer and thawed for 
analysis. Samples were processed by the microbiology laboratory team and involved ELISA 
testing for H. pylori IgG antibodies.  
 
3.8 Duodenal Fluid Collection  
Whilst the second part of the duodenum was intubated, after images had been obtained, and 
prior to biopsies being taken, duodenal fluid was aspirated from the lumen using a suction 
trap. Approximately 1ml of fluid was transferred using a sterile syringe and needle into a non-
pyrogenic cryovial for microbiology and labelled accordingly.   
 
3.8.1 Duodenal fluid culture 
1ml of duodenal fluid was transferred using a sterile syringe and needle into a non-pyrogenic 
cryovial for microbiological analysis. Samples were centrifuged at 2500 rpm for 10 minutes 
and the supernatant was removed, ensuring 250 µl of the sample remained in the tube. The 
pellet was re-suspended and 25 µl was inoculated onto the following media: Columbia blood 
agar, MacConkey agar, fastidious anaerobic agar and fastidious anaerobic agar with neomycin 
and incubated for 10 days (plates were examined at 5 and 10 days). A cooked meat-BHI 
overlay broth (EandO laboratories, Bonnybridge, UK) was also inoculated and incubated for 
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ten days prior to subculture onto Columbia blood agar, fastidious anaerobic agar and fastidious 
anaerobic agar with neomycin. These plates were incubated for five days. Significant positive 
isolates were identified by Matrix Assisted Laser Desorption Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry (Bruker Corporation, Bremen, Germany) and stored on 
PROTECT beads (Technical Services Consultants Ltd, Heywood, UK) at -70°C. 
 
3.9 Tissue Acquisition 
Once duodenal intubation had been achieved, and after image acquisition and fluid aspiration, 
6 mucosal biopsies were taken from the second part of the duodenum. 2 samples were 
transferred to formalin and taken to the pathology lab for processing of slides and cassettes of 
duodenal villi. This was in preparation for immune-histochemical analysis, however due to 
the limitations of time, we were unable to perform immunohistochemistry. A further two tissue 
samples were immersed into PBS for a minute then transferred and into 4% PFA as per the 
electron microscopy protocol detailed below. Two tissue samples from the gastric antrum 
were also taken. These were transferred to a slide for H. pylori analysis, as detailed below. 
The final two were immersed into blue cryovials containing isopentane, and were transferred 
to the laboratory in a carrier of liquid nitrogen for the possibility of tissue microbiological 
analyses. Samples were transferred into the GCLP -1500C Freezer. Due to the limitations of 
time, such analyses were not performed. At a late stage in the study, 2 tissue samples were 
sent direct to the laboratory in formalin, for routine histological analysis instead of electron 
microscopy.  
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3.9.1 Helicobacter pylori testing by rapid urease test 
In the cohort of patients recruited in the second or main part of the study, all patients underwent 
rapid urease testing for Helicobacter pylori. Two mucosal biopsies from the antrum were used 
to detect the presence of H. pylori by means of a rapid urease test (Pronto Dry, MIC, Brignais, 
France). The rapid urease test slides were read one hour after sample collection and the results 
were recorded.  
 
3.10 Statistical analysis 
A database was designed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA) 
and data were entered and stored in this program. Statistical analysis was performed using the 
statistical software package GraphPad PRISM version 6 (GraphPad Software, Inc., San Diego, 
CA, USA). A kappa statistic was calculated to determine agreement on image analysis 
between scorers. Normality was assessed using the Shapiro Wilk test. Data were compared 
using the Mann-Whitney U test in the case of quantitative and continuous data, with two tailed 
p values and p<0.05 indicating statistical significance. In the case of categorical or binary data, 
differences were analysed using the 2 test applying Yates’ correction when required. 
Spearman’s R Correlation Coefficient was used to assess for an association between DAO 
concentration and fluorescein leakage. In all analyses, p<0.05 was considered indicative of 
statistical significance. 
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CHAPTER 4 
RESULTS I 
METHOD DEVELOPMENT TO ESTABLISH USE OF A NOVEL TECHNIQUE TO 
ASSESS INTESTINAL PERMEABILITY THROUGH A PILOT STUDY  
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4.1  Introduction 
Recent work conducted in our institution using the new technique of CLE on mouse and 
human small and large intestine has identified epithelial gaps in the intestinal mucosa that 
appear to increase in number dramatically during inflammatory disease states. [21] 
Identification of localised barrier loss in the intestinal epithelium is both novel and highly 
relevant to this project. Intravenous fluorescein was seen using confocal endomicroscopy to 
leak through the epithelium into the intestinal lumen at sites of barrier loss. [279] To our 
knowledge there is no other method of identifying such localised areas of increased IP in vivo. 
The identification of areas of barrier loss at a cellular level accurately complements sugar 
absorption studies that give an integrated measure of IP over a long segment of gut.  
The Royal Liverpool University Hospital has an excellent, fully resourced endoscopy unit and 
is one of three National Endoscopy Training Centres. In 2010, 5,907 gastroscopies were 
carried out; of these, 245 patients had chronic liver disease and at least 47 had CP. There are 
also 150 new referrals with CP to the Liverpool Pancreas Clinics per year. A significant 
proportion of both of these cohorts are stable outpatient referrals who undergo their 
endoscopic procedures as elective out-patients. With this in mind, and considering that there 
are documented intestinal permeability disturbances in CP and CLD, it was thought to be a 
reasonable proposition to study these two disease cohorts, for their own merit, but also to 
enable the setup of a robust protocol in stable, clinically well, patients prior to studying the 
more unwell group of AP subjects. 
Formal power calculations could not be performed since samples from pancreatitis or liver 
disease patients undergoing CLE have not previously been assessed and therefore not all the 
required variables for an accurate sample size calculation were known. However, based on 
previous endoscopic investigations involving analysis of tissue biopsies, group sizes of at least 
20 patients were deemed reasonable to allow detection of significant differences in outcomes.  
The study was deemed entirely feasible as the patient population was available, the necessary 
endoscopic skills were acquired through training by two endoscopists, and all the necessary 
equipment, reagents, image analysis tools, expertise and infrastructure were already available 
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and validated. Confocal microscopy (in vivo and in vitro) is routinely performed in our 
laboratories as is the analysis of cell shedding and assessment of epithelial gaps and so a 
support network was available when interpreting the results of this study. With respect to CLE 
in human subjects, Professor Watson and Professor Kiesslich were important advisors, having 
utilised the modality in subjects with inflammatory bowel disease and reported on intestinal 
permeability assessments in such individuals. [1, 4, 279] Professor Kiesslich provided training 
in the CLE technique at his centre at Mainz University Hospital. Professor Watson explained 
the development and evolution of the Watson Score used to score fluorescein leakage by CLE, 
during meetings in Liverpool and Norwich and by further correspondence thereafter. 
 
4.2 Study Design 
A 2-tier study was conducted due to the nature of the main cohort under consideration. An 
initial pilot study was designed involving two separate groups of patients with chronic illness:  
1. Patients with chronic liver disease – due to the extensive literature reporting 
alterations in intestinal permeability in this condition. 
2. Patients with chronic pancreatitis – as this was also an inflammatory process of the 
pancreas, but in which patients were more stable and the disease was more chronic, 
allowing greater flexibility in scheduling investigations.  
Ethical approval was also sought in a 2-tier process and hence, the initial application was to 
study intestinal permeability using confocal laser endomicroscopy in patients who had chronic 
liver disease and chronic pancreatitis.  
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4.3 Patient Recruitment 
Patients with chronic liver disease (CLD) or cirrhosis were recruited via the endoscopy unit. 
Patients with chronic liver disease who were referred for screening for oesophageal and/or 
gastric varices or those with known varices who were on a surveillance programme were 
contacted by telephone and invited to participate in the study. A small number of inpatients 
with decompensated liver disease were also recruited following direct approach on the wards, 
once the protocol had been established. Due to the nature of this disease and the need for 
endoscopic evaluation and assessment, recruitment was relatively straightforward as the 
invasive element of the study was already being undertaken by patient. This was also the case 
for the potential healthy control subjects. We approached patients who had dyspeptic 
symptoms without alarm symptoms as the reason for endoscopy referral and selected those in 
whom the endoscopy did not reveal an organic cause such as peptic ulcer, thereby suggesting 
an underlying diagnosis of non-ulcer dyspepsia. Patients were contacted by telephone and 
invited to participate in the study. The confocal laser endomicroscopy was a small extension 
to a procedure they were already anticipating, and the other aspects were less invasive than 
that which was already being undertaken. 
Patients with chronic pancreatitis were approached by two methods. Initially, it was felt that 
patients who required an endoscopic procedure for a clinical indication (e.g. assessment of 
abdominal pain or vomiting) should be recruited, as described above for CLD and healthy 
control subjects. However, due to the nature of the disease, diagnostic gastroscopy is not a 
common requirement for most patients with chronic pancreatitis. Such patients do however 
sometimes require endoscopic ultrasound examinations, so the initial few patients recruited 
were offered back to back procedures. It however became rapidly apparent that this was too 
much for subjects to tolerate and so we re-visited the recruitment strategy for this cohort. 
Subsequently therefore, patients with stable CP were approached in the out-patient setting 
following their routine clinic review. They were invited to participate in the study solely for 
research purposes.  
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All patients were initially informed about the study and were provided with the relevant 
information leaflet explaining the study. They were then asked if they agreed to take part and 
written consent was obtained. At this time, initial blood sampling was also undertaken. They 
were then given two appointments – one for the endoscopic procedure and another for the 
sugar absorption test.  
 
4.4 Study Population 
A total of 128 patients were recruited in this initial pilot study. Baseline demographics of these 
patients are detailed in tables 7-8. Of these, not all participants underwent all aspects of the 
study due to a range of reasons including withdrawal of consent, missed appointment, 
technical difficulties, delay in acquisition of test solution. All 128 recruits did however 
undergo blood sampling and subsequent analyses of plasma and serum. This included cytokine 
analysis, endotoxin, and blood cultures.  
For healthy controls, 48 patients who had been referred for endoscopy to investigate symptoms 
of dyspepsia, but who did not have alarm symptoms, were recruited. Medical history was 
taken at the time of initial consultation. 13 H. pylori negative patients who had no major co-
morbidities and who also had a macroscopically normal endoscopy were subsequently 
selected as ‘healthy controls’. A co-morbidity was defined as any long-standing health 
problem requiring medication such as hypertension or diabetes mellitus, or any history of 
previous surgery except ENT or ophthalmic surgery. Of the 48 potential controls referred for 
gastroscopy, 39 underwent confocal laser endomicroscopy and 24 of these had normal 
endoscopic findings. Eleven of these were however subsequently excluded from the healthy 
control group based on positive H. pylori status or pre-existing co-morbidities. Thus leaving 
a total of 13 healthy controls. 
Patients with CLD and CP were recruited as described above. Not all subjects however 
attended all their appointments; this explains the different numbers undergoing the various 
different elements of the study. The recruitment cohort for the pilot study is summarised in 
the Prisma diagram below. (Figure 14) 
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PILOT STUDY
128 - Blood & Medical History
48HC:47CP:33CLD
82 L:M Test
34HC:30CP:18CLD
48 Successful CLE and Duodenal Aspirate
13HC:18CP:17CLD
46Withdrew Consent
Figure 14. PRISMA diagram to summarise key components of recruitment and analysis 
during pilot study.   
Key: n:m:p:q = Healthy Controls (HC) : Acute Pancreatitis (AP) : Chronic Pancreatitis 
(CP) : Chronic Liver Disease (CLD) 
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4.5 Study Cohorts 
Details of the healthy control cohort have been described above. Patients recruited with 
chronic liver disease comprised a range of aetiologies including alcoholic liver disease (16); 
non-alcoholic steatohepatitis (3); hepatitis B or C virus (5); primary biliary cirrhosis (3); 
primary sclerosing cholangitis (1); hereditary haemochromatosis (2); unknown / idiopathic 
(3). Of these, 26 patients were classified as Child’s Pugh A at the time of recruitment; 4 
subjects as Child’s Pugh B and 3 as Child’s Pugh C. (Table 5)  
 
 
Table 5. Characteristics of Patients with Chronic Liver Disease 
 
Characteristic 
 
Chronic Liver Disease (n=33) 
Sex M:F 23:10 
Median age (range), yrs 53 (22-53) 
Aetiology, n (%)  
Alcohol 16 (48) 
Idiopathic 3 (9) 
Hepatitis B/C virus 5 (15) 
Other 9 (27) 
Child’s Pugh Score, n (%)  
Child’s Pugh A 26 (79) 
Child’s Pugh B 4 (12) 
Child’s Pugh C  3 (9)  
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The chronic pancreatitis cohort comprised 20 patients who had excess alcohol consumption 
as the primary cause; 20 patients had idiopathic chronic pancreatitis; 4 patients had a genetic 
aetiology; 2 had autoimmune pancreatitis and 1 had chronic pancreatitis secondary to trauma. 
Pancreatic exocrine insufficiency was common in this cohort, with endocrine insufficiency 
being less commonly reported. 57% of patients who had chronic pancreatitis in our study had 
undergone surgery involving the pancreas or biliary tract during their disease course or for 
prior acute pancreatitis: 9 Whipple’s procedure; 3 Hepaticojejunostomy / cyst resection; 1 
Berne’s procedure; 1 Beger’s procedure; 1 trauma surgery; and 12 necrosectomy for previous 
AP, or other. (table 6) 
Table 6. Characteristics of Patients with Chronic Pancreatitis 
Characteristic Chronic Pancreatitis (n=47) 
Sex M:F 29:18 
Median age (range), yrs 47 (19-75) 
Aetiology, n (%)  
Alcohol 20 (43) 
Idiopathic 20 (43) 
Genetic 4 (8) 
Other 3 (6) 
Manifestations of Disease Progression, n (%)  
Exocrine Insufficiency 43 (91) 
No Exocrine Insufficiency  4 (9) 
Endocrine Insufficiency 12 (26) 
No Endocrine Insufficiency  35 (74) 
Patient Management               
             Surgically Managed, n (%) 27 (57) 
             Conservatively Managed, n (%) 20 (43) 
Tertiary Referral Patients, n (%) 0 (0) 
Time since diagnosis to recruitment, n (%)  
<12 months 3 (6) 
1 – 5 years 10 (21) 
             5 -10 years 14 (30) 
             >10 years 20 (43) 
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4.6 Assessment of Intestinal Permeability by CLE 
4.6.1 Method development for image interpretation 
The process of image selection was consistent throughout the study. Images of poor quality 
were discarded according to the exclusion criteria detailed previously (section 3.6.1, table 4). 
Initial assessment of pilot study data was based on the Watson Grade (Table 7). [1] Image 
acquisition, selection and interpretation were initially all performed by the same investigator. 
Two further blinded investigators also scored the images. However, due to variable 
interpretation of specific elements of this scoring system, concordance rates between the 
scorers were poor and the process was also potentially biased by one investigator (the author) 
both selecting and scoring images.  
 
 Cell shedding Local barrier dysfunction 
I. Normal 
Cell shedding confined to single 
cells per shedding site  
None 
II. 
Functional 
defect 
Cell shedding confined to single 
cells per shedding site 
Fluorescein signal visible in the 
intestinal lumen with an intensity the 
same or brighter than the epithelium or 
fluorescein plumes out of the 
epithelium into the lumen   
III. 
Structural 
defect 
Microerosions in any field. 
Microerosion is defined when the 
lamina propria is exposed to the 
lumen with multiple cells being 
shed per site  
Fluorescein signal visible in the 
intestinal lumen with an intensity the 
same or brighter than the epithelium or 
fluorescein plumes out of the 
epithelium into the lumen  
  
Table 7. Watson Endomicroscopic Grade for in vivo identification of local barrier 
dysfunction. [1] 
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After much consideration and discussion, it was decided to simplify the scoring process to 
reduce bias and the possibility of variable image interpretation. A major factor leading to this 
process was the inability to confirm the presence of true z-stacks in the images acquired as 
even slight movement of the confocal probe during the endoscopic procedure led to images 
being acquired from different locations. It was therefore deemed to be more accurate to 
identify images from different stacks and not to analyse more than one image from the same 
‘z’ stack. Interpretation of the level of fluorescence and signal intensity was also felt to be 
subjective, whereas detection of its presence or absence alone was more objective. Hence, a 
more simplified scoring system, as detailed in chapter 3, was introduced and separate blinded 
investigators were recruited to select and score the confocal images. Two objective scores 
were acquired – one rendering binary data and the other continuous. Each image was scored 
as either ‘1’ or ‘0’ using the method detailed previously. A numeric value was therefore 
acquired and this was divisible by the number of images examined for that patient leading to 
an ‘average score’ – a continuous variable. The presence of any positive score suggested the 
presence of fluorescein leakage into the intestinal lumen and hence generated the binary score. 
(Figure 15) Images of poor quality were discarded based on the exclusion criteria detailed in 
chapter 3. Examples of discarded images are shown below. (Figure 16)  
Figure 15. Confocal imaging of small intestine with intravenous fluorescein from 
pilot study: (A) ‘Plume’ of fluorescein entering intestinal lumen through epithelial gap in 
a patient with chronic liver disease. See arrow. (B) Normal villi with no evidence of 
fluorescein leakage in a control patient. 
A B 
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Figure 16. Examples of discarded 
confocal images.  
 
a. Lack of full contact across image;  
b. Too dark;  
c. Movement artefact;  
d. Too bright. 
 
 
a b 
c d 
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4.7 Discussion 
The methods of confocal microscopy and in vivo (mice) confocal probe microscopy have 
previously been established in our institution. Fluorescein is a dye that has been deemed safe 
and efficacious in human experimentation and is utilised as a spray once the focal point is 
seen endoscopically. [267]  
The Watson score described a method of analysing a z-stack of images 7 µm apart that had 
been taken from villi in the en face orientation up to a depth of 70 µm. [1] Whilst this formed 
the initial method used for image analysis, it was later amended and developed so that it was 
workable for the clinical and laboratory teams and so that the degree of inter-observer 
variability was minimised. In the early stages of the study, control subjects and volunteers 
were recruited to master the technique of confocal laser endomicroscopy and to consolidate 
training. Multiple images were taken from the second part of the duodenum (D2), prior to 
any other intervention, to prevent interference. To begin with, a stack of images from one 
focal point in D2 were acquired up to a depth of approximately 70 µm, or until the images 
became faint, by enabling contact between the tissue and the confocal window. Images were 
then acquired as the direction of image capture was changed into reverse to return to the top 
of the z-stack, maintaining the same stable position. Image numbers were noted and the 
method was repeated for up to 6 sites, the aim being to acquire a minimum of 3 stacks of 
good quality images. The images from each site were separated and then images were 
selected as per previously detailed criteria. 3 sets of images from 3 sites were selected for 
interpretation and scoring. A very large number of images were acquired in this way and it 
was found that due to invariable peristaltic movement, stacks became inconsistent and 
images thought to be from a single stack, were actually independent of each other.  
In these initial stages of the study, the Watson score was performed and attempts were made 
to score images identifying the point and extent of leakage, and scoring where an actual 
defect or ‘gap’ could be seen.  This method resulted in a continuous scale for analysis, but 
led to considerable variability between scorers and it was found to be a subjective method 
of assessment. A variable number of images were scored from each stack and an average 
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score was calculated. There was also considerable variation in the numbers of images 
analysed per subject using this method. Once the pilot study recruitment was completed, the 
method was fully evaluated and a decision was made that it was too cumbersome and not 
the best method for analysing the images acquired in this study. 
A review of the method was therefore undertaken. Image numbers were consolidated so that 
only one image per duodenal site was taken and all good quality images were analysed as 
long as they had been definitively acquired from independent positions. The scoring was 
also changed from a subjective, continuous variable to a discrete value of positive or 
negative. This significantly improved inter-observer variability. This method did not 
however allow for the identification of gaps, but proved to be far more accurate for 
assessment of fluorescein leakage. Hence, this method was utilised for the remainder of the 
study and the details have been outlined in chapter 3.  
Whilst the study protocols were being established, the numbers of subjects who successfully 
completed the various aspects varied due to a number of factors. This improved by the time 
the main study was established. Some of the problems faced and the reasons for them are 
briefly outlined here: 
Electron microscopy was undertaken using duodenal tissue samples obtained from the initial 
recruits in the pilot study, but it was later abandoned due to difficulties in interpreting the 
images and the complexity of acquiring them. 
Helicobacter pylori status was not initially tested by urease test on a gastric biopsy. Urease 
testing was done during the main study but not during the pilot study. Thus, the patients from 
the pilot study were tested for H. pylori by serology instead.  
Blood samples were taken at the time of recruitment and hence, serum, plasma and blood 
culture samples were available from all subjects. The endoscopic procedure and sugar 
absorption tests were undertaken at separate appointments and so this was dependant on the 
subject’s attendance. There was a significant withdrawal rate for one or both of these tests.  
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Duodenal biopsies were only sent for routine histology later in the study. This analysis was 
therefore only undertaken for a small number of patients who had acute pancreatitis and a 
few control subjects who were recruited at a late stage in the study.  
Images were excluded based on exclusion criteria as detailed previously. In the first few 
subjects who underwent confocal laser endomicroscopy, the endoscopists were acquiring 
new skills in this procedure. In some of these subjects no interpretable images were obtained. 
In a small number of patients who underwent gastroscopy, the procedure had to be 
abandoned prematurely due to patient intolerance, a technical fault with CLE or anatomical 
variation causing a difficulty in duodenal intubation. This resulted in CLE not being 
performed or lack of duodenal tissue or fluid acquisition in these subjects.  
The pilot study also served its second purpose, and generated invaluable results from two 
very important patient cohorts, namely patients with chronic pancreatitis and chronic liver 
disease. These findings were combined with those from the main study of AP patients and 
all analyses were undertaken once recruitment was completed.  
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CHAPTER 5 
RESULTS II 
METHOD ADAPTED TO INVESTIGATE PATIENTS WITH ACUTE 
PANCREATITIS 
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5.1  Introduction 
This study was thus designed to examine the role of CLE in identifying alterations in the 
intestinal barrier in patients with AP, and to compare these findings with a well-recognised 
gold-standard test, the lactulose:mannitol test. Due to the aggressive clinical course and 
severity of AP, patients are often acutely unwell in-patients. It was therefore imperative to 
establish a robust experimental protocol before embarking on an AP study that employed 
this relatively invasive test protocol (CLE).  
Over a hundred patients a year are admitted to the Royal Liverpool University Hospital, 
either as direct admissions or tertiary centre referrals. This rendered it an excellent centre to 
investigate this cohort of patients.  
 
5.2 Study Design and Recruitment 
Ethical approval was also sought in a 2-tier process and so once a protocol and standard 
operating procedure had been firmly established from the pilot study, we sought ethical 
approval to enrol patients who had acute pancreatitis and thereafter, patients who had severe 
acute pancreatitis and who were on the intensive care unit. 
In the second phase of the study, patients with acute pancreatitis were approached at the time 
of hospital admission and were invited to participate. It was however soon evident that 
subjects with severe disease were not being recruited and numbers in this subgroup were 
small. We established that those patients who had severe acute pancreatitis tended to be 
admitted directly to the intensive care unit from other centres, as tertiary referrals. A large 
number of these patients were intubated and sedated and therefore we submitted a separate 
ethics application to request approval to recruit such subjects with assent from a relative or 
next of kin. This application was however declined as it was deemed by the local ethics 
committee that the study participant themselves must be able to give consent for such a study 
and that a relative’s assent was inadequate. On this basis, potential subject numbers in the 
severe acute pancreatitis group were limited. All patients were then recruited by the same 
method as used during the pilot study.  
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5.3 Study Population 
A total of 54 patients were recruited during the second part of the study. Baseline 
demographics of these patients are detailed in table 8. All patients who had been admitted 
directly to the Royal Liverpool University Hospital with AP were recruited within 4 days of 
symptom onset and 48 hours of admission. Two patients with moderate disease and 6 with 
severe were recruited at a later stage in their illness due to different referral pathways.  
 
Table 8. Characteristics of Patients with Acute Pancreatitis 
Characteristic Mild Acute 
Pancreatitis 
Moderate 
Acute 
Pancreatitis 
Severe Acute 
Pancreatitis 
Sex M:F 17:18 10:1 5:3 
Median age (range), yrs 49.5 (17-82) 49 (22-76) 58.5 (37-80) 
Aetiology, n (%)    
Gallstones 14 (40) 6 (55) 3 (38) 
Alcohol 6 (17) 4 (36) 4 (50) 
Idiopathic 2 (6) 0 (0) 0 (0) 
Other (structural, post-ERCP, 
unknown) 
13 (37) 1 (9) 1 (12) 
Classification* (DBC), n (%)    
Sterile Local Complications 0 (0) 3 (27) 4 (50) 
Sterile Peripancreatic Necrosis 0 (0) 5 (45) 2 (25) 
Infected Peripancreatic Necrosis 0 (0) 0 (0) 2 (25) 
Persistent Organ Failure 0 (0) 0 (0) 8 (100) 
Transient Organ Failure 0 (0) 3 (27) 0 (0) 
Patients requiring necrosectomy, n 
(%) 
0 (0) 5 (45) 5 (63) 
Tertiary Referral Patients, n (%) 0 (0) 3 (27)  6 (75) 
Time since onset of symptoms to 
recruitment, n (%) 
   
12-24 hrs 21 (60) 5 (46) 1 (12.5) 
>24 hrs - 4 days 14 (40) 4 (36) 1 (12.5) 
>4 - 59 days 0 (0) 2 (18) 6 (75) 
* Nil with Critical Acute Pancreatitis recruited in patient cohort 
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5.4 Study Cohorts 
Of the patients who had acute pancreatitis, gallstones were the most common aetiological 
factor in those who had mild and moderate disease, whereas excess alcohol consumption 
was most prevalent in the severe group. Causes included gallstones (23 subjects), alcohol 
(14 subjects), unknown / idiopathic (13 subjects), structural (2 subjects), genetic (1 subjects), 
and post-ERCP (1 subject). Patients were diagnosed with clinical symptoms consistent with 
acute pancreatitis and had raised serum amylase activity. C-reactive protein levels were 
documented to range between 5 mg/l and 450 mg/l over the course of patients’ illnesses. 
White cell counts ranged from 5 x 109/l to 32.8 x 109/l. 
Of the patients with mild AP, none developed organ failure. 3 of 11 patients with moderate 
disease had transient organ failure and all 8 patients with severe AP had documented 
evidence of organ failure. Most of the 35 patients with mild AP were recruited within 48 
hours of direct admission to the Royal Liverpool University Hospital with a slight delay up 
to 4 days in a few cases due to logistical reasons. Of the moderate and severe AP cohorts, 3 
of 11 and 6 of 8 patients respectively were tertiary referrals from other centres. These patients 
were frequently enrolled later in their disease course and were recruited up to 59 days post 
presentation in the most extreme case. All patients underwent radiological or endoscopic 
evaluation at some stage during their admission and 41% (22 of 54) patients underwent a 
surgical procedure. These investigations and the surgical procedures undertaken are 
summarised in tables 9 and 10 below. 
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Number of Patients 
US CT EUS MRCP ERCP Total 
Mild Acute Pancreatitis 28 13 7 4 10 35 
Moderate Acute 
Pancreatitis 4 11 2 1 2 11 
Severe Acute 
Pancreatitis 3 8 0 0 2 8 
 
 
 
 
Number of Patients 
Laparoscopic 
Cholecystectomy 
Pancreatic Necrosectomy 
Mild Acute Pancreatitis 10 0 
Moderate Acute Pancreatitis 2 5 
Severe Acute Pancreatitis 0 5 
 
         
Table 10. Representation of patients with acute pancreatitis in study cohort undergoing 
surgical intervention within the time-frame of this study. 
Table 9. Representation of patients with acute pancreatitis in study cohort undergoing 
radiological or endoscopic intervention. 
Key: US - ultrasound; CT – computed tomography; EUS – endoscopic ultrasound; 
MRCP – magnetic resonance cholangiopancreatography; ERCP – endoscopic retrograde 
cholangio-pancreatography 
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5.5 Discussion 
The pilot study enabled us to identify potential problems with recruitment and data 
interpretation so that the protocol was fine tuned for this second main stage of the study. 
Patients with acute pancreatitis were intuitively a more unwell group and thus the 
recruitment process more challenging.  
The problems identified were addressed during the pilot study and prior to the ethics proposal 
submission for the recruitment of AP patients. It confirmed our suspicions that there would 
be a number of issues requiring resolution and confirmed the value of the pilot study in stable 
patients.  
The findings from this part of the study were combined with those from the pilot study of 
CP and CLD patients and all analyses were undertaken once recruitment was completed.  
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CHAPTER 6 
RESULTS III 
STUDY COHORTS COMBINED FOR ANALYSIS 
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6.1 Introduction 
Once recruitment was complete, data from both arms of the study were combined and 
analysed using established methods. The general cohorts and numbers evaluated are 
described in this chapter.  
 
6.2 Study Population 
A total of 182 patients were recruited in this prospective study between 2011 and 2014. All 
patients had negative blood cultures at the time of recruitment and H. pylori status was 
consistent across all cohorts with 25% positivity overall. 61 subjects withdrew consent after 
initial assessment and prior to undergoing a lactulose:mannitol test and CLE, and a further 
20 did not attend for CLE following the lactulose:mannitol test. In these cases, only serum 
and plasma samples were available for analysis. Thus, a total of 121 subjects underwent the 
lactulose:mannitol test and 84 attempted CLE due to a further 17 withdrawing consent.  
Of the 182 subjects, a total of 62 underwent successful CLE with images suitable for 
analysis, and aspiration of duodenal fluid following technical difficulties with 17 patients 
who underwent the procedure.  Duodenal aspirate was retrieved in a total of 62 patients also. 
The study population and summary of recruitment and analysis is depicted below in figures 
17 and 18.
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182 RECRUITED PATIENTS: 48 Healthy Controls : 54 AP : 47 CP : 33 CLD
CLE
31:16:20:17
IMAGE ACQUISITION
SELECTION OF 
IMAGES 
IMAGE 
SCORING
13:14:18:17
OGD REPORT
31:16:20:17
LACTULOSE:MANNITOL 
TEST
34:39:30:18
BLOOD
48:54:47:33
SERUM DAO
13 CONTROLS : 14 AP
CULTURES
48:54:47:33
PLASMA –
ENDOTOXIN
48:54:47:33
SERUM –
CYTOKINES
48:54:47:33
EDTA STORED
48:54:47:33
DUODENAL 
TISSUE
13:14:18:17
PATHOLOGY
13:14:18:17
SNAP FROZEN
13:14:18:17
ROUTINE 
HISTOLOGY
4 CONTROLS: 
12 AP
DUODENAL 
FLUID
13:14:18:17
CULTURE
13:14:18:17
MEDICAL 
HISTORY
48:54:47:33
Figure 17. Summary flow diagram to demonstrate recruitment cohort and all variables tested.   
Key: n:m:p:q = Healthy Controls : Acute Pancreatitis (AP) : Chronic Pancreatitis (CP) : Chronic Liver Disease (CLD) 
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2011- 2014
182 - Blood & Medical History
48HC:54AP:47CP:33CLD
121 L:M Test
34HC:39AP:30CP:18CLD
101 CLE RECRUITS
22 Unsuccessful CLE 62 Successful CLE
13HC:14AP:18CP:17CLD
62 Duodenal Fluid Aspirate
13HC:14AP:18CP:17CLD
84 attempted CLE
31HC:16AP:20CP:17CLD
17 DNA or withdrew consent
20 DNA
61Withdrew 
Consent
Figure 18. PRISMA diagram to summarise key components of recruitment and analysis.   
Key: n:m:p:q = Healthy Controls (HC) : Acute Pancreatitis (AP) : Chronic Pancreatitis 
(CP) : Chronic Liver Disease (CLD) 
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CONTROLS
19%, n=35
HEALTHY CONTROLS
7%, n=13
ACUTE 
PANCREATITIS (AP)
30%, n=54
CHRONIC 
PANCREATITIS (CP)
26%, n=47
CHRONIC LIVER 
DISEASE (CLD)
18%, n=33
TOTAL RECRUITED COHORT
CONTROLS
HEALTHY CONTROLS
ACUTE PANCREATITIS (AP)
CHRONIC PANCREATITIS (CP)
CHRONIC LIVER DISEASE (CLD)
Figure 19. Representation of recruited cohort of patients.    
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6.3 Image analysis  
A total of 498 confocal images were analysed; these were taken from macroscopically 
normal duodenal mucosa from 62 subjects (10 mild / moderate AP; 4 severe AP; 18 CP; 17 
CLD and 13 controls). A mean of 8 (4<n<17) images per patient, from distinctly separate 
mucosal points, were analysed by 2 independent scorers. Scoring was undertaken as 
previously detailed. Figure 20 is an example of a set of images analysed from a subject with 
acute pancreatitis, whilst figure 21 is an example of a set of images from a healthy control 
subject with no evidence of fluorescein leakage. Following the exclusion of images of poor 
quality, images from 62 patients were analysed by the 2 independent scorers using consistent 
criteria. To assess concordance, Cohen's kappa coefficient was performed as a statistical 
measure of inter-rater agreement. Binary data of each scorer’s total assessment of subjects 
with leakage and non-leakage were tabulated in a 2x2 table and the calculation was 
performed using a statistical calculator. Cohen's kappa coefficient was calculated at 0.603, 
consistent with substantial agreement and concordance as demonstrated in Table 11. 
 Scorer A 
Leakage No Leakage Total 
S
co
re
r 
B
 
Leakage 42 9 51 
No Leakage 6 23 29 
Total 48 32 80 
Number of observed agreements: 65 (81.25% of the observations) 
Number of agreements expected by chance: 42.2 (52.75% of the observations) 
95% confidence interval: From 0.424 to 0.783 
The strength of agreement is considered to be ‘good’. 
 
Table 11. Cohen’s Kappa co-efficient to assess inter-rater concordance between the 
two image scorers. 
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Figure 20. A set of images from a 
subject with acute pancreatitis, 
post-selection, ready for scoring 
by separate blinded investigators. 
Each image was selected based on 
being of good quality without 
movement artefact and with 
adequate fluorescence. Images 
were acquired from distinctly 
separate points on the duodenal 
mucosa. The arrows demonstrate 
sites of fluorescein leakage 
rendering a positive score for each 
image. 
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Figure 21. A set of images from a healthy control subject, post-selection, ready for scoring by separate 
blinded investigators. There was no evidence of fluorescein leakage in the images from this particular 
control subject. 
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6.4 Helicobacter pylori detection 
All patients were tested for Helicobacter pylori by means of either rapid urease test on gastric 
antral biopsy or antibody testing of serum samples. All patients recruited during the pilot study 
had retrospective serum H. pylori IgG tested and those within the main study cohort had 
prospective urease testing of gastric tissue. 24% of the overall population in the study were 
positive for Helicobacter pylori, confirming current or past infection. 76% were negative. The 
urease test only detects active current infection. The serum antibody test is also positive in 
active infection, but can also be positive if there has been past infection, hence a positive 
results indicates either past or current infection. Individual cohorts were similar in their 
distribution (positive:negative): Controls: (23%:77%); AP (36%:64%); CP (24%:76%) and 
CLD (22%:78%). (Figure 22) 
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Figure 22. A. Percentage prevalence of H. pylori in the study population cohorts.  
B. Overall prevalence of H. pylori in the study population.  
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 Healthy Controls Acute Pancreatitis 
Chronic 
Pancreatitis 
Chronic Liver 
Disease 
Total 
Number of patients recruited 
48 
54 47 33 182 
Number of patients endoscoped 39 16 24 22 101 
Number of patients with blood tests only 9 38 23 11 81 
Cytokines analysed 48 54 47 33 182 
Direct endotoxin analysed 24 13 25 21 83 
Endotoxin IgG analysed 48 54 47 33 182 
Endotoxin IgM analysed 48 54 47 33 182 
Helicobacter pylori tested 43 11 25 23 102 
Number of patients with scorable images 31 16 20 17 84 
Number of patients with L:M ratio tested  34 39 30 18 121 
Number of patients with blood cultures taken 48 54 47 33 182 
Number of patients with duodenal fluid cultured 33 16 20 20 89 
 
 Table 12. Tabulated summary of recruitment.  
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 Control Subjects Acute Pancreatitis Chronic Pancreatitis Chronic Liver Disease 
Total number of gastroscopies 
performed 
39 16 24 22 
 
Normal 
24 13 17 4 
Portal hypertensive gastropathy and / or 
varices 
0 0 2 12 
Gastric / Duodenal Ulcer 1 0 1 2 
Gastritis / duodenitis 1 2 4 2 
Oesophagitis 
 
4 1 0 3 
Hiatus Hernia 
 
4 0 1 1 
Pyloric stenosis 
 
1 0 0 0 
Benign fundic gland polyps 
 
2 0 0 0 
Barrett’s oesophagus 
 
1 0 0 0 
 
Table 13. Table of gastroscopy findings across all cohorts.  
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6.5 Discussion 
By means of the two combined studies a good number of patients were recruited allowing 
meaningful analyses. Multiple factors and variables were assessed generating a large depth of 
data and invaluable information from three pivotal study cohorts. Concordance of the new 
variable under scrutiny was measured and cohorts were divided into appropriate subgroups.  
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CHAPTER 7 
RESULTS IV 
CONFOCAL LASER ENDOMICROSCOPY AND LACTULOSE MANNITOL 
STUDIES DEMONSTRATE CHANGES  
IN INTESTINAL PERMEABILITY  
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7.1 Introduction 
Further to the successful development of a protocol that could be adhered to for all cohorts 
studied, and completion of the pilot study, ethical approval was successfully obtained to study 
AP subjects. CLE was therefore used to assess fluorescein leakage as a measure of intestinal 
permeability in patients with CP, CLD and AP.  
Various comparisons were feasible between disease groups and healthy controls, and 
subsequent sub-group analyses were also undertaken. These subgroups included patients with 
different severities of AP and conservatively versus surgically managed patients with CP. 
CLE findings were also compared to the results of another intestinal permeability test in the 
same subjects, namely the lactulose:mannitol ratio. Lactulose:mannitol tests were sent to 
another laboratory at Alder Hey children’s hospital for processing using high pressure liquid 
chromatography.  
To consolidate our findings further in subjects with AP, we also measured the concentration 
of serum DAO (an enzyme expressed at the apical end of mature villus cells, which has been 
reported to demonstrate changes in activity with IP changes). 
 
7.2 Fluorescein Leakage as a measure of intestinal permeability 
7.2.1 CLE demonstrated increased fluorescein leakage in AP patients 
Fluorescein is detected as the white element within each CLE image. It can be distinguished 
from villous architecture and is present within inter-villous capillaries when the intestinal 
barrier is intact (Figure 23A). Loss of barrier integrity results in fluorescein leaking out of the 
capillaries into the lumen (Figure 23B).  
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Figure 24 demonstrates examples of images that were analysed from each of the study cohorts: 
chronic liver disease, chronic pancreatitis, severe acute pancreatitis, mild acute pancreatitis, 
moderate acute pancreatitis and healthy controls.  
FL 
A 
B 
Figure 23.  
(A) Duodenal villi in a control patient with no evidence of fluorescein 
leakage into the gastrointestinal lumen.  
(B) Duodenal villi in a patient with Acute Pancreatitis showing fluorescein 
leakage (FL) into the gastrointestinal lumen consistent with loss of the 
permeability barrier. 
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CLD 
Figure 24. Representative images from each of the cohorts examined. Key: CLD – chronic liver disease; CP – chronic pancreatitis; SAP 
– severe acute pancreatitis; MAP – mild acute pancreatitis; HC – healthy control; MOD AP – moderate acute pancreatitis 
CP 
HC 
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Patients with mild, moderate and severe AP were grouped as ‘AP’ for initial analysis with 
further sub-group analysis being undertaken according to disease severity. Similarly, CP 
patients were initially analysed as a pooled cohort with further sub-group analysis being 
performed according to whether the disease was conservatively or surgically managed. By 
chi-square analysis, fluorescein leakage was found to be significantly higher in patients with 
AP compared with healthy controls (p=0.035) (Figure 25) and in patients with severe AP 
compared with healthy controls (p=0.015). This was the same in patients with CP compared 
with healthy controls (p=0.027) (Figure 25) and in patents with surgically managed CP 
compared with healthy controls (p=0.032) (Figure 26). Fluorescein leakage was also 
significantly higher in patients with mild AP compared to healthy controls (p=0.049) and in 
patients with severe AP compared with healthy controls (p=0.015). (Figure 27) A higher 
proportion of patients with CLD were also found to have fluorescein leakage than no leakage, 
but this was not statistically significant when compared with healthy controls.  
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Figure 25. Fluorescein Leakage (FL) was significantly higher in patients with AP compared to healthy 
controls (*p=0.035) & in patients with CP compared with controls (*p=0.027) (chi-square *p<0.05). 
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Figure 26. Chi-Square Analysis to compare the presence of fluorescein leakage on duodenal CLE images between cohort 
groups.  Fluorescein leakage was significantly higher in patients with AP compared to healthy controls (*p=0.035) & in patients 
with surgically managed CP compared with healthy controls (*p=0.032). 
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Figure 27. Chi-Square and Fisher’s Exact Test Analyses to compare the presence of fluorescein leakage between 
patients with increasing severity of AP. Fluorescein leakage was significantly higher in patients with mild AP compared to 
healthy controls by chi-square test (*p=0.049) & in patients with severe AP compared with healthy controls by Fisher’s Exact 
Test (*p=0.03). 
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7.2.2 CLE demonstrated increased fluorescein leakage in CP patients with a history of 
gastrointestinal surgery when compared with healthy controls 
By chi-square analysis, fluorescein leakage was significantly higher in patients with CP who 
had a history of gastrointestinal (GI) surgery when compared with healthy controls (p=0.032). 
(Figure 28) There was no statistical significance between patients with CP who had not 
undergone surgery when compared with healthy controls; nor when compared with patients 
who did have a history of GI surgery. 
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Figure 28. Fluorescein leakage was significantly higher in patients with CP who had a 
history of gastrointestinal (GI) surgery than healthy controls (*p=0.032). 
* 
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7.2.3 CLE demonstrated increased fluorescein leakage in excluded controls when compared 
with healthy controls 
To confirm that other factors have an impact on intestinal permeability, an analysis of subjects 
with dyspepsia who were not included in the ‘healthy control’ group due to co-morbidities 
(including a history of any previous surgery), endoscopic abnormalities or H. pylori positivity 
was undertaken. Figure 29 demonstrates that a combination of these factors in dyspeptic 
subjects resulted in significantly higher fluorescein leakage compared to healthy controls 
(p=0.012). On closer review of these subjects, it was noted that those with evidence of leakage 
frequently had a history of previous gastrointestinal surgery such as cholecystectomy or 
appendicectomy, sterilisation or hernia repair. Figures 30–32 demonstrate a comparison of 
fluorescein leakage between healthy controls and dyspeptic subjects who were not considered 
to be ‘healthy controls’ based on co-morbidities, positive gastroscopy findings, or positive H. 
pylori status, respectively.  
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Figure 29. Fluorescein leakage was significantly higher in patients with non-ulcer dyspepsia who had co-morbidities, including a 
history of a long-standing medical problem requiring long-term medication; previous surgery or positive H. pylori status; and positive 
gastroscopy findings, compared with ‘healthy controls’ (*p=0.012). 
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Figure 30. Fluorescein leakage was not found to be higher in subjects with non-ulcer dyspepsia with co-morbidities when compared 
with healthy controls. (p=0.058). 
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 Figure 31. Fluorescein leakage was not higher in subjects with non-ulcer dyspepsia who had positive gastroscopy findings when 
compared with healthy controls. (p=0.350).  
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Figure 32. Fluorescein leakage was not higher in dyspeptic subjects who were H. pylori positive when compared with healthy controls. 
(p=0.323). 
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7.3 Average Scores of Fluorescein Leakage as a measure of intestinal permeability 
7.3.1 When analysing the continuous variable of average scores of fluorescein leakage, 
there was no evidence to suggest that leakage presence statistically differs between groups  
The parameters that were analysed and compared for the presence or absence of fluorescein 
leakage were also analysed according to average scores of fluorescein leakage. No significant 
differences were found. (Figures 33-34) 
Fisher’s Exact Test was carried out for various group comparisons. In an analysis of subjects 
with CLD compared with healthy controls p=1.00; CP compared with controls p=1.00; MAP 
compared with controls p= 1.00; Moderate AP compared with controls p=0.56 and SAP 
compared with controls p=1.00. Thus there was no evidence to suggest that leakage presence 
statistically differs between these groups. 
In an analysis of CP patients who had a history of prior GI surgery compared to those without 
and healthy controls, comparison of the patients with a history of GI surgery against healthy 
controls reached statistical significance using this methodology (p=0.022). (Figure 35) The 
dyspeptic subjects that were excluded as healthy controls were also compared with healthy 
controls as described above. Average scores of fluorescein leakage in excluded control 
subjects who had positive gastroscopy findings and / or co-morbidities, including a history of 
previous surgery, showed higher levels of fluorescein leakage than healthy controls, and this 
also reached statistical significance (p=0.016). (Figure 36)
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Figure 33. Average scores of fluorescein leakage were not found to be significantly higher in patients with AP, CP and CLD 
when compared to healthy controls. CLD compared with healthy controls p=1.00; CP compared with healthy controls p=1.00; 
AP compared with healthy controls p=0.106. 
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Figure 34. Average scores of fluorescein leakage were not found to be significantly higher than controls in patients with AP 
when sub-classified according to disease severity by Fisher’s Exact Test. MAP compared with healthy controls p=1.00; 
moderate AP compared with healthy controls p=0.56; SAP compared with healthy controls p=1.00. 
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Figure 35. Average scores of fluorescein leakage were found to be significantly higher in subjects with CP who had 
undergone GI surgery when compared with controls. A comparison of the cohort of CP subjects with a history of GI 
surgery compared with healthy controls (p=0.022*) reached statistical significance. CP with GI surgery versus CP with 
no GI surgery p=0.608; CP with no GI surgery versus healthy controls p=0.1687. 
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Figure 36. Average scores of healthy controls compared with controls who were excluded as a result of co-morbidities, 
(p=0.022*); positive H. pylori status (p=0.341); OGD abnormalities (p=0.295); or a combination of these factors (p=0.016**). 
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7.4 Lactulose : Mannitol Ratio as a measure of intestinal permeability  
7.4.1 Lactulose:mannitol ratio confirmed increases in IP in AP patients and surgically 
managed CP patients 
The lactulose:mannitol (L/M) ratio was measured as a standard assay of IP in 96 patients (9 
controls; 39 AP; 30 CP; 18 CLD). Control subject numbers were lower due to a delay in 
acquisition of the solution and a lack of uptake of recall appointments in this group. Serum 
absorption was measured 90 minutes after ingestion of the L:M solution with higher ratios 
indicating higher levels of intestinal permeability. Patients were grouped for analysis in the 
same way as described above for the confocal image analysis. HPLC analysis was performed 
by Andrew Hodgkinson at Alder Hey children’s hospital, Liverpool. This is not a standard 
clinical test and therefore it is not readily available in all laboratories. The team had acquired 
the equipment and expertise for a previous research study investigating gut permeability in a 
paediatric cohort and were willing to assist our study both with equipment and skillset.   
In the example chromatograph, (figure 37) the x-axis corresponds to elution time in minutes 
and the y-axis the current generated at the electrochemical cell. The time to elute from the 
chromatography column is displayed against each sugar, with the smaller sugars eluting 
earlier. The concentration of mannitol and lactulose in each sample is calculated from a 3 point 
standard curve for each sugar. The internal standard, melibiose is added to all standards and 
unknowns and taken through the extraction process which is then used in the calculation to 
correct for any losses in sample preparation or injection. The L:M ratio is simply the 
concentration of lactulose divided by the concentration of mannitol for each sample. 
Mann-Whitney U tests were used to compare groups. The serum 90-minute L:M ratio was 
significantly increased in patients with AP compared to healthy controls (p=0.031). (Figure 
38) An increase was also observed in patients who had surgically managed CP compared with 
healthy controls (p=0.017), and compared with CP patients who were  conservatively managed 
(p=0.013). (Figure 39)
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Figure 37. An example HPLC chart demonstrating concentrations of mannitol and lactulose and a standard sugar, melibiose. 
Generated and interpreted by Dr Andrew Hodgkinson, Alder Hey Hospital, Liverpool. 
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Figure 38. The lactulose:mannitol (L/M) ratio was recorded as a standard measure of intestinal permeability. Serum 
absorption was measured at 90 minutes with higher ratios indicating higher levels of permeability. Patients with AP were 
found to have significantly higher L/M ratios when compared to healthy controls (*p=0.031). (MW *p<0.05); (Kruskal 
Wallis – p=0.32).  
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Figure 39. Mann-Whitney U Tests to compare intestinal permeability index between cohorts. Serum 90 minute 
lactulose/mannitol ratio was significantly increased in patients with AP compared to healthy controls (*p=0.031) & in 
patients with surgically managed CP compared with healthy controls (*p=0.017) and patients with conservatively managed 
CP (*p=0.013); (Kruskal Wallis – p=0.03*). 
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7.4.2 Lactulose:mannitol ratio confirmed statistically significant increase in IP in patients 
with moderate AP, and in excluded controls when compared with healthy controls 
The serum 90-minute lactulose:mannitol ratio was significantly higher in patients who had 
moderate AP compared to controls (p=0.033*). (Figure 40) An increase was also evident in 
patients who had moderate AP compared with those who had mild AP (p=0.028*), and 
compared with patients who had severe AP (p=0.046*). A comparison of healthy controls and 
dyspeptic subjects who were excluded from being controls also demonstrated significant 
differences. Serum 90-minute lactulose:mannitol ratio was significantly increased in dyspeptic 
patients with co-morbidities, including a history of previous surgery (p=0.011*); positive H. 
pylori status (p=0.0007***); abnormal gastroscopy findings (p=0.017*); and a combined 
group of one or more of these factors (p=0.004**) compared with healthy controls.  
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Figure 40. Serum 90-minute lactulose:mannitol ratio was significantly increased in 
patients with moderate AP compared to controls (p=0.033*); moderate AP compared 
with mild AP (p=0.028*), and moderate AP compared with severe AP (p=0.046*). 
Mild AP compared with controls p=0.173; MAP compared with SAP p=0.119; SAP 
compared with healthy controls p=0.633; (ANOVA – p=0.01*). 
  * 
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7.5 In patients with AP, Diamine oxidase concentration increased with increasing 
fluorescein leakage 
Diamine oxidase (DAO) is specifically located at the apical end of mature villus cells. Its 
activity reflects the integrity and maturity of the small intestinal mucosa and it enters the blood 
as intestinal permeability increases. Serum DAO concentration was measured only in AP 
patients and those healthy controls who also underwent CLE, 14 and 13 subjects respectively. 
The serum concentration of DAO was analysed against the continuous variable of average 
score for fluorescein leakage, by means of Spearman’s R correlation. This showed that serum 
DAO concentration increased with increasing fluorescein leakage, as demonstrated by CLE. 
Spearman’s rank correlation was statistically significant between these two parameters 
(p=0.035). (Figure 41) When the discrete variable of fluorescein leakage and the 
lactulose:mannitol ratio were analysed for the same variables, statistical significance was not 
reached as demonstrated in figures 42 and 43 below.  
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Figure 41: The concentration of DAO increased relative to the amount of fluorescein leakage, as demonstrated 
by CLE. Spearman’s rank correlation was found to be statistically significant between these two parameters 
(r = 0.40, 95% CI – 0.02 to 0.68, p = 0.035) 
). 
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 Figure 42: Patients with AP were not found to have higher serum DAO concentrations when 
compared with healthy controls. (p=0.150) 
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Figure 43. The concentration of DAO was not found to have increased significantly relative to the 
lactulose:mannitol ratio. Spearman’s rank correlation p=0.363. 
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7.6 Duodenal Tissue 
Due to the limitations of time on the study, duodenal tissue analysis could not be undertaken. 
Immuno-histochemical analysis was initially planned with staining for active caspase 3 
activity and DNA fragmentation ELISA. Wax blocks were prepared by a pathology technician 
and initial discussions with experts undertaking immunohistochemistry were held, but this 
aspect was subsequently excluded from the study prior to experimental planning. For part of 
the main study cohort however, duodenal tissue was sent from patients with AP and controls 
to the laboratory in formalin for H&E analysis. (table 14) Tissue acquisition was impractical 
for those patients who were endoscoped on the intensive care unit. Thus, due to very limited 
numbers, meaningful analysis of this dataset is not feasible. Of the 16 patients with AP who 
underwent CLE, 12 had duodenal biopsy histology assessed, but only one of these was from 
the severe AP cohort, rendering it difficult to assess for changes based on severity. 10 of the 
12 distal duodenal biopsy samples from patients with AP, and all 4 biopsies taken from control 
subjects, were reported as showing normal histology. Two patients with AP (1 mild, 1 
moderate) were reported to have evidence of duodenal inflammation.   
 Normal Inflammation Total 
Healthy Controls 4 0 4 
Mild Acute Pancreatitis 8 1 9 
Moderate Acute 
Pancreatitis 
1 1 2 
Severe Acute Pancreatitis 1 0 1 
 
 
 
 
 
Table 14. Summary table of duodenal histology results. 
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CHAPTER 8 
RESULTS V 
ASSESSMENT OF PARAMETERS OF INFECTION INCLUDING MICROBIAL 
FLORA AND ENDOTOXINAEMIA 
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8.1 Introduction 
On the basis that intestinal permeability is associated with bacterial translocation and 
endotoxaemia, we undertook multiple further analyses to consolidate our findings further and 
investigate the potential of infection associated with the process. 
We analysed cultures of duodenal aspirates from all patients undergoing CLE and assessment 
of endotoxinaemia using anti-endotoxin antibodies and a direct endotoxin assay. We have 
compared the findings from the various modalities used, to investigate the extent to which 
alterations in intestinal permeability correlated with changes in duodenal microbial growth 
and endotoxinaemia. We have focussed on subjects with acute pancreatitis but have also made 
comparisons between the other cohorts studied where relevant.  
 
8.2 Intestinal Permeability and associated changes in duodenal fluid microbial growth 
8.2.1 Fluorescein leakage and the presence of duodenal organisms in AP  
Duodenal fluid was aspirated and cultured in all 62 patients who underwent CLE. Chi square 
analysis showed that patients with AP had significantly higher microbial growth in their 
duodenal fluid than healthy controls (p=0.004). (Figure 44B) The identification of fluorescein 
leakage by CLE into the gastrointestinal lumen was also significantly associated with the 
presence of cultured duodenal organisms in patients with AP (p=0.003). (Figure 44A) Patients 
with severe AP were also found to have significantly higher microbial growth in their 
duodenal fluid compared to healthy controls (p=0.002). (Figure 44B) 
A sub-group analysis of patients with CP who had been managed surgically or conservatively 
did not show any statistically significant differences. (Figure 45) 
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 Figure 44. Chi Square analyses to assess association between fluorescein 
leakage and positive duodenal fluid cultures. (A) Patients with AP were found 
to have significantly higher microbial growth in the duodenal fluid than healthy 
controls (**p=0.004). The identification of fluorescein leakage by CLE into the 
gastrointestinal lumen was also significantly associated with the presence of 
positive duodenal cultures in patients with AP (p=0.003). (B) Patients with 
severe AP were found to have significantly higher microbial growth in the 
duodenal fluid than healthy controls (**p=0.002).  
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8.2.2 Distribution of identified duodenal organisms within the study cohorts 
Several duodenal organisms were identified within subjects who had CP, CLD and 
particularly AP. These were grouped as positive duodenal fluid culture and included: 
• Yeasts, Staphylococcus aureus, Coliforms, Pseudomonas, Enterococcus, Gut 
anaerobes 
The majority of controls had negative duodenal fluid culture and were primarily reported as: 
• No Growth or Mixed Oral Flora  
Charts below demonstrate the distribution of organisms within the cohorts. (Figure 43) 
Approximately 2/3 of subjects with CP, CLD and non-ulcer dyspepsia had negative duodenal 
fluid cultures. The small proportion of patients with positive duodenal fluid cultures in the 
CLD and CP cohorts showed the presence of Staphylococcus aureus, coliforms or yeast. The 
patients with AP had much higher proportions of positive cultures and diversity in microbial 
growth. Positive cultures in this cohort included the above organisms but also Pseudomonas 
and Enterococcus species. (Figure 44A and 44B) 
Figure 45. The identification of fluorescein leakage by confocal endomicroscopy 
into the gastrointestinal lumen was not significantly associated with the presence of 
positive duodenal fluid cultures in patients with conservatively (non-surgically) 
managed CP (p=0.488; p=1.00). 
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Figure 46. The pie charts demonstrate the duodenal culture findings from the 
patients from each of the cohorts: A – healthy controls; B – CP; C – CLD; The 
figures represent the number of patients with each of the gut flora mentioned. 
Approximately two thirds of subjects with CP, CLD and healthy controls had 
negative duodenal fluid cultures with either no growth or mixed oral flora only.  
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Figure 47. The pie charts demonstrate the duodenal culture findings from the 
patients from each of the cohorts: D – mild AP; E – moderate AP; F – severe 
AP. The figures represent the number of patients with each of the gut flora 
mentioned. (D-F) Patients with AP had a much higher proportion of positive 
cultures and diversity in growth.  
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Figures 48: 
A and B. Bar chart and area graph to further demonstrate differences in duodenal 
fluid microbial growth within cohorts. 
Key: MOF – mixed oral flora; COL – coliforms; STAPH – staphylococci; YEAST 
– yeast; PSD – pseudomonas; ENT – enterococci; GUT AN – Gut Anaerobes 
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8.3 Assessment of endotoxinaemia 
8.3.1 Anti-endotoxin antibodies showed inverse correlation to severity of AP 
We measured the Endocab ELISA IgG and IgM and performed Mann Whitney U analyses to 
compare levels between 54 patients with AP (35 mild AP; 11 moderate AP; 8 severe AP) and 
13 healthy controls. IgG anti-endotoxin antibodies (EndoCab IgG) were significantly lower in 
patients with severe AP when compared to those with mild AP (p=0.046) and also in severe 
AP and moderate AP when compared to healthy controls (p=0.022; p=0.025, respectively). 
(Figure 49A) IgM anti-endotoxin antibodies (EndoCab IgM) were also significantly lower in 
patients with severe AP when compared to those with mild AP (p=0.036) and also in patients 
with severe AP, moderate AP and mild AP when compared to healthy controls (p=0.001; 
p=0.011; and p=0.041, respectively). (Figure 49B) Circulating endotoxins are bound by anti-
endotoxin antibodies, hence the levels decrease inversely to the amount of endotoxin 
challenge, and the level of decline is a reflection of clinical severity.  
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Figure 49.  (A) IgG Anti-endotoxin antibodies (EndoCab IgG) were significantly 
lower in patients with severe AP when compared to mild AP (*p=0.046) and also 
in severe AP and moderate AP when compared to healthy controls (*p=0.022; 
*p=0.025, respectively). (B) IgM Anti-endotoxin antibodies (EndoCab IgM) were 
significantly lower in patients with severe AP when compared to mild AP 
(*p=0.036) and also in severe AP, moderate AP and mild AP when compared to 
healthy controls (**p=0.001; *p=0.011; & *p=0.041, respectively).   
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8.3.2 Direct Endotoxin Assay 
The results from the Limulus amoebocyte assay were deemed unsuitable for further analysis. 
Of 90 randomly selected patients (24 controls; 20 AP; 25 CP and 24 CLD), only 4 discrete 
values were acquired: 2 from CP patients; 1 from a CLD patient and 1 from a healthy control 
subject. Due to interference, significant dilution was required meaning that the assay could 
only report values above 0.5 IU/ml with the first batch analysis or above 0.1 IU/ml with the 
second batch.  86 values were reported as <0.5 or <0.1, rendering further comparison difficult. 
Further testing using this assay for the full cohort was therefore not undertaken.  
 
8.4 Blood Cultures 
All patients in all cohorts were reported to have negative blood cultures from samples taken 
at the time of recruitment. It is however important to note that blood cultures in the patients 
with SAP on the intensive care unit were often performed at a late stage in their course of 
illness, after they had received antibiotic treatment for infective episodes.  
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CHAPTER 9 
RESULTS VI 
ANALYSIS OF IMMUNE RESPONSE BY  
REVIEW OF CYTOKINE RESPONSE 
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9.1 Introduction 
In the final stages of our study, we investigated immunological responses by means of 
analysing serum cytokine concentrations. We investigated variations as severity of acute 
pancreatitis increased, and also in the pilot study cohorts of chronic pancreatitis and chronic 
liver disease. 
 
9.2 Cytokine Analysis 
9.2.1 Measurement of Serum Cytokine concentrations to differentiate severity of AP 
patients 
A comparison of the serum concentrations of various cytokines in patients with mild (n=8), 
moderate (n=11) and severe AP (n=35) and healthy controls is demonstrated in figure 50. IL-
6 levels showed a statistically significant increase between each tier of AP disease severity 
(Kruskal Wallis: p=<0.0001). (Figure 51) A number of cytokines also demonstrated 
statistically significant increases in expression in mild AP, moderate AP and severe AP when 
compared with healthy controls, by Mann Whitney U tests. (Figure 52)  These included IL-6, 
IL-12, GCSF, IL-1b, 1L-10, VEGF, IL-8, MIP-1a and FGF-Basic. A combination of (A) 
Immune stimulatory mediators, (B) Immunoregulatory mediators, (C) Vascular remodelling 
mediators, and (D) Chemotactic Mediators were identified as being up-regulated in AP.  
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Figure 50 (A-D). Median and interquartile ranges for 24 cytokines in patients with varying severity of AP and healthy controls. Several 
cytokines demonstrated statistically significant increases in expression in MAP, moderate AP and SAP when compared with controls (* 
p=<0.05, **p<0.01, ***p<0.001, ****p,0.0001 - MW); and also in SAP when compared with MAP (# p=<0.05, ## p<0.01, ### p<0.001, 
#### p,0.0001 - MW). A combination of (A - above) 12 Immune stimulatory mediators, (B - below) 3 Immunoregulatory mediators, (C - 
below) 3 Vascular remodelling mediators, and (D - below) 6 Chemotactic Mediators were identified to be up-regulated in acute pancreatitis. 
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Figure 51. Log 2 IL-6 levels showed a statistically significant increase between each tier of acute 
pancreatitis correlating closely with disease severity and enabling differentiation between sub-
groups (Kruskal Wallis: p=<0.0001).  
 
Log 2 
IL-6 
184 
 
 
 
 
 
Fig. 52. Hierarchical Clustering Diagram showing 9 of 24 cytokines which demonstrated a 
significant increase in expression in patients with SAP when compared with healthy controls and 
patients with MAP – figure produced by Brian Lane.  
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9.2.2 Measurement of Serum Cytokine concentrations in CP and CLD cohorts 
The same cytokines were also analysed for the patients with CLD and CP. Only one of the 
cytokines, IP-10, demonstrated a statistically significant increased serum concentration in 
CLD, by Mann Whitney test as shown in figure 54. The results from the other cytokines 
examined are also shown in figure 53. Although up-regulation of cytokine expression was 
seen in patients with CP and CLD, in many cases it was also seen in the healthy controls also 
and hence the differences were not found to be statistically significant.  
The chemokine that did show a statistically significant rise in expression in CLD, IP-10, was 
further analysed to look at sub-groups of patients with liver disease as shown in figure 55. No 
statistically significant differences were seen between patients with CLD of varying severity 
and aetiology in this cohort.  
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Figure 53. Box and whisker plots of cytokine expression as analysed using the LUMINEX assay, for patients with CP, CLD 
and non-ulcer dyspepsia (NUD). Only IP-10 in CLD showed a statistically significant up-regulation in any cohorts compared 
with NUD.  
Key: Cytokine expression on y axis expressed in pg/ml. 
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Figure 54. Mann Whitney analysis confirmed statistically significant up-regulation of IP-10 in 
patients with CLD when compared with the non-ulcer dyspepsia cohort (p=0.007). 
Key: y axis – IP10 in pg/ml 
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 Figure 55. A sub-analysis of IP-10 expression in sub-groups of patients with liver disease was undertaken to see 
if expression was affected by aetiology (A) or severity (B). No statistically significant differences were found.  
Key: C. Pugh = Child’s Pugh Score of liver cirrhosis; y axis – IP10 in pg/ml 
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10.1 Overview 
Using fluorescein leakage by CLE, we demonstrated an increase in intestinal permeability in 
patients with acute pancreatitis, severe acute pancreatitis, chronic pancreatitis and surgically 
managed patients with CP, when compared with healthy controls. We were also able to 
demonstrate that other co-morbidities and positive gastroscopy findings and H. pylori status 
also impacted on intestinal permeability and showed statistically significant increases in 
fluorescein leakage, when compared with healthy controls. The discrete variable of positive 
or negative fluorescein leakage was found to be of greater utility during this study, than the 
continuous variable of ‘average score’. Trends for ‘average score’ were similar to those 
described above but analyses did not reach statistical significance when this parameter was 
analysed. The concentration of the enzyme DAO also increased relative to the amount of 
fluorescein leakage in patients with acute pancreatitis. The trend was also higher in patients 
with AP compared with healthy controls, but this did not reach statistical significance. 
The lactulose:mannitol ratio confirmed an increase in intestinal permeability in patients with 
acute pancreatitis and in patients with chronic pancreatitis who had been managed surgically. 
Also, similar to CLE, L:M ratios were also increased in those dyspeptic patients who had other 
co-morbidities, positive gastroscopy findings or positive H. pylori status. In this study, 
lactulose:mannitol ratios did not show statistically significant increases in patients with severe 
acute pancreatitis when compared with healthy controls or patients with mild and moderate 
AP. L:M ratios in moderate AP, were however found to be higher than in patients with mild 
and severe AP and healthy controls. It is important to note however, that the number of patients 
with severe AP was very small. These patients were also recruited at a later stage in their 
disease process than those with mild and moderate disease, who were mostly recruited at the 
time of admission. It is therefore possible that L:M ratio is maximum at the onset of disease, 
whereas epithelial changes may persist for longer, potentially explaining the findings of this 
study.  
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In our study of infection and microbiology, patients with acute pancreatitis, and particularly 
those with severe acute pancreatitis, had significantly higher microbial growth in their 
duodenal fluid compared with healthy controls. Organisms that were demonstrated in 
‘positive’ duodenal cultures included Pseudomonas, Enterococcus, gut anaerobes, yeasts, 
Staphylococcus aureus and coliforms, whereas ‘negative’ duodenal cultures were reported as 
showing either no growth or mixed oral flora. Patients with AP had much higher proportions 
of positive cultures and a greater diversity of cultured organisms, including the presence of 
Pseudomonas and Enterococcus. 
In summary, the measurement of fluorescein leakage using CLE was found to be a useful 
means of detecting increased intestinal permeability in patients with acute pancreatitis, chronic 
pancreatitis and chronic liver disease. Findings were confirmed by the lactulose:mannitol ratio 
and further corroborated by the results of duodenal fluid cultures. These findings support the 
concept that bacterial translocation is associated with increases in intestinal permeability, 
though our methodology does not allow us to comment on the mechanism by which this 
occurs. Fluorescein leakage has been identified by in vivo histology, but the site of leakage or 
‘gap’ in epithelium has not been identified as may have been the case if the Watson grading 
system had been used.  
Positive duodenal cultures were more commonly observed in the severe acute pancreatitis 
cohort, along with increased fluorescein leakage by means of CLE. Both these findings 
support the hypothesis that intestinal permeability increases as the severity of acute 
pancreatitis increases, along with bacterial translocation. A key aim in the management of 
patients who have acute pancreatitis, is the identification of the level of severity of disease at 
the time of presentation.  
Further to the intestinal permeability changes demonstrated by CLE, we have also investigated 
a number of parameters that have been reported to alter with increasing severity of disease to 
further support our findings. For example anti-endotoxin antibodies showed a significant 
inverse correlation with the severity of acute pancreatitis. In terms of immunological response, 
we have demonstrated that the serum concentrations of a number of cytokines were also found 
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to be statistically significantly increased in patients with AP, with IL-6 found to enable 
differentiation of disease severity. 
In summary, the key findings of our study are in keeping with the literature reports with 
relation to intestinal permeability, infection and the gut microbiome and immunology. Most 
significantly, we have demonstrated a rise in gut flora, IL-6, and a relative correlation with 
endotoxinaemia as intestinal permeability rises also with increasing severity of acute 
pancreatitis.  
 
10.2 The Gut Microbiome in Acute Pancreatitis 
The typical healthy person is inhabited with trillions of microbes whilst no two healthy people 
will share the same microbiome. Multiple factors influence the microbiome from the time in 
utero through birth, infancy and life, including diet, environment, the aging process, 
medications and stress. [284] Most of the human adult microbiota lives in the gut with the 
colonisation of over 1000 different species. A core gut microbiome is shared by healthy adults 
and plays a role in the maintenance of health status, digestion, immune system development, 
defense against infections, synthesis of vitamins, fat storage, angiogenesis regulation, and 
behaviour development. Thus, it is postulated that alterations of the human gut microbiome 
can play a role in disease development. Interestingly, microbial richness, intended as bacterial 
diversity, is usually considered an indicator of a healthy status whilst reduced bacterial 
diversity has been related to obesity and immune-related and inflammatory diseases. [285, 
286] There is an overlapping developmental course of the gut microbiota and intestinal barrier. 
The intestinal barrier acts as a shield which can be modified by the gut microbiota or its 
metabolites.  
Actual evidence of the link between microbiota imbalance and pancreatic diseases remains 
limited. Dysbiosis appears to be present in acute and chronic pancreatitis.  As compared to 
healthy controls, the blood and neutrophil-associated microbiomes in the patients were 
significantly altered, with an expansion in Bacteroidetes and Firmicutes as well as a decrease 
in Actinobacteria. [287] Another study investigated alterations of the intestinal bacteria and 
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its associations with the inflammation in acute pancreatitis. Dramatic alterations in the 
predominant faecal microbiota were observed in most of both MAP and SAP patients. In 
addition, the rates of the multiorgan failures and infectious complications in the patients with 
SAP with altered intestinal microbiota were significantly higher than in those whose intestinal 
microbiota remained unaltered. Enterococcus increased and Bifidobacterium decreased in the 
patients with SAP compared to the patients with MAP. Serum IL-6 were positively correlated 
with Enterobacteriaceae and Enterococcus and negatively correlated with Bifidobacterium, 
whereas plasma endotoxin positively correlated with Enterococcus. The intestinal bacteria 
most frequently altered in both the patients with MAP and those with SAP significantly 
correlated with inflammation, which indicated that the intestinal microbiota may be involved 
in the progression of AP. [288] The increase in Enterococcus reported in this study, along with 
the findings related to IL-6 and endotoxin are in keeping with our own findings strengthening 
further the outcomes from our evaluation.  
More recently, Li et al conducted a prospective observational case series exploring the 
microbial landscape in peripheral blood and neutrophils in SAP patients. They were able to 
identify diverse bacterial microbiomes within peripheral blood and neutrophils and discovered 
that the microbiome is altered in SAP patients. They also suggest that the perturbation of blood 
microbiota, which likely represents a disease-provoking state, might be involved in the 
progression of sepsis. They report that the blood microbiome is mainly composed of gut-
associated organisms in SAP patients. It is therefore speculated that a bacterial consortium 
from the gut, rather than single or several organisms, might migrate into systemic circulation 
during sepsis. [289] 
The symbiosis between the microbe and its host has been described to be disturbed in a 
multitude of diseases, especially in critically ill patients. Trauma, sepsis, systemic 
inflammatory response syndrome, and other conditions lead to shifts in the composition of the 
intestinal microbiome, which are correlated with clinical outcome. Studies have shown that 
critical illness though not related directly to bacterial infections, demonstrate alterations in the 
microbiome and the subsequent dysbiosis impacts on the pathogenesis of critical illness. The 
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microbiome can be manipulated therapeutically, as has been shown by the success of faecal 
microbiota transplantation in the treatment of refractory Clostridium difficile infection. [290, 
291] 
The intestinal microbiota is described as symbiotic in nature and involved in various 
processes, including the breakdown and absorption of nutrients, the production of vitamins 
and hormones, and the prevention of colonization by pathogens. The gut barrier plays a key 
role in the avoidance of inflammatory responses to the microbiota and is regulated by a finely 
tuned network of immune mechanisms for microbial recognition and tolerance. [292]  
Several studies report the use of commensal bacteria and probiotics to promote intestinal 
barrier integrity in vivo [293] although some studies have been negative or inconclusive. Many 
studies report enhancement of the intestinal barrier in vitro or protection from barrier 
disruption by probiotics. For example, the probiotic E.coli Nissle 1917 has been shown to 
prevent barrier disruption caused by infection with an enteropathogenic E. coli strain. [294] 
Metabolites secreted by Bifidobacterium infantis Y1, one of the components of the probiotic 
product VSL#3, leads to an increase in expression of ZO-1 and occludin while reducing 
expression of claudin-2 leading to enhanced effects on transepithelial resistance and altered 
ion secretion. [295] Probiotics have been shown to have beneficial effects in patients with IBD 
where E.coli Nissle 1917 is used to support maintenance of remission in patients with UC and 
VSL#3 reduces and protects against pouchitis in patients with UC. [296] [297] Recent reports 
have also demonstrated the value of probiotics for treatment in IBS and in fatty liver disease. 
Some of the probiotic trials in IBS demonstrated that the effects are correlated with an 
improvement of the intestinal permeability. An example is short-term active lactic acid 
bacteria treatment for diarrhoea-predominant IBS improved mucosal barrier function. [298]  
Since the intestinal permeability barrier has been shown to be compromised in critically 
unwell patients, we could assume that probiotic use would be of benefit in those patients who 
are generally treated on the intensive care setting. The classical treatment of loss of barrier 
function in the ICU patient is usage of antibiotics directed against gram-negative bacteria and 
improvement of intestinal perfusion by catecholamines and volume. Some studies suggested 
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a beneficial effect of selected probiotics and synbiotics on sepsis complications in patients 
with major abdominal surgery, but trials are few and patient numbers small to be able to extract 
a meaningful outcome of probiotic use in these patients. [299] Early evidence from animal 
studies and a small placebo-controlled trial suggested that probiotic prophylaxis stabilised 
intestinal barrier dysfunction, minimised bacterial translocation and reduced infectious 
complications. [181] [182] A major randomised placebo-controlled trial of probiotic 
prophylaxis in severe acute pancreatitis however contradicted these findings and demonstrated 
a significant increase in mortality associated with probiotic administration (due to jejunal 
necrosis), and showed no reduction in infection rates. [35].  
Enteral feeding on the other hand is thought to be effective in these patients as described earlier 
in this thesis.  
We have shown that CLE can be used to demonstrate increased intestinal permeability as AP 
severity increases, and that duodenal bacterial growth is also increased. CLE has enabled non-
invasive assessment of the cellular and molecular properties of tissues in real time, resulting 
in the concept of optical biopsy. [300] It is rapidly evolving and continues to be developed for 
new applications having been used in early studies in inflammatory bowel disease and 
Barrett’s oesophagus. [1, 301] More recent reports demonstrate its usefulness in the 
identification of pancreatobiliary pathology and GI malignancies. [302] [303, 304] Recent 
literature has shown that the intestinal permeability barrier is being identified as a significant 
aspect of many disease processes and hence a potential therapeutic target, not just in acute 
pancreatitis. With this in mind, the method of direct visualisation by confocal laser 
endomicroscopy and the identification of leakage or even mucosal barrier defects has been 
investigated and methodology improved. [305] [306] An interesting study conducted in 
Lusaka, Zambia evaluates the use of CLE to evaluate intestinal permeability to investigate 
patients with Environmental Enteropathy. [306] They comment that CLE is the only technique 
that can visualise epithelial cell shedding and potentially sites of barrier loss in patients during 
endoscopy in real time, enabling an understanding of the severity of epithelial disruption. The 
authors propose that it is plausible that initial minor defects in the barrier lead to the ingress 
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of bacteria increasing tissue concentrations of TNF and increasing pathology in a positive 
feedback loop. They report that they have shown a significant epithelial barrier defect in 
Environmental Enteropathy in vivo, which provides a plausible pathway for the bacterial 
translocation observed in many populations.  
 
10.3 A brief overview of immunological aspects in Acute Pancreatitis 
Cytokine concentrations have been demonstrated to be an accurate and objective method for 
the assessment of the severity of acute pancreatitis since they are involved in both the local 
and the systemic inflammatory responses in acute pancreatitis. The inflammatory process 
results in excessive leukocyte activation and increased migration of neutrophils to the 
inflamed area, with a consequent release of pro-inflammatory mediators including interleukins 
which influence progression to necrosis and SIRS (IL-1b, IL-6, IL-8, IL-10, IL-18 and TNF-
α). [202] Multiple studies detailed previously in this thesis have identified IL-6 to be a key 
mediator in the inflammatory response in AP. It is an excellent marker of the severity of acute 
pancreatitis with peak concentrations. TNF- α is also among one of the inflammatory 
cytokines that is produced once necrosis develops. Current research is working towards TNF 
as a potential target for therapy in AP since blocking the production and the effects of this 
cytokines is a strategy that makes sense in its treatment. A trial of infliximab therapy in AP 
patients is currently close to initiation and will provide some very interesting results. One case 
report however reports a case of AP induced infliximab, a monoclonal anti-TNF-α antibody. 
[208] Both pro-inflammatory and anti-inflammatory cytokines are released during the disease 
process. Pro-inflammatory mediators in acute pancreatitis include TNF-α, IL-1, IL-2, IL-6, 
and IL-18, and IL-8, platelet-activating factor, and reactive-oxygen and reactive-nitrogen 
species. With the release of these pro-inflammatory mediators, anti-inflammatory cytokines 
are concomitantly produced, leading to a compensatory response syndrome. Cytokines are 
involved in all aspects of the cascade leading to systemic inflammatory response syndrome 
and multiple organ dysfunction syndrome and indeed also in the release of mediators that are 
likely to exacerbate alterations in intestinal permeability. A recent study reported cytokine 
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responses in AP on day 3 from onset at a tertiary centre. Genotyping was done to correlate IL-
6, TNF-α and MCP-1 gene polymorphisms with cytokine levels. Serum IL-6 added 
significantly to the predictive value of SIRS for severe AP. [307] In a similar study, significant 
differences were found between patients with severe AP and those with mild or moderately 
severe AP in IFN-γ, IL6, TNF-α, GM-CSF, IL4, IL1b, and IL13 concentrations. Interferon-γ, 
IL6, and TNF-α were associated with severe AP, whereas GM-CSF, IL4, IL1b, and IL13 were 
associated with mild or moderately severe AP. The IL13/IFNγ ratio was significantly higher 
in patients with mild AP. The authors concluded that a TH1 profile was associated with severe 
AP and a TH2 profile with mild or moderately severe AP. [213] Infection with microbes 
results in upregulated expression of immunoregulatory genes in epithelial cells with increased 
production of pro-inflammatory cytokines or inadequate synthesis of anti-inflammatory 
cytokines. [5] [27]  
 
10.4 Development of a pilot study facilitated a complex protocol to be optimised prior to 
the recruitment of acutely unwell patients with acute pancreatitis 
This thesis aimed to identify the role of confocal endomicroscopy as a tool to measure 
intestinal permeability alterations in patients with acute pancreatitis, and to assess whether this 
method could differentiate between levels of disease severity. The severity of acute 
pancreatitis is a key factor in determining prognosis and the severe forms of the disease are 
associated with a mortality of 20-30%. [90] Identification of those patients who have severe 
disease is central to optimisation of treatment, but remains a controversial clinical assessment. 
The development of novel clinical tools to assess disease severity early during the course of 
illness is therefore of high clinical importance. 
As previously discussed, the nature of this translational study was complex. The different 
components required significant patient involvement and cooperation. Patients with acute 
pancreatitis are often acutely unwell in-patients albeit with a broad spectrum of clinical 
severity. It was thus important to establish a practical and robust protocol prior to embarking 
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upon the recruitment of this patient cohort. With this in mind, we conducted a pilot study 
involving groups of patients who are also reported to have intestinal permeability 
disturbances, but who have more chronic stable courses of disease. We therefore decided to 
investigate patients with stable, compensated chronic liver disease or cirrhosis and patients 
with chronic pancreatitis, as well as control subjects.  
The study was conducted at the Royal Liverpool University Hospital. This centre had large 
patient cohorts in all study groups as well as the clinical, endoscopic and scientific equipment 
and expertise required.  
Training in the skill of confocal endomicroscopy was initially acquired from Professor 
Kiesslich in Mainz. Meetings were also held with Professor Watson in order to learn how to 
assess the ‘Watson score’ [1] While this formed the initial structure of our imaging process, 
the method was subsequently amended and simplified in order to minimise inter-observer 
variability. Watson’s group had previously reported the identification of plumes of fluorescein 
leakage from identifiable sites in the epithelium and developed the concept of ‘epithelial gaps’, 
which allow the entry of bacteria into the lumen by a combination of transcellular and 
paracellular pathways. [4, 21, 22] Our modified scoring system simply assessed for the 
presence of fluorescein leakage rather than assessing the individual sites from which this 
leakage occurred. 
Following completion of the pilot study we developed a revised, optimised protocol for use in 
the acutely unwell AP cohort. The pilot study also served its second purpose of generating 
important results from patients who had chronic pancreatitis and chronic liver disease.  
 
10.5 Protocol implemented in patients with acute pancreatitis 
Following completion of the pilot study and development of a final protocol, ethical approval 
was granted to recruit patients who had acute pancreatitis. Approximately 120 patients per 
annum are admitted to the Royal Liverpool University Hospital with acute pancreatitis. All 
such patients were identified daily by means of an alert through the clinical biochemistry 
laboratory for patients who had elevated serum amylase activity. Such patients were 
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approached for recruitment to the NIHR PBRU biobank and to this current study. The number 
of patients in the mild AP cohort was significantly greater than in the moderate and severe AP 
cohorts. Moreover, the severe AP patients were mostly recruited at a later stage in their disease 
course than those with mild and moderate disease, who were mostly recruited at the time of 
admission.  
 
10.6 Intestinal permeability alterations were observed in patients with AP, CP, CLD and 
patients with a history of gastrointestinal surgery 
The intestinal permeability barrier becomes defective in AP 48-72 hours after disease onset 
and further increases gradually during the course of disease. [101, 144, 180, 200] Increased 
severity of pancreatitis appears to correlate with an increase in intestinal permeability and in 
turn, this results in increased bacterial and endotoxin translocation. Evidence for the 
association between gut injury and subsequent development of local infection, infected 
necrosis, multi-organ failure, mortality and outcome continues to increase. [107] Early gut 
mucosal dysfunction appears to contribute to the pathophysiology of severe AP by permitting 
the entry of endotoxin and bacteria from the intestinal lumen through the intestinal epithelium 
into the systemic circulation as IP increases. [104] [199]  
In CP, reports of changes in intestinal permeability are limited, but there is extensive evidence 
to suggest that increased IP affects the pathogenesis of chronic liver disease, cirrhosis and its 
complications. In this condition, dysfunction of the intestinal epithelial barrier may again 
enhance the risk of translocation of bacteria and bacterial products into the systemic 
circulation. [244] A number of studies (as described in chapter 1) have also reported alterations 
in intestinal permeability in patients who have undergone gastrointestinal and even cardiac 
surgery.  
Using the detection of fluorescein leakage by CLE, we have demonstrated an increase in 
intestinal permeability in patients who had acute pancreatitis, severe acute pancreatitis, 
chronic pancreatitis, conservatively or surgically managed, when compared with healthy 
controls. We were also able to demonstrate that other co-morbidities, positive gastroscopy 
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findings and positive H. pylori status also affected intestinal permeability and showed 
statistically significant increases in fluorescein leakage in such patients relative to healthy 
control subjects.  
The serum concentration of the enzyme DAO increased relative to the amount of fluorescein 
leakage in patients with acute pancreatitis. There was also a trend towards higher serum DAO 
concentrations in patients with AP compared with healthy controls, but this difference did not 
reach statistical significance. 
Lactulose:mannitol ratios also confirmed an increase in intestinal permeability in patients with 
acute pancreatitis, as well as in patients with chronic pancreatitis which had been managed 
surgically.  The lactulose:mannitol ratio was also increased in control patients who had other 
co-morbidities, positive gastroscopy findings or positive H. pylori status. It is probable that 
the lactulose:mannitol ratio peaks at the onset of disease and may subsequently decrease, 
whereas epithelial changes are likely to persist for longer, hence fluorescein leakage may still 
be seen in patients at a later stage in their disease course, as reflected in the results from 
fluorescin leakage.  
 
10.7 Confocal Laser Endomicroscopy was used to investigate intestinal permeability 
alongside a commonly reported measure of the same variable  
Our study confirmed that patients with AP have increased IP compared to healthy controls. 
We however used serum lactulose:mannitol ratios as described by Fleming, instead of the 
more frequently reported urinary test. [144] [145] [104] [146] [19]. These biochemical 
findings were supported by the new technique under investigation in our study, CLE. By 
means of CLE, we demonstrated that fluorescein leakage, the marker of IP for this method, 
was also significantly higher in AP patients compared to healthy controls and that this was 
particularly apparent in patients who had severe AP. Reports of CLE as a measure of IP, 
though limited, support our findings. [4, 274, 275] We took great care to use a robust method 
to assess fluorescein leakage to reduce the possibility of selection bias. The selection and 
scoring processes were conducted separately and involved blinded co-investigators who were 
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unaware of patients’ clinical details and comorbidities. A unique and unidentifiable 
identification number was allocated to each subject and only this was provided at the stage of 
image selection and scoring. Cohen's kappa coefficient, which was used to assess the level of 
concordance between scorers, showed significant agreement.  
Increased IP was also observed in surgically managed CP patients by both lactulose:mannitol 
testing and CLE. However, conservatively managed CP patients were not significantly 
different from healthy controls using either technique. In fact, there was a significant 
difference in lactulose:mannitol ratios between the surgically and conservatively managed CP 
cohorts, suggesting that the gut barrier may be compromised in CP patients who have 
undergone surgical intervention.  
In all the above cases, fluorescein leakage as a discrete variable gave similar results to 
intestinal permeability assessed by lactulose:mannitol ratios. However, when fluorescein 
leakage was assessed by means of average scores and as a continuous variable, although the 
patterns were similar, statistical analysis did not demonstrate significant differences.  
The cohort of patients with CLD also demonstrated increases in lactulose:mannitol ratios and 
fluorescein leakage, but these changes were not statistically significant compared to healthy 
controls. A future study involving larger numbers of patients would therefore be required to 
assess this disease state more effectively. 
As a further sub-analysis, we analysed the patients who had been recruited as potential controls 
but who were eventually excluded from the study for one or more reasons. We identified that 
there were increases in intestinal permeability in those patients who had been excluded from 
the study compared to healthy controls. This was confirmed by all three modalities measured: 
lactulose mannitol ratio; fluorescein leakage by CLE and average scores of fluorescein leakage 
by CLE. Exclusion of patients from the ‘healthy control’ group was based on abnormal 
gastroscopy findings including the presence of oesophagitis or gastritis; positive H. pylori 
status and/or a history of co-morbidities including a history of previous surgery. On closer 
review of past medical histories, it was interesting to note that a number of subjects who had 
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evidence of increased intestinal permeability had a history of previous surgery such as 
cholecystectomy or duodenal ulcer surgery.  
We also measured serum diamine oxidase (DAO) concentrations in control subjects and in 
those patients with AP who underwent CLE, and demonstrated increased serum DAO 
concentrations in those patients who showed fluorescein leakage. DAO is an enzyme that 
catalyses the oxidation of diamines, and in humans and rodents it is specifically located at the 
apical end of mature intestinal villi. Several studies have demonstrated an inverse correlation 
between DAO and small intestinal permeability, as its activity reflects the integrity and 
maturity of the small intestinal mucosa. [308] We propose that its increased concentration in 
this study may be related to the increased intestinal permeability that was observed in the AP 
patient cohort, though we have not demonstrated that this was a result of cell shedding.   
 
10.8 Bacterial translocation increases with increased intestinal permeability 
AP patients and also subjects who were identified as showing fluorescein leakage by CLE 
demonstrated significantly higher frequencies of positive bacterial/fungal cultures in duodenal 
fluid relative to healthy controls. Organisms that were demonstrated in ‘positive’ duodenal 
cultures included Pseudomonas, Enterococcus, gut anaerobes, yeasts, Staphylococcus aureus 
and coliforms, whereas ‘negative’ duodenal cultures were reported as showing either no 
growth or mixed oral flora. Positive duodenal cultures were most prevalent in patients who 
had severe AP, consistent with previous reports that have suggested a correlation between 
severity of disease, endotoxaemia and bacterial translocation. We found that patients with 
severe AP had the highest levels of endotoxaemia, along with the most positive duodenal 
bacterial cultures. The observation of positive duodenal cultures in those patients who showed 
fluorescein leakage at CLE supports a hypothesis of bacterial translocation, suggesting that 
alteration of the gastrointestinal barrier occurs in AP, though the mechanism remains unclear. 
The identification of fluorescein leakage by CLE was also associated with the presence of 
positive bacterial cultures from the duodenal fluid in patients with CLD. The small proportion 
of patients with CLD and CP who had positive duodenal fluid cultures showed the presence 
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of Staphylococcus aureus, coliforms or yeast. Patients with AP had much higher proportions 
of positive cultures and a greater diversity of cultured organisms. Positive cultures in this 
cohort included the above but also Pseudomonas and Enterococcus. 
In all our subjects, blood cultures were negative at the time of recruitment, suggesting an 
absence of bacteraemia. However, it is important to note that in the patients who had mild AP, 
we would not expect positive blood cultures, and in the moderate and severe cases, recruitment 
often occurred later in the disease course and after antibiotic treatment had been initiated.  
Despite the absence of bacteraemia, endotoxaemia was evident, in particular in those patients 
who had severe AP. Endotoxaemia without bacteraemia is well-recognised and in severe AP 
it may result from local sepsis, or pancreatic and intraabdominal necrosis leading to the 
absorption of gut derived endotoxin. [194] Endotoxaemia is common in patients who have 
sepsis (79%) and liver cirrhosis (46%), and correlates with mortality in patients who have 
severe AP. [309] Circulating endotoxins are bound by anti-endotoxin antibodies. Hence the 
levels of these antibodies decrease inversely to the amount of endotoxin challenge and the 
level of decline is a reflection of clinical severity.  
 
10.9 The effect of surgery, and other factors, on intestinal permeability, in particular in 
CP  
It was apparent from the sub-analyses that were performed that multiple factors contribute to 
intestinal permeability changes. In patients with CP, it is not clear whether the increased IP 
that is observed occurs due to the combined effect of surgery and CP or due to the effect of 
surgery alone. IP changes have not previously been extensively investigated and reported in 
CP; similarly, there are very few published reports of IP changes in post-operative patients. 
One study which investigated bacterial translocation and IP in patients following abdominal 
surgery, concluded that increased IP was closely related to bacterial translocation, but this 
observation was made only a few hours after abdominal surgery. [252] In our cohort, surgical 
intervention occurred months or years prior to recruitment, rendering the relative contributions 
of CP and previous surgery to increased IP unclear.  
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The sub-analysis involving patients who were excluded from the healthy control cohort further 
supports the concept that surgery and other factors that affect the gastrointestinal tract affect 
intestinal permeability. A combined group of dyspeptic subjects who had co-morbidities 
including previous surgery; positive H. pylori status and/or abnormal findings on gastroscopy 
showed a statistically significant increase in IP compared to ‘healthy controls’.  
 
10.10 Differentiating severity in acute pancreatitis 
A comparison of serum cytokine concentrations between patients who had different severities 
of AP demonstrated statistically significant increases in the concentrations of multiple 
cytokines in patients with severe AP when compared with healthy controls. In the subset of 
pro-inflammatory cytokines, we found significantly higher serum concentrations of IL-6 in 
particular, but also IL-8, and IL-10 in patients who had severe AP. [144] Serum IL-6 
concentrations showed a statistically significant increase between each tier of severity of AP, 
suggesting that further investigation of this cytokine is warranted to explore its suitability as 
a biomarker of severity in patients with AP.  
It has been postulated that endotoxaemia is a key component of a positive feedback loop that 
is associated with cytokine release and increased IP, impaired host immunity and enhanced 
bacterial translocation. It is also possible that the inflammatory response and cytokine release 
are key to the subsequent release of endotoxin and that these factors initiate an inflammatory 
cascade which results in intestinal epithelial cell shedding, epithelial gaps and bacterial 
translocation. [7]  
The titres of IgG and IgM anti-endotoxin antibodies were significantly lower in patients who 
had severe AP when compared to patients with mild AP and controls. This is consistent with 
increased endotoxaemia in patients who had increased severity of disease. These results are 
similar to those previously reported. [7, 99, 101, 104, 140, 144, 180]  
The histopathological analysis of duodenal tissue was incomplete and so we cannot reach any 
meaningful conclusions from these data. Nonetheless, there was evidence of duodenal 
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inflammation in two patients who had AP. It would be interesting to investigate this further to 
assess whether duodenal inflammation increases with increasing severity of AP.  
 
10.11 A significant increase in the serum concentration of IP-10 was seen in the CLD 
cohort 
The chemokine IP-10, also called IFN-γ induced protein or CXCL-10 is secreted in response 
to IFN-γ. The only report of note of its mention in liver disease is in hepatitis C viral infection, 
where it has been shown to play a role in the assessment of treatment response. [310] Although 
we analysed whether this chemokine was associated with a specific aetiology or severity of 
chronic liver disease, no associations were identified.   
 
10.12 Limitations of the study 
The main limitation of this study was the difficulty that we had in recruiting patients with 
severe AP immediately after the onset of their disease. Many of these patients were tertiary 
referrals and were therefore recruited sometime after their initial presentation. Other patients 
who had more severe forms of the disease were unable to consent to participating in the study 
due to a lack of consciousness or capacity. This particularly limited the numbers of patients 
with severe acute pancreatitis, which was the cohort of most interest. 
The study of patients with CLD and CP was primarily undertaken with the aim of establishing 
a protocol by studying stable patient cohorts. More valuable results could have been generated 
by recruiting larger numbers of patients with compensated and decompensated disease in the 
former group, and patients with more recent surgery in the latter group.  The time taken to 
establish a protocol and then re-submit an ethics proposal for the AP cohort also reduced the 
time available to actually recruit this group of patients.  
The scoring system that we formulated and utilised reduced inter-observer variability, but 
limited our ability to identify the point of release of fluorescein and hence the ability to identify 
epithelial gaps. Further work to establish an improved scoring system that assesses this 
parameter but still maintains good inter-observer agreement level, would be very useful. 
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Similarly, we have established that there was a significant change in duodenal microbial 
growth in patients with AP, but we have been unable to demonstrate how this has occurred. 
Analysis of the microbiome rather than culture would also have provided more informative 
results and remain a potential consideration for investigation. 
An analysis of cytokine responses at different stages in the disease process along with IP 
analysis in a similar way would render meaningful data but was not feasible during the course 
of this study. It was also not possible to randomise patients treated with enteral feeding against 
those without and to assess reciprocal changes in intestinal permeability. 
  
10.13 Future Directions 
This study has provided an excellent platform for further studies using CLE as a modality to 
assess intestinal permeability using a direct in vivo technique.  
Further studies involving larger cohorts of patients would be of great benefit to assess the 
clinical implications of assessing IP by CLE in patients with AP, but also in CP and 
particularly in CLD of varying severity. In patients who had chronic pancreatitis, we have 
found an interesting connection between increased IP and a history of previous surgery. It 
would therefore be interesting to directly study subjects with CP prior to and following 
surgical intervention to be able to objectively assess intestinal permeability changes post-
operatively more closely. 
With respect to patients with acute pancreatitis, it would be useful to increase the number of 
patients studied in the moderate and severe AP cohorts, particularly as the numbers in these 
groups were limited due to the reasons outlined earlier, and to assess IP at different timepoints.  
Much further research is needed to improve the treatment of acute pancreatitis which is 
sometimes a life-threatening condition. Improved understanding of the mechanisms 
responsible for alterations in intestinal permeability and bacterial and endotoxin translocation 
would permit further research into potential therapeutic targets. Labelled fluorescein with 
closer investigation of paracellular and transcellular pathways similar to investigations in 
mouse models, could be a potential means of studying these variables. 
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This study has therefore highlighted that intestinal permeability changes and alterations in 
duodenal bacterial growth are key features of acute pancreatitis. It would also be very useful 
to enhance the work on the gut microbiome by assessing stool for intestinal pathogens and 
blood also as comparative factors to the duodenal cultures for a broader analysis of the 
microbiome.  
The actual mechanisms involved in gut barrier dysfunction, intestinal permeability changes 
and bacterial translocation have not been investigated in this study and are crucial to 
understand to be able to develop therapies and targeted treatments.  
 
10.14 Conclusions 
We have shown that patients with AP had evidence of increased IP by two methods, namely 
fluorescein leakage at CLE and lactulose:mannitol tests. They were also found to have 
increased concentrations of serum DAO. Endotoxaemia, positive duodenal bacterial cultures, 
and increased serum concentrations of several cytokines were associated with increasing 
severity of AP.  
The increase in positive duodenal bacterial cultures in patients who also demonstrated 
fluorescein leakage at CLE supports a hypothesis of bacterial translocation, suggesting that 
the gastrointestinal barrier is altered in AP. We were unable to confirm the mechanism for 
bacterial translocation, hence further work is required to establish whether this occurs through 
epithelial gaps. Evidence for increased IP was also observed in surgically managed CP 
patients, suggesting that the gut barrier may also be compromised in some CP patients.  
CLE is therefore a novel technique that may have a role in assessing gut barrier function in 
patients with acute and chronic pancreatitis and also subjects who have chronic liver disease. 
Further studies should probably concentrate on investigating the mechanisms involved to 
potentially allow the development of targeted therapies in the future. Further work is also 
needed to develop clinically relevant scoring tools to assess intestinal permeability, as our 
work suggests that alteration in the gut barrier plays a major role in exacerbating the clinical 
manifestations of acute pancreatitis. 
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Appendix A: Patient Invitation Letter - Pilot Study 
 
         
                                      
 
Prescot Street 
Liverpool 
L7 8XP 
Tel no: 0151 706 2000 
Ext:       4487 / 4877 
Mobile: 07931 246347   
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT OF PATIENTS 
WITH CHRONIC PANCREATITIS AND CHRONIC LIVER DISEASE 
 
DEAR SIR / MADAM, 
 
You have been invited to attend the gastroenterology department 
on______________________ for an upper gastrointestinal endoscopy or endoscopic 
ultrasound as part of a research study.  Before you decide, it is important for you to understand 
why the research is being done and what it will involve. To allow for this, I have arranged to 
meet you before the procedure so that I can discuss details with you fully and give you an 
information leaflet that details the study; the reasons for the study and what involvement would 
be required from you.  
Please report to the main desk in the foyer at the main entrance of the ground floor of 
the Royal Liverpool University Hospital with this letter on 
______________________________ at _________.  
I shall come to see you on the day of your procedure to check that you have had a chance to 
read the information and to discuss everything with you again in person, in more detail. If there 
is anything that is not clear, or if you would like more information, please ask at this time. If 
you have any questions beforehand, please do not hesitate to contact myself on the telephone 
number at the top of this letter. We appreciate your time and thank you for reading the attached 
information. This is a voluntary project and, if when you have heard about the study, you would 
prefer not to take part; your decision will be accepted without question and will not affect the 
standard of care you receive.  
 
Many Thanks, 
Dr S Bharucha, Clinical Research Fellow 
Patient details  
 
PATIENT INVITATION 
LETTER 
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Appendix B: Patient Information Leaflet - Pilot Study 
                                      
 
 
 
 
 
 
 
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND 
MANAGEMENT OF PATIENTS WITH CHRONIC 
PANCREATITIS AND CHRONIC LIVER DISEASE 
 
 
 
You are being invited to take part in a research study.  Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read the following information carefully. If there is anything that is not clear, or if you would 
like more information, please ask.  
  
We appreciate your time and thank you for reading this information leaflet. 
 
This is a voluntary project and if, when you have heard about the study, you would prefer not 
to take part your decision will be accepted without question and will not affect the standard of 
care you receive.  
 
What is the purpose of the study? 
Pancreatic diseases develop in >50,000 people per year in the UK, causing major illness and 
even death. Chronic pancreatitis (CP) is a disease that occurs over a period of time and results 
in permanent structural changes in the pancreas. This can result in hormonal problems such 
as diabetes and other significant problems with the digestive system that cause symptoms of 
pain, weight loss and an unusual form of diarrhoea called steatorrhoea. How chronic 
pancreatitis occurs has not been completely understood. It is a painful, wasting disease that 
has a greatly increased risk of pancreatic cancer. The risk of pancreatic cancer developing in 
people with chronic pancreatitis is over ten times that of normal. The diagnosis of chronic 
pancreatitis is challenging and prevention and effective treatment are difficult to achieve. 
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Liver cirrhosis is a consequence of chronic liver disease characterized by replacement of liver 
tissue by fibrosis, scar tissue and regenerative nodules (lumps that occur as a result of a 
process in which damaged tissue is regenerated), leading to loss of liver function. Cirrhosis is 
most commonly caused by alcoholism, hepatitis B and C, and fatty liver disease, but has many 
other possible causes. Some cases are idiopathic, i.e., of unknown cause. There are an 
estimated 30,000 people living with cirrhosis in the UK and at least 7000 new cases being 
diagnosed each year. The disease is recognised to have significant complications which are 
life-threatening and mortality rates are high. 
 
New ways of identifying the earliest stages of inflammation are needed, as are new ways of 
identifying how well the body is responding to this and healing. Confocal endoscopy offers a 
means to identify inflammation at the earliest stage, and to predict what will happen more 
correctly. This work will be a thorough test of new methods of diagnosis, to find new ways to 
improve the care of patients with pancreatic and liver disease. The use of confocal 
endomicroscopy will be assessed to identify inflammation and its effects at an earlier stage, 
to prevent it or to treat, and to monitor the effects of treatment. 
 
The ultimate goal of this study is to study the use of confocal microscopy to assess and identify 
inflammation and its effects in patients with chronic pancreatitis and chronic liver disease, to 
prevent it or to treat, and to monitor the effects of treatment. 
 
We aim to recruit about 100 patients with chronic pancreatitis or liver cirrhosis or neither 
(control subjects) and investigate them with confocal endomicroscopy (a camera with an end 
microscope inserted into the stomach and duodenum or bowel). Patients will be identified and 
recruited for the study from the Gastroenterology unit at the Royal Liverpool University 
Hospital.  
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with a disease of the digestive 
tract and we aim to study factors involved in the severity of these disease processes. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part, you will be 
given this information sheet to keep and be asked to sign a consent form.  You are still free to 
withdraw from the study at any time without giving a reason. This will not affect the standard 
of care you receive in any way. 
 
What will happen to me if I take part? 
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All patients who decide to take part in this study will receive the usual clinical care. If you 
decide to take part, the following will also take place: 
a) A blood sample (approximately 20 mls) will be taken to try and identify genes and markers for 
diagnosis and assessment of severity.  
b) A camera test with a confocal endomicroscope (a camera with an end microscope) will be 
carried out and tissue samples and fluid will be removed from the small or large bowel. Multiple 
images will be taken with the camera and the confocal endomicroscope. Suitable, safe 
chemicals will be developed to obtain fluorescence in relevant parts of the body. The test will 
be carried out in the Gastro Unit at the Royal Liverpool University Hospital. 
• In most cases a gastroscopy will be carried out with the confocal endomicroscope. You will be 
asked to fast before attending for the test. You will be given two lots of sedative agents and 
throat spray to make sure you are comfortable throughout the test. A thin tube will be passed 
through the back of the throat, into the gullet, the stomach and the first part of the small bowel. 
The test will take about twenty minutes to complete.  
• In some patients, we may conduct a colonoscopy which is an examination of the large bowel 
and a tube is passed through the back passage until the small bowel is reached. The same 
sedation would be given. This test may take approximately thirty to forty minutes to complete. 
c) The tissue samples that are taken at endoscopy will be utilised for processing in our research. 
The samples used for research purposes will be those that are surplus to that which is required 
for clinical purposes. 
d) The images that are taken at endoscopy will be analysed for our research.  
e) We will also ask you for a few questions about your general health and that of your family in 
relation to digestive diseases, in the form of a questionnaire. 
f) A review of you case-notes will be carried out by the research doctor. 
g) On another occasion, we will ask you to drink a sugary liquid which will be a solution of sugar 
and a diuretic. This will be made up into approximately 100ml of liquid. After ninety minutes, 
we will take a very small amount of blood from you before you are discharged. This test will 
look at the absorption of sugar in your body. 
 
 
IMPORTANT NOTE related to point g): 
Not all patients will be asked to participate in part g) detailed above. The first 5-10 patients in 
the study (at least) will not be asked to take part in this section of the study. Thereafter, patients 
will be given the option to take part in g) or to refuse, and to only participate in the rest of the 
study. 
 
What are the possible disadvantages and risks of taking part? 
There may be some minor but short-lasting discomfort from having a blood test. The camera 
test comes with a 1 in 1000 risk of causing a small hole in your digestive tract (perforation) or 
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of bleeding (haemorrhage). The procedure will be carried out by a specialist with extensive 
experience to minimise these risks. Taking part in the study will not affect your current 
treatment. 
What are the possible benefits of taking part? 
The study will not be of direct benefit to you however, it may benefit patients in the future who 
develop chronic pancreatitis or cirrhosis of the liver. 
What will happen to my tissue samples, blood tests and images? 
Blood will be divided into serum and genetic samples which will be stored at the University of 
Liverpool. DNA will also be extracted from the genetic sample at the University. If something 
significant is found when your DNA is analysed, we will inform you of the results. If necessary 
we will advise you and your family on how to go about having further genetics tests and on 
how to seek further opinions from a clinical geneticist, who is a specialist in this field. 
 
A large number of microscopic images will be retrieved and analysed. We shall identify 
patterns which are deemed to be normal and make a comparison with more abnormal 
patterns. Particularly meaningful images will be developed in photoimages for further analysis. 
The urine sample will be assessed for the concentration of the sugar absorbed previously and 
compared to the concentration of the diuretic within the same solution.   
Your tissue samples will be frozen in liquid nitrogen or fixed in formalin for subsequent 
sectioning, staining and analysis. 
Some of the results obtained from these blood and tissue tests will be linked with information 
that we obtain about your current and past medical history from the questionnaire and from 
your casenotes. 
 
It is important to note that all blood and tissue samples going outside the hospital, and any 
notes relating to it, will be identified only by a code number. All clinical details will be kept 
securely, either at the Royal Liverpool University Hospital or the University of Liverpool. Once 
the study has been completed, we will anonymise your clinical details and blood and tissue 
samples, and therefore it will not be possible to trace the samples back to you.  After 
anonymisation, it will also not be possible for you to withdraw the samples.  Once anonymised, 
the DNA samples may be used for other research, but as this cannot be traced back to you, it 
will have no direct bearing on your clinical care. Approval will be sought from the ethics 
committee for any future studies. 
 
Your blood and tissue samples will be considered to be a gift to the University of Liverpool, 
which will act as custodian of all the samples obtained as part of this project.  In some cases, 
a small amount of your sample will be provided to other researchers either in the UK or other 
parts of the world.  However, it is important to remember that this will only be identified by a 
code. 
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In the short-term, it is unlikely that the samples will be of any commercial value to the 
University or the hospital. However, it is possible that they may be some commercial value in 
the future, although it is important to note that any commercial value is likely to be due to 
findings in a group of patients rather than from samples from a single patient.  You will not be 
paid for taking part in the study, nor will you get financial benefit from future discoveries. 
Will my taking part in this study be kept confidential? 
As stated above, your sample will be anonymised, and therefore the genetic information 
obtained from it will be kept strictly confidential and not be disclosed to anyone.  All information 
collected about you during the course of the research will also be kept strictly confidential.  
Any information about you, which leaves the research centres taking part, will have your name 
and address removed so that you cannot be recognised from it. We will inform your GP that 
you have participated in the study. 
What will happen to the results of the research study? 
Results from the project will be published in leading international medical journals. 
 
Who is organising and funding the research? 
This study has been designed by The University of Liverpool and the Royal Liverpool and 
Broadgreen University Hospital NHS Trust. It is funded by the National Institute of Health 
Research (NIHR) and the Pancreatic Biomedical Research Unit. The principal investigators 
are Professor Robert Sutton and Professor Mark Pritchard. 
 
Who has reviewed the study? 
The research has been reviewed by the North West Research Ethics Committee and has been 
granted approval. 
 
Contact for further information 
If you need further information or have any concerns or questions, do not hesitate to contact 
Dr Shameena Bharucha, the Research Fellow running the study, on 0151 706 4487/4877. 
 
 
Thank you for reading this information leaflet.
 
 
233 
 
Appendix C: Consent Form - Pilot Study 
                                     
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT 
OF PATIENTS WITH CHRONIC PANCREATITIS AND CHRONIC LIVER 
DISEASE 
 
Name of principal investigators:  Professor Robert Sutton, Professor Mark Pritchard 
 
Name of Researcher:                       
 
 
1. I confirm that I have read and understood version 4 of the information 
sheet                      dated 27/06/11, for the above study and have had 
the opportunity to discuss the research and ask questions  
 
2. I understand that my participation is voluntary and that I may withdraw 
at any time without needing to give a reason, and without my medical 
care or legal rights being affected 
 
3. I understand that the results will not be added to my medical records 
but that my medical notes and data collected during the study may be 
looked at by individuals from regulatory authorities or from the NHS 
Trust                       where it is relevant to my taking part in this research. 
I give permission to these individuals to have access to this information 
 
4. I agree to have an endoscopic procedure with additional samples of 
intestinal                tissue and images to be taken with the confocal 
endomicroscope  
 
5. I agree to have blood samples taken for tests on factors that may be 
involved in the process of digestive disease  
 
6. I have/have not been asked to undertake a further test called the 
lactose:mannitol test which involves drinking a liquid given to me, and 
collecting a small blood sample after ninety minutes. If asked, I 
have/have not agreed to undertake this test 
 
7. I understand that my samples will be anonymised and will be stored, 
and it will not be possible to trace the samples back to me 
 
8. I understand that my samples may be used in the future for more 
genetic tests as there are more scientific advances 
 
9. I agree to take part in the study 
 
……………………………        ………………..         ……………………………… 
Name of patient   Date   Signature 
……………………………        ………………..         ……………………………… 
Name of researcher   Date   Signature 
 
 
 
 
 
 
 
 
Please initial boxes 
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Appendix D: GP Letter - Pilot Study 
 
                                      
Prescot Street 
Liverpool 
L7 8XP 
Tel no: 0151 706 4487 
 
 
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT OF PATIENTS 
WITH CHRONIC PANCREATITIS AND CHRONIC LIVER DISEASE 
 
Dear Doctor, 
Your patient has kindly consented to participate in the above study which is one of the projects taking 
place in the NIHR-funded Pancreatic Biomedical Research Centre at Royal Liverpool and 
Broadgreen Hospitals NHS Trust in collaboration with the University of Liverpool. The study has been 
approved by Liverpool (Adult) Research Ethics Committee. The aims of this project will be to 
determine the role and prognostic significance of intestinal epithelial gaps in patients with 
gastrointestinal diseases including chronic pancreatitis, chronic liver diseases and non-ulcer 
dyspepsia, and to define clinical applications of in vivo confocal endoscopic microscopy in these 
digestive diseases. 
The patient has consented to having an additional endoscopic examination in the form of confocal 
endomicroscopy with additional gastrointestinal biopsies and multiple image capture of endoscopic 
findings. Consent has also been given for just over 20ml blood test to be taken. Some patients will 
also undertake a lactose:mannitol test to investigate intestinal permeability. The first patients in the 
study will not undergo this test and thereafter, patients will be given the option to participate, or not, 
with this particular additional test. 
The clinical findings at endoscopy will be sent to you in the usual way. These blood and biopsy 
samples, and images, will be analysed in an anonymised fashion and used to identify relationships 
between epithelial gaps, biomarkers and disease processes. The patient will not be required to 
participate any further in the study. If you require any further information please contact Professor 
Robert Sutton, Executive Director of the Liverpool NIHR Pancreatic Biomedical Research Unit, 
Professor Mark Pritchard, Professor of Gastroenterology and Honorary Consultant 
Gastroenterologist, or Dr Shameena Bharucha, Clinical Research Fellow / Gastroenterology SpR at 
Royal Liverpool University Hospital. 
  
Yours sincerely, 
Professor Robert Sutton, Professor Mark Pritchard, Dr Shameena Bharucha
GP name and address Patient details  
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Appendix E: Participant Information Form - Pilot Study 
  
PARTICIPANT INFORMATION SHEET FOR CEM STUDY 
 
IDENTIFICATION NUMBER  
PATIENT NAME  
DATE OF BIRTH  
AGE  
HOSPITAL RQ6 NUMBER  
REASON FOR ENDOSCOPY  
PAST MEDICAL HISTORY  
MEDICATIONS  
SMOKER Y / N         QUANTITY: 
ALCOHOL IN UNITS / WEEK  
ENDOSCOPY FINDINGS  
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Appendix F: Patient Invitation Letter - Main Study 
 
 
Prescot Street 
Liverpool 
L7 8XP 
Tel no: 0151 706 2000 
Ext:       4487 / 4877   
Mob:  07931 246347 
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT OF PATIENTS 
WITH ACUTE PANCREATITIS  
 
DEAR SIR / MADAM, 
 
I would like to invite you to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. I have attached an 
information leaflet with this letter that details the study; the reasons for the study and what 
involvement would be required from you. Please take time to read the information carefully. If 
you agree to take part, an appointment will be made for you to attend the gastroenterology 
department for an upper gastrointestinal endoscopy. If you are on a higher level care bed, we 
shall transfer the equipment to you and conduct the procedure on the Intensive Care or High 
Dependency Care Unit. 
 
I shall come to see you on the day of your procedure to check that you have had a chance to 
read the information and to discuss everything with you again in person, in more detail. If there 
is anything that is not clear, or if you would like more information, please ask at this time. If 
you have any questions beforehand, please do not hesitate to contact myself on the telephone 
number at the top of this letter. If you are too sick to contact a member of the research team 
yourself, or in case of an emergency, or for any other reason, the nursing team or a member 
of your family can contact the team on internal extension 4487, or the above telephone 
number, on your behalf.  
 
We appreciate your time and thank you for reading the attached information. This is a 
voluntary project and, if when you have heard about the study, you would prefer not to take 
part, your decision will be accepted without question and will not affect the standard of care 
you receive.  
 
Many Thanks, 
 
Dr S Bharucha, Clinical Research Fellow 
Patient details  
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Appendix G: Patient Information Leaflet - Main Study 
 
 
 
 
 
 
 
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT OF PATIENTS 
WITH ACUTE PANCREATITIS  
 
 
You are being invited to take part in a research study.  Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. If there is anything that is not clear, or if you 
would like more information, please ask.   
We appreciate your time and thank you for reading this information leaflet. 
This is a voluntary project and if, when you have heard about the study, you would prefer 
not to take part your decision will be accepted without question and will not affect the 
standard of care you receive.  
 
What is the purpose of the study? 
Pancreatic diseases develop in over 50,000 people per year in the UK and cause major 
illness and death. Acute pancreatitis is a common disease with many causes. It is severe 
in one of four people affected, and one out of every four people with severe disease dies. 
Infection in the blood makes this illness worse but it is often difficult to tell when infection is 
present, making the disease difficult to treat and even more difficult to prevent.  
The gastrointestinal tract is one of the largest points of contact the human body has to the 
outside environment. One of its jobs is to stop harmful intruders from getting into the 
bloodstream. This is called the gut barrier. A lot of work has been done to show that the 
gut barrier is damaged in pancreatitis.  
Confocal microscopy allows us to look at a slice of tissue too small to be seen with the 
naked eye. We can see cells, tiny building blocks of living things, to help us with the 
diagnosis and treatment of disease. Endoscopes are long, black tubes passed into body 
cavities like the gullet or stomach to look for disease. Confocal probes have been put into 
endoscopes to look at the bowel lining at microscopic level, to find disease more accurately. 
The technique is called confocal endomicroscopy. Recent work using this technique has 
identified gaps in the lining of the bowel that increase in certain diseases, which let harmful 
substances into the bloodstream.  
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New ways of identifying the earliest stages of major illness are needed, as are new ways 
of identifying how well the body is responding to this and healing. Confocal endoscopy 
offers a means to identify inflammation at the earliest stage, and to predict what will happen 
more correctly. This work will be a thorough test of new methods of diagnosis, to look for 
disease and then look to see how providing earlier treatment can improve the condition of 
the patient and the course of illness.  
We aim to recruit up to 50 patients with acute pancreatitis and investigate them with 
confocal endomicroscopy (a camera with an end microscope inserted into the stomach and 
duodenum or bowel). Patients will be identified and recruited for the study from the Surgical 
Wards at the Royal Liverpool University Hospital.  
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with Acute Pancreatitis and we 
aim to study factors involved in the severity of this disease. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form.  You are 
still free to withdraw from the study at any time without giving a reason. This will not affect 
the standard of care you receive in any way. 
 
What will happen to me if I take part? 
All patients who decide to take part in this study will receive the usual clinical care. If you 
decide to take part, the following will also take place: 
h) A blood sample (approximately 20 mls/4 teaspoons) will be taken to try and identify 
genes and markers for diagnosis and assessment of severity.  
a) A camera test with a confocal endomicroscope (a camera with an end microscope) 
will be carried out. The test involves passing a slim endoscope through the mouth 
and down into oesophagus and stomach and the first part of your small bowel. 
Please see the attached gastroscopy information leaflet for more detailed 
information about the actual procedure. Please note that the procedure will be 
slightly longer than the time detailed on this sheet. The total procedure time is 
between 15-30 minutes. To ensure that you are as comfortable throughout this 
period, you will be given both sedation and throat spray by the endoscopist. 
b) During this procedure, tissue samples and fluid will be removed from the small or 
large bowel. Multiple images will be taken with the camera and the confocal 
endomicroscope. Suitable, safe chemicals will be developed to obtain fluorescence 
in relevant parts of the body. 
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c) The tissue samples that are taken at endoscopy will be utilised for processing in 
our research. The samples used for research purposes will be those that are 
surplus to that which is required for clinical purposes. 
d) The images that are taken at endoscopy will be analysed for our research.  
e) We will also ask you for a few questions about your general health and that of your 
family in relation to digestive diseases, in the form of a questionnaire. 
f) A review of you medical notes will be carried out by the research doctor. 
g) Soon after your endoscopy, and possibly during your observation and recovery 
period, we will ask you to drink a sugary liquid which will be a solution of sugar and 
a laxative. This will be made up into approximately 100ml (20 teaspoons) of liquid. 
After ninety minutes, we will take a very small amount of blood from you also. This 
test will look at the absorption of sugar in your body. 
h) We would look to repeat the procedure, blood test and sugar test again once the 
illness has settled down, to assess disease progression. If you have a long hospital 
stay, we shall do this during this time, but if you improve quickly and are 
discharged, we would invite you back as an out-patient to see how things have 
improved, and to conduct the repeat endoscopic procedure. We are likely to carry 
out the procedure twice, but up to a maximum of three times, if you were willing to 
have the repeat procedure(s). We would discuss this with you prior to every 
planned procedure and allow you time to make an informed decision each time, 
separately. 
 
What are the possible disadvantages and risks of taking part? 
There may be some minor but short-lasting discomfort from having a blood test.  
The camera test comes with a 1 in 1000 risk of causing a small hole in your digestive tract 
(perforation). This is rare and if it happened would require an admission into hospital for 
treatment. There is a very small risk of bleeding if samples of tissue are taken (usually 
minor).  There is a small chance of a reaction to the medicines used for sedation or 
occasionally even from throat spray. You may have a slightly sore throat following the 
procedure, which will usually wear off within 24 hours. You must let the nurse know if you 
have any loose teeth, caps or crowns, as there is a risk they could become dislodged. The 
risks from this procedure, including the risk of death, are minimal and are not increased in 
the context of acute pancreatitis. The procedure will be carried out by a specialist with 
extensive experience to minimise these risks. Please also read the more detailed 
gastroscopy information leaflet that is enclosed with this leaflet).  
The dye given to you may cause slight discoloration of your skin, eyes and urine for twenty 
four hours, but it will then pass out of your system in your urine. The sugar test involves a 
laxative, which may cause you to open your bowels. Taking part in the study will not affect 
your current treatment. 
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What are the possible benefits of taking part? 
The study will not be of direct benefit to you however, it may benefit patients in the future 
who develop Acute Pancreatitis. 
What will happen to my tissue samples, blood tests and images? 
Blood will be divided into serum and genetic samples which will be stored at the University 
of Liverpool. DNA will also be extracted from the genetic sample at the University. If 
something significant is found when your DNA is analysed, we will inform you of the results. 
If necessary we will advise you and your family on how to go about having further genetics 
tests and on how to seek further opinions from a clinical geneticist, who is a specialist in 
this field. 
A large number of microscopic images will be retrieved and analysed. We shall identify 
patterns which are deemed to be normal and make a comparison with more abnormal 
patterns. Particularly meaningful images will be developed in photoimages for further 
analysis. 
Some blood will be assessed for the concentration of the sugar absorbed previously and 
compared to the concentration of the diuretic within the same solution.   
Some of the results obtained from these blood and tissue tests will be linked with 
information that we obtain about your current and past medical history from the 
questionnaire and from your medical notes. 
It is important to note that all blood and tissue samples going outside the hospital, and any 
notes relating to it, will be identified only by a code number. All clinical details will be kept 
securely, either at the Royal Liverpool University Hospital or the University of Liverpool. 
Once the study has been completed, we will anonymise your clinical details and blood and 
tissue samples, and therefore it will not be possible to trace the samples back to you.  After 
anonymisation, it will also not be possible for you to withdraw the samples.  Once 
anonymised, the DNA samples may be used for other research, but as this cannot be 
traced back to you, it will have no direct bearing on your clinical care. Approval will be 
sought from the ethics committee for any future studies. 
Your blood and tissue samples will be considered to be a gift to the University of Liverpool, 
which will act as custodian of all the samples obtained as part of this project.  In some 
cases, a small amount of your sample will be provided to other researchers either in the 
UK or other parts of the world.  However, it is important to remember that this will only be 
identified by a code. 
In the short-term, it is unlikely that the samples will be of any commercial value to the 
University or the hospital. However, it is possible that they may be some commercial value 
in the future, although it is important to note that any commercial value is likely to be due 
to findings in a group of patients rather than from samples from a single patient.  You will 
not be paid for taking part in the study, nor will you get financial benefit from future 
discoveries. 
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Will my taking part in this study be kept confidential? 
As stated above, your sample will be anonymised, and therefore the genetic information 
obtained from it will be kept strictly confidential and not be disclosed to anyone.  All 
information collected about you during the course of the research will also be kept strictly 
confidential.  Any information about you, which leaves the research centres taking part, will 
have your name and address removed so that you cannot be recognised from it. We will 
inform your GP that you have participated in the study. 
What will happen to the results of the research study? 
Results from the project will be published in leading international medical journals and 
disseminated through oral and poster presentations at national and international 
conferences. 
 
Who is organising and funding the research? 
This study has been designed by The University of Liverpool and the Royal Liverpool and 
Broadgreen University Hospital NHS Trust. It is funded by the National Institute of Health 
Research (NIHR) and the Pancreatic Biomedical Research Unit. The principal investigators 
are Professor Robert Sutton and Professor Mark Pritchard. The study is being undertaken 
as part of a PhD project by a gastroenterology registrar, Dr Shameena Bharucha. 
 
Who has reviewed the study? 
The research has been reviewed by the North West / Preston Research Ethics Committee 
and has been granted approval. 
 
Contact for further information 
If you need further information or have any concerns or questions, do not hesitate to contact 
Dr Shameena Bharucha, the Research Fellow running the study, on 0151 706 4487/4877 
or 07931 246347.  
 
If you wish to complain about any aspect of the study or wish to discuss any concerns or 
questions with someone that is not linked to the investigations, please feel free to speak to 
a member of the clinical team on your ward. Alternatively, PALS (Patient Advice and Liaison 
Services) is a service that provides on the spot help for patients, relatives and carers. PALS 
is independent of all the hospital wards and departments where patients are seen and 
treated. The PALS team can be contacted on 0151 706 4903 or freephone Kerfone #159 
from the bedside in-patient phone. You can find more information and contact options on 
the PALS website: www.rlbuht.nhs.uk/pals.asp. 
 
 
Thank you for reading this information leaflet.
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Appendix H: Consent Form - Main Study 
 
                                
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT OF PATIENTS 
WITH ACUTE PANCREATITIS  
 
Name of Principal Investigators:  Professor Robert Sutton, Professor Mark Pritchard 
 
Name of Researcher:    
 
1. I confirm that I have read and understood version 
2 of the information sheet dated 06/06/12, for the above study and have 
had the opportunity to discuss the research and ask questions  
 
2. I understand that my participation is voluntary and that I may withdraw at 
any time without needing to give a reason, and without my medical care or 
legal rights being affected 
 
3. I understand that the results will not be added to my medical records but 
that my medical notes and data collected during the study may be looked 
at by individuals from regulatory authorities or from the NHS Trust                       
where it is relevant to my taking part in this research. I give permission to 
these individuals to have access to this information 
 
4. I agree to allow the research team to consult my medical notes 
 
5. I agree to have an endoscopic procedure with additional samples of 
intestinal                tissue and images to be taken with the confocal 
endomicroscope  
 
6. I agree to have blood samples taken for tests on factors that may be 
involved in the process of digestive disease  
 
7. I agree to undertake a further test called the lactulose:mannitol test which 
involves drinking a liquid given to me, and collecting a small blood sample 
after ninety minutes 
 
8. I agree to have the endoscopic procedure, blood sampling, and 
lactulose:mannitol test repeated upto a maximum of two further times 
 
9. I understand that my samples will be anonymised and will be stored, and it 
will not be possible to trace the samples back to me 
 
10. I understand that my samples may be used in the future for more genetic 
tests as there are more scientific advances 
 
11. I agree to take part in the study 
 
12. I agree for my GP  to be informed of my participation in the study and for 
them to be informed of any results generated from the tests related to the 
study 
 
 
 
……………………………        ………………..         ……………………………… 
Name of patient   Date   Signature 
……………………………        ………………..         ……………………………… 
Name of researcher  Date   Signature
 
 
 
 
 
 
 
 
Please initial boxes 
 
CONSENT FORM 
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Appendix I: Participation Information Form - Main Study 
 
 
PARTICIPANT INFORMATION SHEET FOR CEM STUDY 
 
 
IDENTIFICATION NUMBER  
PATIENT NAME and GENDER  
DATE OF BIRTH and AGE  
HOSPITAL RQ6 NUMBER  
TIME and DATE OF ONSET OF 
SYMPTOMS OF AP 
 
SYMPTOMS OF AP  
PAST MEDICAL HISTORY INC CO-
EXISTING GI DISEASE 
 
MEDICATIONS  
US / CT / MR FINDINGS   
SMOKER Y / N         QUANTITY: 
ALCOHOL IN UNITS / WEEK Y / N         QUANTITY: 
HELICOBACTER PYLORI  
AMYLASE  
ENDOSCOPY FINDINGS  
HISTOLOGY FINDINGS  
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ORIGINAL 1992 ATLANTA 
CLASSIFICATION: 
 
MILD = Parenchymal inflammation with 
no local comp. or sys. Involvement 
SEVERE = Above with local 
complication: 
• Necrosis on Enhanced CT ≥3cm 
or 1/3 of pancreas 
• Pseudocysts or acute fluid 
collection 
• Abscess  
or systemic complications: 
• Transient or persistent 
organ failure 
 
OVERALL GRADING BY 1992 
ATLANTA CLASSIFICATION 
 
REVISED 2012 ATLANTA 
CLASSIFICATION:  
 
MILD = No local or sys comp 
  
MODERATE  
• Local or sys comp without 
persistent organ failure 
• Transient organ failure < 48hrs 
 
SEVERE  
• Persistent single or multiple 
organ failure > 48hrs 
 
OVERALL GRADING BY 2012 
ATLANTA CLASSIFICATION 
 
SOFA SCORE: 
 
MILD = No local or sys comp 
 
MODERATE 
• Necrosis OR transient organ 
failure 
 
SEVERE 
• Persistent organ failure OR 
Infected pancreatic necrosis 
 
CRITICAL 
• Persistent organ failure AND 
infected pancreatic necrosis 
 
OVERALL GRADING BY SOFA 
SCORE 
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Appendix J – Case Record Form - Main Study 
 
WORKSHEET FOR THE COLLECTION OF SAMPLES FOR THE CEM STUDY 
 
SAMPLE COLLECTION    KIT GENERIC LABEL START 
CODE:  
 
Consent Taken By: Date: PATIENT REF NO: AP 
  
       CEM______ 
 
 
DATA SHEET 
COMPLETED 
COLLECTED OGD 
FORM 
IMAGES 
DOWNLOADED 
IMAGES SAVED TO 
DISC AND HARD 
DRIVE 
    
 
 
Date of Endoscopy: _________________ 
 
Image Stacks 
 
 
D2 STACK 
 
IMAGE NUMBERS SELECTED IMAGES 
SITE 1  
 
SITE 2  
 
SITE 3  
 
SITE 4  
 
SITE 5  
 
 
 
Collection of Tissue 
 
3 Bx for Path 
 
Time into Formalin 
 
3 Bx to snap freeze in 
3 Blue Cryovials  
 
Time into Liquid Nitrogen 
 
 
 
Collection of Fluid  
 
 Fluid for Micro in Cryovial 
 
Time Taken 
 
Volume into 
Pyrogen Free 
Cryovial 
 
Fluid for Neat Storage in 
Falcon 
 
Time Taken 
 
Volume into Falcon 
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Collection of Blood:       Date: 
_______________ 
 
 
Sample Type 
Date and Time 
Collected 
Collected By Inverted x 10 
2 ml EDTA    
3.5 ml Serum    
4.5ml Na Cit     
Blood Cultures 5ml x 2     
 
 
Intestinal Permeability Test:       Date: 
_______________ 
 
 
Date of Test  
Collected / 
Administered 
By 
 
 
1. 2ml Serum at start  
 
Time Taken 
 
Sugar Solution Drink 
completed 
 
 
Time Given 
 
2. 2ml serum at 
90mins  
 
 
Time Taken 
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BLOOD SAMPLE PROCESSING 
  
  EDTA TUBE 
 
Time Stored 
at -800C 
Label Freezer Confocal Box 
Position  of 
tube 
     
 
   
   SERUM 
 
Stood for 30 mins after 
collection 
Time centrifuged 
at 1500g for 10 mins 
No of White 
Cryovials 
Labels 
    
Time Stored at -
800C 
Freezer Tray Box 
Position  of 
tubes 
     
 
 
NA CITRATE TUBE 
 
Time centrifuged at 1600g 
for 15 mins AT 200C 
No of Red Cryovials with 
Plasma 
No of Eppendorfs with cell 
pellet 
   
Time Red 
Top 
Cryovials 
Stored at -
800C 
Labels Freezer Tray Box 
Position  of 
tubes 
   
   
Time 
Eppendorfs 
Stored at -
800C 
Labels Freezer Tray Box 
Position  of 
tubes 
      
 
BLOOD CULTURE BOTTLES 
 
Contacted 4718 Collected By Micro Time 
   
 
SERUM FOR IP TEST –     Date:_________ 
 
 
Sample 
Stood for 30 mins 
after collection 
Time centrifuged 
at 1500g for 10 mins 
No of 
Cryovials 
Labels 
1 at 0 mins 
    
2 at 90 mins     
 
Sample Time Stored at -80
0C Freezer Tray Box 
Position  
of tube 
1 at 0 mins   
   
2 at 90 mins   
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PROCESSING / STORAGE OF TISSUE and FLUID 
 
 
Tissue for Paraffin Wax Embedding: 
 
 
No. of samples  (Max=3)  
Date and Time taken to Pathology  
Slides received from Pathology  
 
 
Tissue for Storage in Isopentane: 
 
 
No. of samples  (Max=3)  
Labels of Cryovials  
Location in Freezer 
Time Stored 
at -1500C 
Freezer Tray Box 
Position  
of tube 
     
 
 
PROCESSING / STORAGE OF FLUID 
 
 
Fluid for Microbiology 
 
 
Contacted 4718 Collected By Micro Time 
  
 
 
 
Neat Fluid  
 
 
Time Stored at 
-800C 
Label Freezer Confocal Box 
Position  of 
tube 
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Appendix K: Microbiology Request Form 
 
       FAO: PAUL ROBERTS:4718 
 
  
 
 
 
 
 
 
SHAMEENA BHARUCHA / PBRU 
CONFOCAL STUDY : MICROBIOLOGY FORM 
 
 PATIENT NUMBER: CEM  
DATE:  
SPECIMEN OF: 
 
 
 
Name of Medical Officer: Dr Shameena Bharucha 
Signature of Medical Officer:  
Contact Details: 
07931 246347 / 0151 706 4487 
 
shameena_b@yahoo.co.uk 
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Appendix L: Pathology Request Form 
FAO: LEAH CLEMENT                 
 
 
SHAMEENA BHARUCHA / PBRU 
CONFOCAL STUDY : PATHOLOGY FORM 
 PATIENT NUMBER: CEM  
DATE:  
SPECIMEN OF:  
 
Name of Medical Officer: Dr Shameena Bharucha 
Signature of Medical Officer:  
Contact Details: 
07931 246347 / 0151 706 4487 
shameena_b@yahoo.co.uk 
 
For Laboratory Use 
No. Of Cassettes:  
No. Of Ribbons:  
Date of Collection:  
Signatures: MO: Lab: 
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Appendix M: Lactulose Mannitol Test PI Leaflet 
 
                                     
 
 
 
 
 
 
 
 
 
 
CONFOCAL IMAGING IN THE INVESTIGATION AND 
MANAGEMENT OF PATIENTS WITH CHRONIC PANCREATITIS 
AND CHRONIC LIVER DISEASE 
 
 
 
Dear ___________________________________, 
 
Many thanks for agreeing to attend for the sugar absorption test, which is the second 
part of the study that you previously took part in.  
 
Please find enclosed a leaflet detailing the test and your appointment. 
 
I look forward to seeing you again. If you need further information or have any 
concerns or questions, do not hesitate to contact me on 0151 706 4487 / 0151 706 
4877 or 07931 246347. 
 
 
 
Many Thanks, 
 
 
 
Dr Shameena Bharucha 
 
Pancreas Biomedical Research Unit 
 
 
 
PATIENT INFORMATION: MANNITOL & LACTULOSE SMALL 
INTESTINAL PERMEABILITY TEST 
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CONFOCAL IMAGING IN THE INVESTIGATION AND MANAGEMENT OF 
PATIENTS WITH CHRONIC PANCREATITIS AND CHRONIC LIVER DISEASE 
Brief Outline 
Sugar absorption tests can be used to assess leakiness of the bowel, in a variety of 
diseases.  The sugars are given in water and blood levels of two sugars are 
determined before and after the solutions are given.  
Patient Preparation and Procedure 
• Please do not eat or drink anything after midnight before your appointment. 
• You are allowed to drink small amounts of water.  
• Please avoid taking aspirin/diclofenac/ibuprofen/nurofen or other drugs from 
this group the night before the test.  
• Do not drink any alcohol the day before the test. 
• Please report to the main desk in the foyer at the main entrance of the 
ground floor of the Royal Liverpool University Hospital with this letter 
on ___________________ at _________.  
• A small blood test will be taken on your arrival and then you will be asked to 
drink a sugar solution containing lactulose*, mannitol and water. 
• You will be asked to stay in the facility for ninety minutes. It may be beneficial 
to bring reading material to occupy yourself during this time.  
• A second small blood test will be taken at this point and then you will be 
discharged. 
 
* Please note that lactulose is a laxative and may cause you to open your bowels 
and pass loose motions. It is however a negligible dose and therefore is more 
likely to have no effect. 
 
Contact for further information 
If you need further information or have any concerns or questions, do not hesitate to 
contact me on 0151 706 4487 / 0151 706 4877 or 07931 246347. 
Thank you for reading this information leaflet
PATIENT INFORMATION: MANNITOL & LACTULOSE SMALL 
INTESTINAL PERMEABILITY TEST 
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Appendix N: Lactulose Mannitol Prescription 
 
 
SCOPE STUDY PRESCRIPTION 
 
Trust reference number: 4067 
 
To be completed by Investigator or Designée 
 
Patient Name:     _________________________________________ 
 
Patient Hospital Number:     ____________________ 
 
 
Pt hospital label: 
  (Affix here)         
                     
                                         
       
 
 
         
 
 
 
Please Supply:  100ml of Lactulose Mannitol Oral Solution 
 
 
Date and time of patient visit:   _____________________________ 
                                                                                   
Doctor’s name (Please print): ___________________________
 Date: ___ / ___ / ___ 
                                  
                                      
 Signed:         ________________________    Ext. No/Bleep No. ________   
 
 To be completed by Pharmacy 
 
Dispensed by (Print Name and Sign): 
_________________________________ Date: __/__/__ 
                                                                               
Checked by (Print Name and Sign): ______________________________           
Date: __/__/__ 
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Appendix O: Regional Ethics Committee Approval 
 
 
  
 National Research Ethics Service  
NRES Committee North West –Preston  
3rd Floor  
Barlow House  
4 Minshull Street  
Manchester  
M1 3DZ  
Telephone: 0161 625 7434 
 
07 June 2012  
Professor Robert Sutton  
Executive Director Liverpool NIHR Pancreas Biomedical Research Unit  
NIHR Pancreas Biomedical Research Unit; Royal Liverpool University Hospital  
Royal Liverpool University Hospital  
Daulby Street  
Liverpool  
L69 3GA  
 
Dear Professor Sutton  
 
 
Study title:  
 
 
 
STUDY TO INVESTIGATE THE ROLE 
OF CONFOCAL IMAGING IN THE 
INVESTIGATION AND MANAGEMENT 
OF PATIENTS WITH ACUTE 
PANCREATITIS  
 
REC reference:  
 
12/NW/0420  
Protocol number:  UoL000874  
 
Thank you for your email of 06 June 2012, responding to the Committee’s request for further 
information on the above research and submitting revised documentation.  
 
The further information has been considered on behalf of the Committee by the Chair and Dr Monks.  
 
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation as 
revised, subject to the conditions specified below.  
 
Ethical review of research sites  
NHS sites  
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC RandD office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Non-NHS sites  
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Conditions of the favourable opinion  
The favourable opinion is subject to the following conditions being met prior to the start of the study.  
Management permission or approval must be obtained from each host organisation prior to the start of 
the study at the site concerned.  
Management permission ("RandD approval") should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements.  
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from the 
RandD office on the information it requires to give permission for this activity.  
For non-NHS sites, site management permission should be obtained in accordance with the procedures 
of the relevant host organisation.  
Sponsors are not required to notify the Committee of approvals from host organisations  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with before 
the start of the study or its initiation at a particular site (as applicable).  
Approved documents  
 
The final list of documents reviewed and approved by the Committee is as follows: 
Document  Version  Date  
Covering Letter  08 May 2012  
Evidence of insurance or indemnity  31 July 2011  
Investigator CV  Robert Sutton  
Investigator CV  Shameena Bharucha  
Letter from Sponsor  Liverpool University  08 May 2012  
Letter from Sponsor  NHS Co-Sponsor Letter  02 May 2012  
Letter from Statistician  Trevor Cox  10 May 2012  
Letter of invitation to participant  1  21 March 2012  
Letter of invitation to participant  2  06 June 2012  
Other: RandD Application Form  21 March 2012  
Other: Research Registration Form Liverpool University  
Other: NHS Indemnity Cover  
Other: In-patient gastroscopy information leaflet from Royal Liverpool University Hospital  
Participant Consent Form  1  21 March 2012  
Participant Consent Form  2  06 June 2012  
Participant Information Sheet  1  21 March 2012  
Participant Information Sheet  2  06 June 2012  
 
Protocol  1  21 March 2012  
REC application  3.4  10 May 2012  
Referees or other scientific critique report  08 May 2012  
Response to Request for Further Information  06 June 2012  
 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK.  
After ethical review  
Reporting requirements  
The attached document “After ethical review – guidance for researchers” gives detailed guidance on 
reporting requirements for studies with a favourable opinion, including:  
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Notifying substantial amendments  
Adding new sites and investigators  
Notification of serious breaches of the protocol  
Progress and safety reports  
Notifying the end of the study  
 
The NRES website also provides guidance on these topics, which is updated in the light of changes in 
reporting requirements or procedures.  
Feedback  
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure. If you wish to make your views known please use the 
feedback form available on the website.  
 
 
Further information is available at National 
Research Ethics Service website > After  
 
 
Please quote this number on all 
correspondence: 12/NW/0420  
 
 
 
 
 
With the Committee’s best wishes for the success of this project  
Yours sincerely  
 
 
 
Dr Patricia Wilkinson  
Chair  
 
 
 
Email: Anna.bannister@northwest.nhs.uk 
Enclosures:  
“After ethical review – guidance for 
researchers”  
 
Copy to:  
 
Mrs Lindsay Carter  
Professor Robert Sutton, NIHR Pancreas 
Biomedical Research Unit; Royal Liverpool 
University Hospital  
 
 
